<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:DSS="http://dssinc.com/20260930"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dss-20260930.xsd" xlink:type="simple"/>
    <context id="From2026-01-01to2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-11-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <instant>2026-11-11</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-07-012026-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_PrintedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_PrintedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_PrintedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_PrintedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_RentalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_RentalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_RentalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RentalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommercialLendingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommercialLendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommercialLendingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommercialLendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CommercialLendingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommercialLendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommercialLendingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommercialLendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommissionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommissionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CommissionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommissionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CustomerFourMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CustomerFiveMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">DSS:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ImpactBioMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:ImpactBioMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-14_custom_NoteOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="AsOf2021-05-14_custom_NoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="From2021-05-142021-05-14_custom_NoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-14</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-02_custom_NoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-02</instant>
        </period>
    </context>
    <context id="From2022-03-022022-03-02_custom_NoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-02</startDate>
            <endDate>2022-03-02</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-09_custom_NoteThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="From2022-05-092022-05-09_custom_NoteThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-29_custom_NoteFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-29</instant>
        </period>
    </context>
    <context id="From2022-08-292022-08-29_custom_NoteFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_BMICapitalInternationalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">DSS:BMICapitalInternationalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-05-08_custom_NoteFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="From2023-05-082023-05-08_custom_NoteFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_NoteSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_NoteSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-19_custom_NoteSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-19</instant>
        </period>
    </context>
    <context id="From2021-02-192021-02-19_custom_NoteSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-19</startDate>
            <endDate>2021-02-19</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_NoteEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-03-312023-03-31_custom_NoteEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-29_custom_NoteNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="From2024-08-292024-08-29_custom_NoteNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-04-16_custom_NoteTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-16</instant>
        </period>
    </context>
    <context id="From2026-04-162026-04-16_custom_NoteTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-16</startDate>
            <endDate>2026-04-16</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-06-23_custom_NoteElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-23</instant>
        </period>
    </context>
    <context id="From2026-06-232026-06-23_custom_NoteElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-23</startDate>
            <endDate>2026-06-23</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-08-26_custom_NoteTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-26</instant>
        </period>
    </context>
    <context id="From2026-08-262026-08-26_custom_NoteTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-26</startDate>
            <endDate>2026-08-26</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_NoteTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NoteTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-27</instant>
        </period>
    </context>
    <context id="From2026-03-272026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-27</startDate>
            <endDate>2026-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-26_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-26</instant>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-03-312026-03-31_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-31</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-29</instant>
        </period>
    </context>
    <context id="From2026-04-292026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-29</startDate>
            <endDate>2026-04-29</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">DSS:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">DSS:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">DSS:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">DSS:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">DSS:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">DSS:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_LoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">DSS:LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_LoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">DSS:LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_GeneralLoanPortfolioReserveMember_custom_AmericanPacificBancorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:GeneralLoanPortfolioReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_GeneralLoanPortfolioReserveMember_custom_AmericanPacificBancorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:GeneralLoanPortfolioReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_AsiliLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AsiliLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_VEIIIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:VEIIIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_VEIIIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:VEIIIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_BMICapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:BMICapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_BMICapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:BMICapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_BMICapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:BMICapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_WUURIICommerceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:WUURIICommerceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_WUURIICommerceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:WUURIICommerceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SpecificLoanReservesMember_custom_WUURIICommerceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:WUURIICommerceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_WUURIICommerceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:WUURIICommerceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_us-gaap_IndividualMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:IndividualMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_us-gaap_IndividualMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:AmericanPacificBancorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">DSS:SpecificLoanReservesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:IndividualMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-03-272025-03-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2025-03-27</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <context id="From2026-07-242026-07-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2026-07-24</startDate>
            <endDate>2026-07-24</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_AlsetInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AlsetInternationalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_AlsetInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AlsetInternationalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_AlsetInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AlsetInternationalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_AlsetInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AlsetInternationalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2022-02-282022-02-28_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2025-02-202025-02-20_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-27</instant>
        </period>
    </context>
    <context id="From2026-03-272026-03-27_custom_ConvertibleBondInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-27</startDate>
            <endDate>2026-03-27</endDate>
        </period>
    </context>
    <context id="From2026-04-292026-04-29_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-29</startDate>
            <endDate>2026-04-29</endDate>
        </period>
    </context>
    <context id="AsOf2026-04-29_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-29</instant>
        </period>
    </context>
    <context id="AsOf2026-04-28_custom_ConvertibleBondInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-28</instant>
        </period>
    </context>
    <context id="From2026-04-282026-04-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2026-04-28</startDate>
            <endDate>2026-04-28</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_TruePartnersCapitalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:TruePartnersCapitalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2020-12-292020-12-30_custom_WestParkCapitalGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:WestParkCapitalGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-29</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_WestParkCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:WestParkCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WestParkCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:WestParkCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-10_custom_DSSSecuritiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">DSS:DSSSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-10</instant>
        </period>
    </context>
    <context id="From2020-09-092020-09-10_custom_DSSSecuritiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:DSSSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-09</startDate>
            <endDate>2020-09-10</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-31_custom_DSSSecuritiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:DSSSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-31_custom_BMICapitalInternationalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:BMICapitalInternationalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-31_custom_BMICapitalInternationalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">DSS:BMICapitalInternationalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_BMICapitalInternationalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:BMICapitalInternationalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_BMICapitalInternationalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">DSS:BMICapitalInternationalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-20_custom_PremierPackagingBankOfAmericaNAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PremierPackagingBankOfAmericaNAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-20</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_PremierPackagingBankOfAmericaNAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PremierPackagingBankOfAmericaNAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PremierPackagingBankOfAmericaNAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PremierPackagingBankOfAmericaNAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_PremierPackagingBankOfAmericaNAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PremierPackagingBankOfAmericaNAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_PremierPackagingBankOfAmericaNAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PremierPackagingBankOfAmericaNAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="From2021-07-292021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-29</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="From2021-07-292021-08-01_custom_FacilityMember_custom_LoanAgreementMember_custom_AMRESheltonLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">DSS:FacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-29</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="From2021-07-292021-08-01_us-gaap_LandMember_custom_LoanAgreementMember_custom_AMRESheltonLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-29</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="From2021-07-292021-08-01_custom_TenantImprovementsMember_custom_LoanAgreementMember_custom_AMRESheltonLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">DSS:TenantImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-29</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_LoanAgreementMember_custom_AMRESheltonLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_LoanAgreementMember_custom_AMRESheltonLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_AMRESheltonLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_AMRESheltonLLCMember_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_AMRESheltonLLCMember_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRESheltonLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-10-13_custom_BMICLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:BMICLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="From2021-10-132021-10-13_custom_BMICLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:BMICLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_BMICLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:BMICLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_BMICLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:BMICLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-10-13_custom_WilsonLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:WilsonLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="From2021-10-132021-10-13_custom_WilsonLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:WilsonLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_WilsonLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:WilsonLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WilsonLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:WilsonLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-11-02_custom_PinnacleBankMember_custom_LifeCareAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="From2021-11-012021-11-02_custom_PinnacleBankMember_custom_LifeCareAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="From2021-11-012021-11-02_custom_FacilityMember_custom_LifeCareAgreementMember_custom_PinnacleBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">DSS:FacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="From2021-11-012021-11-02_us-gaap_LandMember_custom_LifeCareAgreementMember_custom_PinnacleBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="From2021-11-012021-11-02_custom_SiteImprovementsMember_custom_LifeCareAgreementMember_custom_PinnacleBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">DSS:SiteImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-02_custom_LifeCareAgreementMember_custom_PinnacleBankMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="AsOf2021-11-02_custom_LifeCareAgreementMember_custom_PinnacleBankMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_AMRELifeCarePortfolioLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AMRELifeCarePortfolioLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-07-29_custom_PinnacleBankMember_custom_LifeCareAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PinnacleBankMember_custom_LifeCareAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LifeCareAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-30_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:UnionBankAndTrustCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="From2023-03-302023-03-30_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:UnionBankAndTrustCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:UnionBankAndTrustCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:UnionBankAndTrustCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_UnionBankAndTrustCompanyMember_custom_SecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:UnionBankAndTrustCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_UnionBankAndTrustCompanyMember_custom_SecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:UnionBankAndTrustCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-31_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-26_custom_ConvertibleBondInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-26</instant>
        </period>
    </context>
    <context id="AsOf2026-03-26_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-26</instant>
        </period>
    </context>
    <context id="From2026-03-262026-03-26_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-26</startDate>
            <endDate>2026-03-26</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-23_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-23</instant>
        </period>
    </context>
    <context id="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-23</startDate>
            <endDate>2026-06-23</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-17</instant>
        </period>
    </context>
    <context id="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-17</startDate>
            <endDate>2026-08-17</endDate>
        </period>
    </context>
    <context id="From2026-08-172026-08-17_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-17</startDate>
            <endDate>2026-08-17</endDate>
        </period>
    </context>
    <context id="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember108129671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-17</startDate>
            <endDate>2026-08-17</endDate>
        </period>
    </context>
    <context id="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember108129671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-17</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-15</instant>
        </period>
    </context>
    <context id="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-15</startDate>
            <endDate>2026-09-15</endDate>
        </period>
    </context>
    <context id="From2026-09-152026-09-15_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-15</startDate>
            <endDate>2026-09-15</endDate>
        </period>
    </context>
    <context id="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember108129687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-15</startDate>
            <endDate>2026-09-15</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember108129687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-15</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-09-152026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-15</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_ConvertibleNotePayableRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:ConvertibleNotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2022-03-192022-03-19_custom_LicenseAgreementMember_custom_BioMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:BioMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-19</startDate>
            <endDate>2022-03-19</endDate>
        </period>
    </context>
    <context id="From2022-03-192022-03-19_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-19</startDate>
            <endDate>2022-03-19</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_FirstYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">DSS:MrHeuszelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">DSS:FirstYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_SecondYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">DSS:MrHeuszelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">DSS:SecondYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_ThirdYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">DSS:MrHeuszelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">DSS:ThirdYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_FirstYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">DSS:MrHeuszelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">DSS:FirstYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_SecondYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">DSS:MrHeuszelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">DSS:SecondYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_FirstYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">DSS:MrHeuszelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">DSS:FirstYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_SecondYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">DSS:MrHeuszelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">DSS:SecondYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-02-062025-02-06_custom_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">DSS:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="From2025-03-212025-03-21_custom_ImpactBioMedicalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:ImpactBioMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-30_custom_ImpactBioMedicalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:ImpactBioMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="From2026-02-042026-02-04_custom_AegisCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AegisCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-04</startDate>
            <endDate>2026-02-04</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-04_custom_AegisCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AegisCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-04</instant>
        </period>
    </context>
    <context id="From2026-03-192026-03-19_custom_AegisCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">DSS:AegisCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-19</startDate>
            <endDate>2026-03-19</endDate>
        </period>
    </context>
    <context id="From2025-02-252025-02-25_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-06-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <instant>2025-06-23</instant>
        </period>
    </context>
    <context id="From2025-10-162025-10-16_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="From2025-11-242025-11-24_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-24</startDate>
            <endDate>2025-11-24</endDate>
        </period>
    </context>
    <context id="From2025-11-242025-11-24_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-24</startDate>
            <endDate>2025-11-24</endDate>
        </period>
    </context>
    <context id="From2026-09-232026-09-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2026-09-23</startDate>
            <endDate>2026-09-23</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <instant>2026-09-23</instant>
        </period>
    </context>
    <context id="AsOf2026-09-23_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-23</instant>
        </period>
    </context>
    <context id="AsOf2026-09-23_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-23</instant>
        </period>
    </context>
    <context id="From2024-10-012024-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <instant>2024-10-01</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpense">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:SellingGeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:ProductPackagingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialBankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:ProductPackagingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialBankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:ProductPackagingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialBankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:ProductPackagingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialBankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_PackagingPrintingandFabricationMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:PackagingPrintingandFabricationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommercialandSecurityPrintingMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialandSecurityPrintingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_PackagingPrintingandFabricationMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:PackagingPrintingandFabricationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommercialandSecurityPrintingMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialandSecurityPrintingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_RealPropertyRentalIncomeMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:RealPropertyRentalIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_PackagingPrintingandFabricationMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:PackagingPrintingandFabricationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CommercialandSecurityPrintingMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialandSecurityPrintingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_RealPropertyRentalIncomeMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:RealPropertyRentalIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_PackagingPrintingandFabricationMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:PackagingPrintingandFabricationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommercialandSecurityPrintingMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialandSecurityPrintingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RealPropertyRentalIncomeMember_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:RealPropertyRentalIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_PrintedProductsRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:PrintedProductsRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommercialLendingRevenueInformationMember_custom_NetInvestmentIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:NetInvestmentIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialLendingRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommercialLendingRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialLendingRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommercialLendingRevenueInformationMember_custom_NetInvestmentIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:NetInvestmentIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialLendingRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommercialLendingRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialLendingRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CommercialLendingRevenueInformationMember_custom_NetInvestmentIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:NetInvestmentIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialLendingRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CommercialLendingRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialLendingRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommercialLendingRevenueInformationMember_custom_NetInvestmentIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:NetInvestmentIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialLendingRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommercialLendingRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:CommercialLendingRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_RetailInternetSalesMember_custom_BiotechnologyRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RetailInternetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_BiotechnologyRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_RetailInternetSalesMember_custom_BiotechnologyRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RetailInternetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_BiotechnologyRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_RetailInternetSalesMember_custom_BiotechnologyRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RetailInternetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_BiotechnologyRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RetailInternetSalesMember_custom_BiotechnologyRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RetailInternetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_BiotechnologyRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:BiotechnologyRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_RentalIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RentalIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_CommissionIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommissionIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-07-012026-09-30_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_RentalIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RentalIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_CommissionIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommissionIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_RentalIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RentalIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_CommissionIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommissionIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RentalIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:RentalIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CommissionIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">DSS:CommissionIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SecuritiesAndInvestmentManagementRevenueInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">DSS:SecuritiesAndInvestmentManagementRevenueInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2022-08-282022-08-29_custom_NoteFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-28</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-29_custom_NoteFourMember_custom_BMICapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">DSS:BMICapitalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-29</instant>
        </period>
    </context>
    <context id="From2023-05-082026-05-08_custom_NoteFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2026-05-08</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-08_custom_NoteFiveMember_custom_BMICapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">DSS:BMICapitalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">DSS:NoteFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="AsOf2026-09-30_custom_AlsetNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:AlsetNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_AlsetNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:AlsetNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_AlsetNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:AlsetNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-26_custom_ConvertibleBondInvestmentMember_custom_AlsetInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertibleBondInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetInternationalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-26</instant>
        </period>
    </context>
    <context id="AsOf2026-03-26_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetInternationalLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-26</instant>
        </period>
    </context>
    <context id="From2026-03-262026-03-26_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetInternationalLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-26</startDate>
            <endDate>2026-03-26</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetInternationalLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetInternationalLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-23</instant>
        </period>
    </context>
    <context id="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-23</startDate>
            <endDate>2026-06-23</endDate>
        </period>
    </context>
    <context id="AsOf2026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-23</instant>
        </period>
    </context>
    <context id="From2026-06-232026-06-23_custom_SecuritiesPurchaseAgreementMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-23</startDate>
            <endDate>2026-06-23</endDate>
        </period>
    </context>
    <context id="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-23</startDate>
            <endDate>2026-06-23</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-17</instant>
        </period>
    </context>
    <context id="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-17</startDate>
            <endDate>2026-08-17</endDate>
        </period>
    </context>
    <context id="From2026-08-172026-08-17_custom_SecuritiesPurchaseAgreementMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-17</startDate>
            <endDate>2026-08-17</endDate>
        </period>
    </context>
    <context id="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-17</startDate>
            <endDate>2026-08-17</endDate>
        </period>
    </context>
    <context id="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-08-17</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteOneMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-15</instant>
        </period>
    </context>
    <context id="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-15</startDate>
            <endDate>2026-09-15</endDate>
        </period>
    </context>
    <context id="From2026-09-152026-09-15_custom_SecuritiesPurchaseAgreementMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-15</startDate>
            <endDate>2026-09-15</endDate>
        </period>
    </context>
    <context id="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-15</startDate>
            <endDate>2026-09-15</endDate>
        </period>
    </context>
    <context id="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-15</instant>
        </period>
    </context>
    <context id="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteTwoMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="From2026-09-152026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_custom_AlsetIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">DSS:AlsetIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-15</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-10-16_us-gaap_SubsequentEventMember_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-10-16</instant>
        </period>
    </context>
    <context id="From2026-10-162026-10-16_us-gaap_SubsequentEventMember_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000771999</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">DSS:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-10-16</startDate>
            <endDate>2026-10-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segments">
        <measure>DSS:Segments</measure>
    </unit>
    <unit id="HKDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:HKD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="From2026-01-01to2026-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2026-01-01to2026-09-30" id="Fact000004">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2026-01-01to2026-09-30" id="Fact000005">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2026-01-01to2026-09-30" id="Fact000006">0000771999</dei:EntityCentralIndexKey>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0052"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0158"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0163"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0164"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendIncomeOperating
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-07-012026-09-30"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0412"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0466"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0478"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-012026-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-012026-09-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2026-01-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2026-01-012026-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2026-01-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2026-01-012026-09-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-01-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-01-012026-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-01-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-01-012026-09-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0532"
      unitRef="Shares"
      xsi:nil="true"/>
    <DSS:IssuanceOfCommonStockForBonus
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:StockBasedPaymentsForProfessionalServicesRendered
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:IncreaseDecreaseAssetsHeldForSale
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:PurchaseOfConvertibleBondRelatedParty
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:ProceedFromSaleOfRealEstate
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:ProceedsFromSaleOfInvestmentRelatedParty
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:IssuanceOfNewNotesReceivableNetOriginationFees
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2026-01-01to2026-09-30"
      id="xdx2ixbrl0663"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl0673"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCash
      contextRef="AsOf2026-09-30"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2026-01-012026-09-30_us-gaap_CashMember"
      id="xdx2ixbrl1009"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2026-09-30_us-gaap_CashMember"
      id="xdx2ixbrl1015"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2026-01-012026-09-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1019"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2026-09-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1025"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2026-09-30_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1033"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2025-01-012025-12-31_us-gaap_CashMember"
      id="xdx2ixbrl1049"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2025-12-31_us-gaap_CashMember"
      id="xdx2ixbrl1055"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2025-01-012025-12-31_custom_RestrictedCashMember"
      id="xdx2ixbrl1059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2025-12-31_custom_RestrictedCashMember"
      id="xdx2ixbrl1065"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2025-01-012025-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1069"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2026-09-30_custom_ConvertibleNotePayableRelatedPartyMember"
      id="xdx2ixbrl1453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1454"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearAfterYearFour
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1459"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:FairValueAdjustmentRelatedToConvertibleBondReceivedFromRelatedParty
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl1612"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:ConversionOfConvertibleBondInvestmentRelatedPartyIntoEquityMethodInvestment
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl1615"
      unitRef="USD"
      xsi:nil="true"/>
    <DSS:IssuanceOfWarrantsInConnectionWithConvertiblePromissoryNoteFromRelatedParty
      contextRef="From2025-01-012025-09-30"
      id="xdx2ixbrl1621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1682"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1731"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1738"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      id="xdx2ixbrl1780"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2026-01-01to2026-09-30" id="Fact000016">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2026-01-01to2026-09-30" id="Fact000017">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2026-01-01to2026-09-30" id="Fact000018">2026-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2026-01-01to2026-09-30" id="Fact000019">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2026-01-01to2026-09-30" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2026-01-01to2026-09-30" id="Fact000021">001-32146</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2026-01-01to2026-09-30" id="Fact000022">DSS,     INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-01-01to2026-09-30" id="Fact000023">NY</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2026-01-01to2026-09-30" id="Fact000024">16-1229730</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2026-01-01to2026-09-30" id="Fact000025">275 Wiregrass Pkwy</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2026-01-01to2026-09-30" id="Fact000026">West Henrietta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2026-01-01to2026-09-30" id="Fact000027">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2026-01-01to2026-09-30" id="Fact000028">14586</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2026-01-01to2026-09-30" id="Fact000029">(585)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2026-01-01to2026-09-30" id="Fact000030">325-3610</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2026-01-01to2026-09-30" id="Fact000031">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2026-01-01to2026-09-30" id="Fact000032">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2026-01-01to2026-09-30" id="Fact000033">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2026-01-01to2026-09-30" id="Fact000034">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2026-01-01to2026-09-30" id="Fact000035">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2026-01-01to2026-09-30" id="Fact000036">false</dei:EntityShellCompany>
    <dei:Security12bTitle contextRef="From2026-01-01to2026-09-30" id="Fact000037">Common Stock, $0.02 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2026-01-01to2026-09-30" id="Fact000038">DSS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2026-01-01to2026-09-30" id="Fact000039">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-11-11"
      decimals="INF"
      id="Fact000040"
      unitRef="Shares">10042518</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000041"
      unitRef="USDPShares">0.02</dei:EntityListingParValuePerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000049"
      unitRef="USD">3275000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000050"
      unitRef="USD">6214000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000055"
      unitRef="USD">1218000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">2254000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000058"
      unitRef="USD">2205000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">1998000</us-gaap:InventoryNet>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000061"
      unitRef="USD">613000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">2694000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2026-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000064"
      unitRef="USD">85000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000065"
      unitRef="USD">198000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000067"
      unitRef="USD">194000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000068"
      unitRef="USD">238000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000070"
      unitRef="USD">194000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000071"
      unitRef="USD">238000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">344000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">649000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">7934000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">14345000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000079"
      unitRef="USD">4078000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">4819000</us-gaap:PropertyPlantAndEquipmentNet>
    <DSS:InvestmentsInRealEstateNetNonCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000082"
      unitRef="USD">16217000</DSS:InvestmentsInRealEstateNetNonCurrent>
    <DSS:InvestmentsInRealEstateNetNonCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">16637000</DSS:InvestmentsInRealEstateNetNonCurrent>
    <DSS:InvestmentsCostMethod
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000085"
      unitRef="USD">500000</DSS:InvestmentsCostMethod>
    <DSS:InvestmentsCostMethod
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">500000</DSS:InvestmentsCostMethod>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000088"
      unitRef="USD">11492000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">113000</us-gaap:EquityMethodInvestments>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000091"
      unitRef="USD">1430000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">6517000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000094"
      unitRef="USD">185000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000097"
      unitRef="USD">61000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">71000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000100"
      unitRef="USD">5351000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">5825000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000103"
      unitRef="USD">1769000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">1769000</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000106"
      unitRef="USD">16172000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">17034000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000109"
      unitRef="USD">65189000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">67630000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000118"
      unitRef="USD">3461000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">2597000</us-gaap:AccountsPayableCurrent>
    <DSS:AccruedExpensesAndDeferredRevenueCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000121"
      unitRef="USD">2692000</DSS:AccruedExpensesAndDeferredRevenueCurrent>
    <DSS:AccruedExpensesAndDeferredRevenueCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000122"
      unitRef="USD">1725000</DSS:AccruedExpensesAndDeferredRevenueCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000124"
      unitRef="USD">2735000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">4367000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000127"
      unitRef="USD">8988000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">7162000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000130"
      unitRef="USD">598000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">611000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2026-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000133"
      unitRef="USD">30503000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000134"
      unitRef="USD">30343000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000136"
      unitRef="USD">1598000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000137"
      unitRef="USD">503000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000139"
      unitRef="USD">178000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000140"
      unitRef="USD">188000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000142"
      unitRef="USD">178000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000143"
      unitRef="USD">188000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000145"
      unitRef="USD">50753000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">47496000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000148"
      unitRef="USD">4886000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">5727000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000151"
      unitRef="USD">5234000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">5692000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000154"
      unitRef="USD">60873000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">58915000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000166"
      unitRef="USDPShares">0.02</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="USDPShares">0.02</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">47000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">47000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000182"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000184"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">0</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">0</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000193"
      unitRef="USDPShares">0.02</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000195"
      unitRef="USDPShares">0.02</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000197"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000199"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000201"
      unitRef="Shares">10042518</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact000203"
      unitRef="Shares">10042518</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000205"
      unitRef="Shares">9092518</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000207"
      unitRef="Shares">9092518</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000190"
      unitRef="USD">200000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">182000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000209"
      unitRef="USD">337723000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">325987000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000212"
      unitRef="USD">-342047000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000213"
      unitRef="USD">-327001000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000215"
      unitRef="USD">-4124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">-832000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000218"
      unitRef="USD">8440000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">9547000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000221"
      unitRef="USD">4316000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">8715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000224"
      unitRef="USD">65189000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">67630000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_PrintedProductsMember"
      decimals="0"
      id="Fact000232"
      unitRef="USD">3371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_PrintedProductsMember"
      decimals="0"
      id="Fact000233"
      unitRef="USD">4994000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_PrintedProductsMember"
      decimals="0"
      id="Fact000234"
      unitRef="USD">10778000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_PrintedProductsMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">13249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_RentalMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">162000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_RentalMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">718000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_RentalMember"
      decimals="0"
      id="Fact000239"
      unitRef="USD">554000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_RentalMember"
      decimals="0"
      id="Fact000240"
      unitRef="USD">2147000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_CommercialLendingMember"
      decimals="0"
      id="Fact000242"
      unitRef="USD">6000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_CommercialLendingMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">7000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_CommercialLendingMember"
      decimals="0"
      id="Fact000244"
      unitRef="USD">17000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_CommercialLendingMember"
      decimals="0"
      id="Fact000245"
      unitRef="USD">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_CommissionMember"
      decimals="0"
      id="Fact000247"
      unitRef="USD">45000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_CommissionMember"
      decimals="0"
      id="Fact000248"
      unitRef="USD">662000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_CommissionMember"
      decimals="0"
      id="Fact000249"
      unitRef="USD">160000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_CommissionMember"
      decimals="0"
      id="Fact000250"
      unitRef="USD">1166000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_BiotechnologyMember"
      decimals="0"
      id="Fact000252"
      unitRef="USD">20000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_BiotechnologyMember"
      decimals="0"
      id="Fact000253"
      unitRef="USD">11000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_BiotechnologyMember"
      decimals="0"
      id="Fact000254"
      unitRef="USD">29000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_BiotechnologyMember"
      decimals="0"
      id="Fact000255"
      unitRef="USD">32000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000257"
      unitRef="USD">3604000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000258"
      unitRef="USD">6392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000259"
      unitRef="USD">11538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000260"
      unitRef="USD">16630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000267"
      unitRef="USD">4850000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000268"
      unitRef="USD">6068000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000269"
      unitRef="USD">14902000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000270"
      unitRef="USD">16753000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000272"
      unitRef="USD">2926000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000273"
      unitRef="USD">3558000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000274"
      unitRef="USD">10082000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000275"
      unitRef="USD">10261000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000277"
      unitRef="USD">7776000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000278"
      unitRef="USD">9626000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000279"
      unitRef="USD">24984000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000280"
      unitRef="USD">27014000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-4172000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000283"
      unitRef="USD">-3234000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000284"
      unitRef="USD">-13446000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000285"
      unitRef="USD">-10384000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000292"
      unitRef="USD">5000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000293"
      unitRef="USD">2000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000294"
      unitRef="USD">8000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000295"
      unitRef="USD">17000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <DSS:InterestIncomeOnNotesReceivableRelatedParty
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000297"
      unitRef="USD">5000</DSS:InterestIncomeOnNotesReceivableRelatedParty>
    <DSS:InterestIncomeOnNotesReceivableRelatedParty
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000298"
      unitRef="USD">7000</DSS:InterestIncomeOnNotesReceivableRelatedParty>
    <DSS:InterestIncomeOnNotesReceivableRelatedParty
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000299"
      unitRef="USD">17000</DSS:InterestIncomeOnNotesReceivableRelatedParty>
    <DSS:InterestIncomeOnNotesReceivableRelatedParty
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000300"
      unitRef="USD">25000</DSS:InterestIncomeOnNotesReceivableRelatedParty>
    <us-gaap:DividendIncomeOperating
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000303"
      unitRef="USD">4000</us-gaap:DividendIncomeOperating>
    <us-gaap:DividendIncomeOperating
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000304"
      unitRef="USD">16000</us-gaap:DividendIncomeOperating>
    <us-gaap:DividendIncomeOperating
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000305"
      unitRef="USD">4000</us-gaap:DividendIncomeOperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000307"
      unitRef="USD">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000309"
      unitRef="USD">-13000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000310"
      unitRef="USD">10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000312"
      unitRef="USD">113000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000313"
      unitRef="USD">38000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000314"
      unitRef="USD">241000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000315"
      unitRef="USD">194000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000317"
      unitRef="USD">-9000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000318"
      unitRef="USD">-1000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000319"
      unitRef="USD">12000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-1000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000323"
      unitRef="USD">595000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000325"
      unitRef="USD">595000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000327"
      unitRef="USD">-491000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000328"
      unitRef="USD">2000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-869000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-4000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000332"
      unitRef="USD">-229000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000333"
      unitRef="USD">477000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000334"
      unitRef="USD">-1760000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000335"
      unitRef="USD">1105000</us-gaap:GainLossOnInvestments>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000340"
      unitRef="USD">600000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-35000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000343"
      unitRef="USD">-43000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000344"
      unitRef="USD">-35000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000345"
      unitRef="USD">-727000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000347"
      unitRef="USD">-5038000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000348"
      unitRef="USD">-2229000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000349"
      unitRef="USD">-16311000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000350"
      unitRef="USD">-10154000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000355"
      unitRef="USD">-67000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-5038000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000358"
      unitRef="USD">-2229000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000359"
      unitRef="USD">-16311000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000360"
      unitRef="USD">-10087000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000362"
      unitRef="USD">-392000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000363"
      unitRef="USD">70000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000364"
      unitRef="USD">-1265000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000365"
      unitRef="USD">-903000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact000367"
      unitRef="USD">-4646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000368"
      unitRef="USD">-2299000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000369"
      unitRef="USD">-15046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000370"
      unitRef="USD">-9184000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000377"
      unitRef="USDPShares">-0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000378"
      unitRef="USDPShares">-0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000379"
      unitRef="USDPShares">-1.52</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000380"
      unitRef="USDPShares">-1.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000382"
      unitRef="USDPShares">-0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000383"
      unitRef="USDPShares">-0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000384"
      unitRef="USDPShares">-1.52</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000385"
      unitRef="USDPShares">-1.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000392"
      unitRef="Shares">10042518</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">9092518</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000394"
      unitRef="Shares">9913031</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000395"
      unitRef="Shares">8957482</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-07-012026-09-30"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">10042518</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000398"
      unitRef="Shares">9092518</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">9913031</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000400"
      unitRef="Shares">8957482</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000410"
      unitRef="Shares">8092518</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000402"
      unitRef="USD">161000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">323150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000405"
      unitRef="USD">-303072000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000406"
      unitRef="USD">20239000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000407"
      unitRef="USD">12477000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000408"
      unitRef="USD">32716000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000416"
      unitRef="USD">190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000418"
      unitRef="USD">190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000420"
      unitRef="USD">190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">5000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">5000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000428"
      unitRef="USD">5000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000430"
      unitRef="USD">1000</DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary>
    <DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000432"
      unitRef="USD">2082000</DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary>
    <DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary
      contextRef="From2025-01-012025-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000434"
      unitRef="USD">2083000</DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary>
    <DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary
      contextRef="From2025-01-012025-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000435"
      unitRef="USD">331000</DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary>
    <DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000436"
      unitRef="USD">2414000</DSS:IssuanceOfCommonStockNetOfExpensesToSubsidiary>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000446"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000438"
      unitRef="USD">20000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000440"
      unitRef="USD">850000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">870000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000444"
      unitRef="USD">870000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000451"
      unitRef="USD">-9184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000452"
      unitRef="USD">-9184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000453"
      unitRef="USD">-903000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000454"
      unitRef="USD">-10087000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000464"
      unitRef="Shares">9092518</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000456"
      unitRef="USD">182000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000458"
      unitRef="USD">326277000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">-312256000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">14203000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">11905000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000462"
      unitRef="USD">26108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000476"
      unitRef="Shares">9092518</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000468"
      unitRef="USD">182000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000470"
      unitRef="USD">325987000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000471"
      unitRef="USD">-327001000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000472"
      unitRef="USD">-832000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000473"
      unitRef="USD">9547000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">8715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-01-012026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000488"
      unitRef="Shares">950000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-012026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000480"
      unitRef="USD">18000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000482"
      unitRef="USD">685000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-012026-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000484"
      unitRef="USD">703000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000486"
      unitRef="USD">703000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2026-01-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000492"
      unitRef="USD">6198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2026-01-012026-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000494"
      unitRef="USD">6198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000496"
      unitRef="USD">6198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-01-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000500"
      unitRef="USD">3571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-01-012026-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">3571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000504"
      unitRef="USD">3571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000508"
      unitRef="USD">1282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000510"
      unitRef="USD">1282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-012026-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000511"
      unitRef="USD">158000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000512"
      unitRef="USD">1440000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">-15046000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000518"
      unitRef="USD">-15046000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000519"
      unitRef="USD">-1265000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000520"
      unitRef="USD">-16311000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000530"
      unitRef="Shares">10042518</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000522"
      unitRef="USD">200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000524"
      unitRef="USD">337723000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000525"
      unitRef="USD">-342047000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-09-30_us-gaap_ParentMember"
      decimals="0"
      id="Fact000526"
      unitRef="USD">-4124000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-09-30_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">8440000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000528"
      unitRef="USD">4316000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000537"
      unitRef="USD">-16311000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000538"
      unitRef="USD">-10087000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000543"
      unitRef="USD">1912000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000544"
      unitRef="USD">2145000</us-gaap:DepreciationAndAmortization>
    <DSS:IssuanceOfCommonStockForBonus
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000547"
      unitRef="USD">870000</DSS:IssuanceOfCommonStockForBonus>
    <DSS:StockBasedPaymentsForProfessionalServicesRendered
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000550"
      unitRef="USD">190000</DSS:StockBasedPaymentsForProfessionalServicesRendered>
    <us-gaap:ShareBasedCompensation
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000552"
      unitRef="USD">1440000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000553"
      unitRef="USD">4000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000555"
      unitRef="USD">-869000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000556"
      unitRef="USD">-5000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000558"
      unitRef="USD">-444000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000559"
      unitRef="USD">1255000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000561"
      unitRef="USD">-474000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000562"
      unitRef="USD">-484000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000564"
      unitRef="USD">32000</us-gaap:AmortizationOfDebtDiscountPremium>
    <DSS:GainLossOnAllowanceForObsolescenceOfInventory
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000567"
      unitRef="USD">-81000</DSS:GainLossOnAllowanceForObsolescenceOfInventory>
    <DSS:GainLossOnAllowanceForObsolescenceOfInventory
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000568"
      unitRef="USD">49000</DSS:GainLossOnAllowanceForObsolescenceOfInventory>
    <DSS:LossOnSaleOfAssets
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000570"
      unitRef="USD">35000</DSS:LossOnSaleOfAssets>
    <DSS:LossOnSaleOfAssets
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000571"
      unitRef="USD">727000</DSS:LossOnSaleOfAssets>
    <DSS:ProvisionForLoansLosses
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000573"
      unitRef="USD">28000</DSS:ProvisionForLoansLosses>
    <DSS:ProvisionForLoansLosses
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000574"
      unitRef="USD">20000</DSS:ProvisionForLoansLosses>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000577"
      unitRef="USD">600000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000580"
      unitRef="USD">599000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000583"
      unitRef="USD">-595000</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000588"
      unitRef="USD">-1036000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000589"
      unitRef="USD">1670000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000591"
      unitRef="USD">288000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000592"
      unitRef="USD">380000</us-gaap:IncreaseDecreaseInInventories>
    <DSS:IncreaseDecreaseAssetsHeldForSale
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000595"
      unitRef="USD">38000</DSS:IncreaseDecreaseAssetsHeldForSale>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000597"
      unitRef="USD">-305000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000598"
      unitRef="USD">-381000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInTradingSecurities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000600"
      unitRef="USD">-3124000</us-gaap:IncreaseDecreaseInTradingSecurities>
    <us-gaap:IncreaseDecreaseInTradingSecurities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000601"
      unitRef="USD">-644000</us-gaap:IncreaseDecreaseInTradingSecurities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000603"
      unitRef="USD">-10000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000604"
      unitRef="USD">1113000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000609"
      unitRef="USD">864000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000610"
      unitRef="USD">315000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000612"
      unitRef="USD">966000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000613"
      unitRef="USD">326000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000615"
      unitRef="USD">-471000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000616"
      unitRef="USD">-463000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000618"
      unitRef="USD">1901000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000619"
      unitRef="USD">1408000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000621"
      unitRef="USD">62000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000624"
      unitRef="USD">-3487000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000625"
      unitRef="USD">-6932000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000630"
      unitRef="USD">269000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000631"
      unitRef="USD">226000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000633"
      unitRef="USD">350000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <DSS:PurchaseOfConvertibleBondRelatedParty
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000636"
      unitRef="USD">2450000</DSS:PurchaseOfConvertibleBondRelatedParty>
    <DSS:ProceedFromSaleOfRealEstate
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000640"
      unitRef="USD">9023000</DSS:ProceedFromSaleOfRealEstate>
    <DSS:ProceedsFromSaleOfInvestmentRelatedParty
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000643"
      unitRef="USD">2414000</DSS:ProceedsFromSaleOfInvestmentRelatedParty>
    <DSS:IssuanceOfNewNotesReceivableNetOriginationFees
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000645"
      unitRef="USD">83000</DSS:IssuanceOfNewNotesReceivableNetOriginationFees>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000648"
      unitRef="USD">27000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000649"
      unitRef="USD">225000</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000651"
      unitRef="USD">-2425000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000652"
      unitRef="USD">11436000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000657"
      unitRef="USD">850000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000658"
      unitRef="USD">11492000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000660"
      unitRef="USD">73000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000661"
      unitRef="USD">3250000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000664"
      unitRef="USD">131000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfLoanCosts
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000666"
      unitRef="USD">1603000</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:PaymentsOfLoanCosts
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000667"
      unitRef="USD">943000</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000669"
      unitRef="USD">4550000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000670"
      unitRef="USD">500000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000672"
      unitRef="USD">703000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000675"
      unitRef="USD">2873000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000676"
      unitRef="USD">-8816000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact000678"
      unitRef="USD">-3039000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact000679"
      unitRef="USD">-4312000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000681"
      unitRef="USD">6314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000682"
      unitRef="USD">11431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000684"
      unitRef="USD">3275000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000685"
      unitRef="USD">7119000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000687"
      unitRef="USD">3275000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000688"
      unitRef="USD">7019000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000691"
      unitRef="USD">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000693"
      unitRef="USD">3275000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000694"
      unitRef="USD">7119000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000696">&lt;p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zg29HreWWBuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1. &lt;span id="xdx_823_zpUHHdGdVO6b"&gt;Nature of Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company, incorporated in the
state of New York in May 1984 has conducted business in the name of DSS, Inc. On September 16, 2021, the board of directors approved an
agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the
sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30,
2021. DSS, Inc. maintained the same trading symbol &#x201c;DSS&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;DSS, Inc. (together with its consolidated
subsidiaries, referred to herein as &#x201c;DSS,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; or the &#x201c;Company&#x201d;)
currently operates four (4) distinct business lines with operations and locations around the globe. These business lines are: (1) Product
Packaging, (2) Biotechnology, (3) Commercial Lending, (4) Securities and Investment Management.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Our divisions, their
business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation,
Inc. (&#x201c;Premier&#x201d;), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer
product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons,
mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in
Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies
in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention,
inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent
medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as
tuberculosis and influenza. (3) Our Commercial Lending business division, driven by American Pacific Financial (&#x201c;APF&#x201d;),
provides financing solutions including commercial business lines of credit, land development financing, inventory financing,
equipment financing, and third-party loan servicing (4) Securities and Investment Management was established to develop and/or
acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers,
and mutual funds management. Also in this segment is the Company&#x2019;s real estate investment trusts (&#x201c;REIT&#x201d;),
organized under our American Medical REIT, Inc. (&#x201c;AMRE&#x201d;) and for the purposes of acquiring hospitals and other acute or
post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing
each property to a single operator under a triple-net lease. The REIT was formed to originate, acquire, and lease a credit-centric
portfolio of licensed medical real estate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0"&gt;On June
21, 2025, Impact BioMedical Inc. (&#x201c;Impact&#x201d; or the &#x201c;Company&#x201d;), Zoar Limited (formerly known as Dr Ashleys Limited),
a Cayman Islands exempted company limited by shares (&#x201c;Zoar&#x201d; or &#x201c;PubCo&#x201d;), Dr Ashleys Nevada Sub, Inc., a Nevada
corporation and wholly-owned subsidiary of PubCo (&#x201c;Merger Sub&#x201d;), Zoar Labs Limited (formerly known as Dr Ashleys Bio Labs
Limited), a Cayman Islands exempted company limited by shares (&#x201c;Zoar Labs&#x201d;), and Kanans Visvanats (a.k.a. Kannan Vishwanatth),
solely in his capacity as the sole shareholder of Zoar Labs (the &#x201c;Zoar Labs Shareholder&#x201d;), entered into a Merger and Share
Exchange Agreement (as subsequently amended, the &#x201c;Merger Agreement&#x201d;). Pursuant to the Merger Agreement, and subject to its
terms and conditions, (i) Merger Sub will merge with and into Impact, with Impact continuing as the surviving entity (the &#x201c;Merger&#x201d;),
and (ii) simultaneously with or immediately following the Merger, PubCo will acquire all issued and outstanding ordinary shares of Zoar
Labs from the Zoar Labs Shareholder (the &#x201c;Share Exchange&#x201d;). On October 23, 2026, the U.S. Securities and Exchange Commission
(&#x201c;SEC&#x201d;) declared effective PubCo&#x2019;s Registration Statement on Form F-4 relating to the proposed business combination.
The transaction remains subject to certain closing conditions, including required stockholder and regulatory approvals and approval for
listing PubCo&#x2019;s ordinary shares on the NYSE American. The parties currently anticipate completing the transaction during the fourth
quarter of 2026, subject to satisfaction or waiver of the remaining closing conditions. There can be no assurance that the transaction
will be completed within the anticipated timeframe.&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000698">&lt;p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zPU6RiPc1Lw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_82F_zqPTkZkZlRW5"&gt;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z79j8FFpcWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_zmyP3dDkxA0b"&gt;Basis of Presentation&lt;/span&gt; -&lt;/i&gt;&lt;/b&gt;
The accompanying condensed unaudited consolidated financial statements contain all adjustments (consisting of normal recurring adjustments,
unless otherwise indicated) necessary to present fairly our consolidated financial position as of September 30, 2026 and December 31,
2025, and the results of our consolidated operations for the interim periods presented in conformity with accounting principles generally
accepted in the United States of America (&#x201c;US GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;), the instructions to Form 10-Q and Article 10 of Regulation S-X. We follow the same accounting policies
when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated
financial statements and the notes included in our latest annual report on Form 10-K, for the fiscal year ended December 31, 2025 (&#x201c;Form
10-K&#x201d;), and our other reports on file with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zemKTD4bmxDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_862_zkqDD59PE9Oa"&gt;Principles of Consolidation&lt;/span&gt;
- &lt;/i&gt;&lt;/b&gt;The consolidated financial statements include the accounts of DSS, Inc. and its subsidiaries. All significant intercompany balances
and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zMYPdms7KV31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_z80Xf3QxYOLk"&gt;Use of Estimates&lt;/span&gt; - &lt;/i&gt;&lt;/b&gt;The
preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires
the Company to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying
notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company evaluates its estimates, including
those related to the accounts receivable, convertible notes receivable, inventory, fair values of investments, intangible assets and goodwill,
useful lives of intangible assets and property and equipment, fair values of options and warrants to purchase the Company&#x2019;s common
stock, preferred stock, deferred revenue and income taxes, among others. The Company bases its estimates on historical experience and
on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying
values of assets and liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zcq15uONi6Qb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zfZ9ysDSgin2"&gt;Cash Equivalents&lt;/span&gt; &#x2013;&lt;/i&gt;&lt;/b&gt;
All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. Amounts
included in cash equivalents in the accompanying consolidated balance sheets are money market funds whose adjusted costs approximate fair
value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ReceivablesPolicyTextBlock_z18Bm1Nd388c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_z27muKqP6Acd"&gt;Accounts Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally
does not require collateral. Payment terms are generally 30 days but up to net 120 for certain customers. The Company carries its trade
accounts receivable at invoice amounts and its rent receivables at contract amounts, less an allowance for credit losses. On a periodic
basis, the Company evaluates its accounts receivable and establishes an allowance for credit losses based upon management&#x2019;s estimates
that include a review of the history of past write-offs and collections and an analysis of current credit conditions. In estimating expected
losses in the accounts receivable portfolio, customer-specific financial data and macro-economic assumptions are utilized to project losses
over a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future
cash flows, collateral values and other factors used to determine the customers&#x2019; abilities to pay.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Accounts receivable, net at September
30, 2026, and December 31, 2025, was $&lt;span id="xdx_90C_eus-gaap--AccountsReceivableNet_iI_c20260930_zFfWP20QTxV8" title="Accounts receivable, net"&gt;1,218,000&lt;/span&gt;, and $&lt;span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20251231_z7d4H2KoiGjc" title="Accounts receivable, net"&gt;2,254,000&lt;/span&gt;, respectively. At September 30, 2026, December 31, 2025, the Company established
a reserve for credit losses of approximately $&lt;span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20260930_zOUlxr9zPMib" title="Reserve for credit losses"&gt;974,000&lt;/span&gt;, and $&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20251231_zSHiyxyu8Opb" title="Reserve for credit losses"&gt;1,014,000&lt;/span&gt;, respectively. The Company does not accrue interest on past due
accounts receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zH33xsSUkx71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_861_zlbzXbzLi5hf"&gt;Concentration of Credit
Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company
believes it is not exposed to any significant credit risk because of any non-performance by the financial institutions. As of September
30, 2026, one customer accounted for approximately &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgGwQYYT16mh" title="Concentration of credit risk percentage"&gt;28&lt;/span&gt;% of our consolidated revenue and two customers accounted for approximately &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zM3EVaNwNMkf" title="Concentration of credit risk percentage"&gt;14&lt;/span&gt;%,
and &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVIn90Mi9RSd" title="Concentration of credit risk percentage"&gt;14&lt;/span&gt;% of our trade accounts receivable balance. As of September 30, 2025, one customer accounted for approximately &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUJ7JF9us3H9" title="Concentration of credit risk percentage"&gt;25&lt;/span&gt;% of our consolidated
revenue and two customers accounted for approximately &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF5OhVb7alEd" title="Concentration of credit risk percentage"&gt;36&lt;/span&gt;%, and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXJbPjr4iX3h" title="Concentration of credit risk percentage"&gt;10&lt;/span&gt;% of our trade accounts receivable balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, five
customers accounted for &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zz0j3yRN8D1"&gt;19&lt;/span&gt;%,
&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQ9T6xDAZa4a"&gt;18&lt;/span&gt;%,
&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbQzWmGVCYNg"&gt;13&lt;/span&gt;%,
&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z753kMts0Jel"&gt;12&lt;/span&gt;%
and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerFiveMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfz4kd32pyT5"&gt;11&lt;/span&gt;%
of our trade accounts receivable balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--NotesReceivableUnearnedInterestAndRelatedRecognitionPolicyTextBlock_zg61RsELPAg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86C_z7U1FwcSM3h6"&gt;Notes receivable, unearned
interest, and related recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - The Company records all future payments of principal and interest on notes as notes receivable,
which are then offset by the amount of any related unearned interest income. For financial statement purposes, the Company reports the
net investment in the notes receivable on the consolidated balance sheet as current or long-term based on the maturity date of the underlying
notes. Such net investment is comprised of the amount advanced on the loans, adjusting for net deferred loan fees or costs incurred at
origination, amounts allocated to warrants received upon origination, and any payments received in advance. The unearned interest is recognized
over the term of the notes and the income portion of each note payment is calculated so as to generate a constant rate of return on the
net balance outstanding. Net deferred loan fees or costs, together with discounts recognized in connection with warrants acquired at origination,
are accreted as an adjustment to yield over the term of the loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--AllowanceForLoansAndLeaseLossesPolicyTextBlock_zMuEuPoPucp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_866_zKO3Ey4hO4ge"&gt;Allowance
For Loans Losses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - ASC Topic 326 which requires an allowance for credit losses to be deducted from the amortized cost
basis of financial assets to present the net carrying value at the amount that is expected to be collected over the contractual term
of the asset considering relevant information about past events, current conditions, and reasonable and supportable forecasts that
affect the collectability of the reported amount. In estimating expected losses in the loan portfolio, borrower-specific financial
data and macro-economic assumptions are utilized to project losses over a reasonable and supportable forecast period. Assumptions
and judgment are applied to measure amounts and timing of expected future cash flows, collateral values and other factors used to
determine the borrowers&#x2019; abilities to repay obligations. After the forecast period, the Company utilizes longer-term
historical loss experience to estimate losses over the remaining contractual life of the loans. At September 30, 2026 and December
31, 2025, the Company established a reserve for credit losses of approximately $&lt;span id="xdx_904_eus-gaap--AllowanceForLoanAndLeaseLossesRealEstate_iI_c20260930_zFCDGcHYqzl9" title="Allowance for loans losses"&gt;7,451,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AllowanceForLoanAndLeaseLossesRealEstate_iI_c20251231_z4JWW8djSfT5" title="Allowance for loans losses"&gt;7,478,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--InvestmentPolicyTextBlock_zhD4UHuIZrCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_869_zoH3S3ycKEph"&gt;Investments&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&#x2013;
Investments in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair
value with unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment
is recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings. For equity method investments, the investments are initially recorded at cost and
subsequently adjusted for the Company&#x2019;s proportionate share of the investee&#x2019;s earnings or losses and other comprehensive income
and reduced by any distributions received. Where an investee&#x2019;s financial information is not available in time for the Company&#x2019;s
reporting deadline, the Company records its share of the investee&#x2019;s results on a lag using the most recent financial information
available, and records adjustment as needed when more current investee financial information becomes available. The Company also regularly
reviews its equity method investments to determine whether there is a decline in fair value below book value. If there is a decline that
is other-than-temporary, the investment is written down to fair value. See Note 10 for further discussion on investments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3IAcdUpfUQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86E_zqgno6e3C35c"&gt;Fair Value of Financial
Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; - &lt;/i&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) establishes a three-tier fair value hierarchy
which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#x25cf; Level 1, defined as observable inputs such
as quoted prices for identical instruments in active markets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#x25cf; Level 2, defined as inputs other than quoted
prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets
or quoted prices for identical or similar instruments in markets that are not active; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#x25cf; Level 3, defined as unobservable inputs in
which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation
techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The carrying amounts reported
in the consolidated balance sheet for cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable and accrued expenses
approximate their fair values due primarily to the short-term nature of these instruments. The carrying amounts of notes receivable, notes
payable and long-term debt generally approximate their fair values based on the stated or discounted interest rates, contractual terms
and expected timing of cash flows. Investments are accounted for in accordance with the applicable U.S. GAAP guidance based on the nature
and classification of the investment. Investments for which fair value is not readily determined are measured in accordance with the applicable
measurement alternative, when eligible. Financial instruments measured at fair value are classified within the fair value hierarchy based
on the observability of the inputs used in the valuation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zntvZnoi49c5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_861_zZm1kqI7dCtl"&gt;Inventory&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&#x2013;
Inventories consist primarily of paper, pre-printed security paper, paperboard, fully prepared packaging, air filtration systems,
and health and beauty products which and are stated at the lower of cost or net realizable value on the first-in, first-out
(&#x201c;FIFO&#x201d;) method. Packaging work-in-process and finished goods included the cost of materials, direct labor and overhead.
At the closing of each reporting period, the Company evaluates its inventory in order to adjust the inventory balance for obsolete
and slow-moving items. An allowance for obsolescence of approximately $&lt;span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_c20260930_zQLJ88qOF2x5" title="Inventory adjustments"&gt;134,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--InventoryAdjustments_iI_c20251231_z1CGcr21Ky0b" title="Inventory, allowance for obsolescence"&gt;53,000&lt;/span&gt;
associated with the inventory at our Premier Packaging subsidiary for September 30, 2026, and December 31, 2025, respectively.
Write-downs and write-offs are charged to cost of revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--RealEstatePolicyTextBlock_zYnQMDVjgoR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_z9FHWVZSV2m3"&gt;Investments in real estate,
net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; &#x2013; Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition.
Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related to finding, analyzing
and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible
and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market
leases, in-place lease value (if applicable). Acquisition date fair values of assets and assumed liabilities are determined based on replacement
costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate
discount and/or capitalization rates and available market information. Depreciation and amortization is computed using the straight-line
method over the estimated useful lives of the assets. Depreciation, amortization, cost to maintain and secure the buildings as well as
interest incurred on the loans to procure the real estate are included in Cost of revenue on the accompanying Condensed consolidated statement
of operations. The Company&#x2019;s policy is to obtain an independent third-party valuation for each major project in the United States
as part of our assessment of identifying potential triggering events for impairment. Management may use the market comparison method to
value the investments. In addition to the annual assessment of potential triggering events in accordance with ASC 360 &#x2013; Property
Plant and Equipment (&#x201c;ASC 360&#x201d;), the Company applies a fair value-based impairment test to the net book value assets on an
annual basis and on an interim basis if certain events or circumstances indicate that an impairment loss may have occurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--ConvertibleBondInvestmentPolicyTextBlock_zR7jNENWZKw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zRRF4kQ3m7Ea"&gt;Convertible bond investment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The Company accounts for its convertible bond investment as a financial asset measured at fair value. The Company has elected the fair
value option under ASC 825, Financial Instruments, and, accordingly, changes in the fair value of the investment are recognized in earnings
in the period of change. Interest income is recognized when earned in accordance with the contractual terms of the bond. Fair value is
determined in accordance with ASC 820, Fair Value Measurement, using valuation techniques appropriate for the instrument and available
market information. The valuation considers, among other factors, the stated interest rate, maturity date, conversion price, market price
of the underlying equity securities, foreign currency exchange rates, issuer credit risk, expected term, volatility, liquidity, and conversion
economics. The convertible bond investment is classified as a Level 3 financial asset because there is no quoted price in an active market
for the identical bond and the valuation requires significant unobservable inputs, including issuer credit risk, expected term, volatility,
liquidity, conversion probability, and conversion economics.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zpIPWkPVzJj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zaOoaV9Qkiv8"&gt;Intangible Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and
cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired
intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually or more frequently whenever
events or changes in circumstances indicate that the carrying amounts of those assets are below their estimated fair values. Impairment
is tested under ASC 350. No circumstances or events have occurred since the most recent analysis that would indicate the need for an impairment
is needed for the nine months ended September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zRBA8Jb0PKs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_866_zSn9jRugIKoi"&gt;Goodwill&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&#x2013;
Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed
in a business combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual
tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides
an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a
determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after completing
the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. The Company may also elect to perform a quantitative test instead of a qualitative test
for any or all of our reporting units. The test compares the fair value of an entity&#x2019;s reporting units to the carrying value of
those reporting units. This quantitative test requires various judgments and estimates. The Company estimates the fair value of the reporting
unit using a market approach in combination with a discounted operating cash flow approach. Impairment of goodwill is measured as the
excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting
unit. The Company performed its annual goodwill impairment test as of December 31, 2025, and no impairment was deemed necessary for the
goodwill associated with Premier Packaging Company of approximately $&lt;span id="xdx_90D_eus-gaap--Goodwill_iI_c20251231__dei--LegalEntityAxis__custom--ImpactBioMedicalMember_z9KYHpmwS1y1" title="Goodwill"&gt;1,769,000&lt;/span&gt;. No circumstances or events have occurred since the most
recent analysis that would indicate the need for an impairment is needed for the nine months ended September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zY0CbuMwgARf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_zK9EQiR8iTK4"&gt;Impairment of Long-Lived
Assets and Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - The Company monitors the carrying value of long-lived assets for potential impairment and tests the recoverability
of such assets whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. If a change in circumstance
occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted
expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine
whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values
are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset
or asset group to its carrying value. No circumstances or events have occurred since the most recent analysis that would indicate the
need for an impairment is needed for the nine months ended September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--ConvertiblePromissoryNotePolicyTextBlock_zQ0YedYkpoK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_zt6w0UVj3n9a"&gt;Convertible Promissory Note&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The Company accounts for convertible promissory notes in accordance with ASU 2020-06 and evaluates embedded and freestanding features
under ASC 815. Convertible notes are initially recorded at principal amount, net of any original issue discount, debt issuance costs,
and discounts arising from the allocation of proceeds to detachable warrants or other freestanding instruments. When a financing transaction
includes multiple instruments, the Company allocates proceeds based on the relative fair values of the instruments, or, when required,
first records liability-classified instruments at fair value with residual proceeds allocated to the remaining instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company evaluates conversion
options, redemption provisions, down-round or anti-dilution features, most-favored-nation provisions, default rights, warrants, and other
terms to determine whether separate accounting is required. Embedded derivatives or liability-classified instruments are measured at fair
value, with changes in fair value recognized in earnings. Debt discounts, original issue discount, and issuance costs are amortized to
interest expense using the effective interest method over the contractual term. Convertible notes are classified as current or noncurrent
based on contractual maturity and settlement provisions. For diluted earnings per share, the Company applies the if-converted method in
accordance with ASC 260.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--BusinessCombinationsPolicy_zOrW1WThyK14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zYtIwTVXoBQc"&gt;Business Combinations and
Acquisitions&lt;/span&gt; - &lt;/i&gt;&lt;/b&gt;Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations.
Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition and
all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill.
If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded.
The application of business combination accounting requires the use of significant estimates and assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Acquisition of assets are recorded
at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are expensed as incurred.
This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that
requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures
and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets
and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to
those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zM5EnN4uRjC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_zcLNYV1XYHBi"&gt;Loss Per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share reflect the actual weighted average
of shares issued and outstanding during the period. Diluted (loss) earnings per share are computed including the number of additional
shares from outstanding warrants, stock options and preferred stock that would have been outstanding if dilutive potential shares had
been issued and is calculated utilizing the treasury stock method. In a loss period, the calculation for basic and diluted (loss) earnings
per share is the same, as the impact of potential common shares is anti-dilutive. For the nine months ended September 30, 2026 and 2025,
there were approximately &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930_zxyOGqO5M7R8" title="Antidilutive securities"&gt;36,444,000&lt;/span&gt; and &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zyjqI24WbYza" title="Antidilutive securities"&gt;0&lt;/span&gt; potential dilutive instruments issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zj1a6eCFHDdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zsnfwc1criq8"&gt;Share-Based Payments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- Compensation cost for stock awards are measured at fair value and the Company recognizes compensation expense over the service period
for which awards are expected to vest. For stock options and similar awards, fair value is estimated on the grant date using an appropriate
valuation model, such as the Black-Scholes option-pricing model, which requires management to make assumptions regarding expected volatility,
expected term, risk-free interest rate, expected dividends, and forfeitures. For restricted stock, restricted stock units, and common
stock awards, fair value is generally based on the market price of the Company&#x2019;s common stock on the grant date. For equity instruments
issued to consultants and vendors in exchange for goods and services the Company determines the measurement date for the fair value of
the equity instruments issued at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached
or (ii) the date at which the consultant or vendor&#x2019;s performance is complete. In the case of equity instruments issued to consultants,
the fair value of the equity instrument is recognized over the term of the consulting agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zAAxUqd7l134" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_861_zH5EiJAg1nq5"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - The
Company recognizes estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future
tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income items is based on enacted tax laws
including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.
We recognize penalties and accrued interest related to unrecognized tax benefits in income tax expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--GoingConcernPolicyTextBlock_zXjoorXPbaX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zbQwrTuF7oj9"&gt;Going
Concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; &#x2013; The accompanying consolidated financial statements have been prepared assuming that the Company will
continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in
the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and
classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. While the
Company has approximately $&lt;span id="xdx_90B_eus-gaap--Cash_iI_pn5n6_c20260930_z1vZkn4e0FJ2" title="Cash"&gt;3.3&lt;/span&gt; million in
cash, the Company has incurred operating losses as well as negative cash flows from operating and investing activities over the past
two years and as of September 30, 2026 has negative working capital of approximately $&lt;span id="xdx_905_ecustom--WorkingCapital_iI_pn5n6_c20260930_zS26XCi6JJW4" title="Working capital"&gt;42.8 &lt;/span&gt;million.
These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year of the date
that the financial statements are issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Aside from its $&lt;span id="xdx_906_eus-gaap--Cash_iI_pn5n6_c20260930_zCgn0sV4PYPa" title="Cash"&gt;3.3&lt;/span&gt; million in
cash as of September 30, 2026, to continue as a going concern, the Company can generate operating cash through the sale of its $&lt;span id="xdx_908_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20260101__20260930_zAxLIUy6TdYg" title="Sale of marketable securities"&gt;0.6&lt;/span&gt; million
of Marketable Securities. To continue as a going concern, historically, the Company has been able to obtain equity and/or debt-based financing
to meet its working capital needs. In addition, the Company has taken steps, and will continue to take measures, to materially reduce
the expenses and cash burn at all corporate and business line levels. Management believes that the combination of cash on hand, potential
proceeds from the sale of marketable securities and real estate, additional financing, and reductions in operating expenditures will provide
the Company with sufficient liquidity to fund its operations and meet its obligations as they become due. However, there can be no assurance
that the Company will be successful in completing asset sales, obtaining additional financing on acceptable terms, or achieving the anticipated
reductions in operating expenditures&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/b&gt; Accordingly, management&#x2019;s plans may not be sufficient to alleviate the substantial
doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--RelatedPartyTransactionsPolicyTextBlock_zhfEN2oOjD9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86C_z92YHKfV02L"&gt;Related Party Transactions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- Transactions with affiliates and other parties that meet the definition of a related party under ASC 850, Related Party Disclosures
are reflected in the accompanying condensed consolidated financial statements. All related-party balances are recorded at the exchange
amounts established and agreed to by the parties. All material transaction not in the normal course of business operations are approved
by the Audit Committee of the Board of Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zdZUFlcXTs58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zrkXyRD4CJfh"&gt;Recently Issued Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&#x2014; The Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to
the treatment and recording of certain accounting transactions. There are several new accounting pronouncements issued by FASB which are
not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In December 2023, the FASB issued
ASU 2023-09, &#x201c;Improvements to Income Tax Disclosures&#x201d; which is intended to simplify various aspects related to accounting
for income taxes and enhance the transparency of income tax disclosures by requiring additional information regarding income tax rate
reconciliations and income taxes paid, including disaggregation by jurisdiction. ASU 2023-09 removes certain exceptions to the general
principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The amendments in ASU 2023-09
are effective for public business entities for fiscal years beginning after December 15, 2024, including interim periods therein. Early
adoption of the standard is permitted, including adoption in interim or annual periods. The Company adopted the amendments for the year
ended December 31, 2025. The adoption did not have a material impact on the Company&#x2019;s consolidated financial position, results of operations,
or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In November 2024, the FASB issued
ASU No. 2024-03 (&#x201c;ASU 2024-03&#x201d;), &lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disaggregation of Income Statement Expenses (&#x201c;DISE&#x201d;)&lt;/i&gt;. ASU 2024-03 requires
disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03 does not change the expense captions an
entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories
in disclosures within the footnotes to the financial statements. As revised by ASU No. 2025-01, Income Statement&#x2014;Reporting Comprehensive
Income&#x2014;Expense Disaggregation Disclosures, the provisions of ASU 2024-03 are effective for fiscal years beginning after December
15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. With the exception
of expanding disclosures to include more granular income statement expense categories, we do not expect the adoption of ASU 2024-03 to
have a material effect on our consolidated financial statements taken as a whole.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In November 2024, the FASB issued
ASU 2024-04 (&#x201c;ASU 2024-04&#x201d;), &lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of
Convertible Debt Instruments&lt;/i&gt;, which clarifies the requirements for determining whether certain settlements of convertible debt instruments
should be accounted for as induced conversions or as extinguishments. The amendments in ASU 2024-04 are effective for annual reporting
periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted
for entities that have adopted ASU 2020-06. The Company adopted the amendments as effective January 1, 2026. The adoption of ASU 2024-04
did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In December 2025, the
Financial Accounting Standards Board issued Accounting Standards Update No. 2025-11, &lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interim
Reporting (Topic 270)&lt;/i&gt;. The amendments are intended to improve interim financial reporting disclosures and clarify the
application of Topic 270. The amendments in ASU 2025-11 are effective for annual reporting periods beginning January 1, 2028, and
interim reporting periods within those annual reporting periods. The Company is currently evaluating the provisions of ASU 2025-11,
including the timing of adoption and the potential impact on its interim financial statement presentation and related disclosures.
The Company does not currently expect the adoption of ASU 2025-11 to have a material impact on its consolidated financial position,
results of operations, or cash flows.&lt;/p&gt;

&lt;p id="xdx_85B_z1aUmiDpLir9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000700">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z79j8FFpcWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_zmyP3dDkxA0b"&gt;Basis of Presentation&lt;/span&gt; -&lt;/i&gt;&lt;/b&gt;
The accompanying condensed unaudited consolidated financial statements contain all adjustments (consisting of normal recurring adjustments,
unless otherwise indicated) necessary to present fairly our consolidated financial position as of September 30, 2026 and December 31,
2025, and the results of our consolidated operations for the interim periods presented in conformity with accounting principles generally
accepted in the United States of America (&#x201c;US GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange
Commission (&#x201c;SEC&#x201d;), the instructions to Form 10-Q and Article 10 of Regulation S-X. We follow the same accounting policies
when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated
financial statements and the notes included in our latest annual report on Form 10-K, for the fiscal year ended December 31, 2025 (&#x201c;Form
10-K&#x201d;), and our other reports on file with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000702">&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zemKTD4bmxDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_862_zkqDD59PE9Oa"&gt;Principles of Consolidation&lt;/span&gt;
- &lt;/i&gt;&lt;/b&gt;The consolidated financial statements include the accounts of DSS, Inc. and its subsidiaries. All significant intercompany balances
and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2026-01-01to2026-09-30" id="Fact000704">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zMYPdms7KV31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_z80Xf3QxYOLk"&gt;Use of Estimates&lt;/span&gt; - &lt;/i&gt;&lt;/b&gt;The
preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires
the Company to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying
notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company evaluates its estimates, including
those related to the accounts receivable, convertible notes receivable, inventory, fair values of investments, intangible assets and goodwill,
useful lives of intangible assets and property and equipment, fair values of options and warrants to purchase the Company&#x2019;s common
stock, preferred stock, deferred revenue and income taxes, among others. The Company bases its estimates on historical experience and
on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying
values of assets and liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000706">&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zcq15uONi6Qb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zfZ9ysDSgin2"&gt;Cash Equivalents&lt;/span&gt; &#x2013;&lt;/i&gt;&lt;/b&gt;
All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. Amounts
included in cash equivalents in the accompanying consolidated balance sheets are money market funds whose adjusted costs approximate fair
value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000708">&lt;p id="xdx_846_eus-gaap--ReceivablesPolicyTextBlock_z18Bm1Nd388c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_z27muKqP6Acd"&gt;Accounts Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally
does not require collateral. Payment terms are generally 30 days but up to net 120 for certain customers. The Company carries its trade
accounts receivable at invoice amounts and its rent receivables at contract amounts, less an allowance for credit losses. On a periodic
basis, the Company evaluates its accounts receivable and establishes an allowance for credit losses based upon management&#x2019;s estimates
that include a review of the history of past write-offs and collections and an analysis of current credit conditions. In estimating expected
losses in the accounts receivable portfolio, customer-specific financial data and macro-economic assumptions are utilized to project losses
over a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future
cash flows, collateral values and other factors used to determine the customers&#x2019; abilities to pay.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Accounts receivable, net at September
30, 2026, and December 31, 2025, was $&lt;span id="xdx_90C_eus-gaap--AccountsReceivableNet_iI_c20260930_zFfWP20QTxV8" title="Accounts receivable, net"&gt;1,218,000&lt;/span&gt;, and $&lt;span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20251231_z7d4H2KoiGjc" title="Accounts receivable, net"&gt;2,254,000&lt;/span&gt;, respectively. At September 30, 2026, December 31, 2025, the Company established
a reserve for credit losses of approximately $&lt;span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20260930_zOUlxr9zPMib" title="Reserve for credit losses"&gt;974,000&lt;/span&gt;, and $&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20251231_zSHiyxyu8Opb" title="Reserve for credit losses"&gt;1,014,000&lt;/span&gt;, respectively. The Company does not accrue interest on past due
accounts receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000710"
      unitRef="USD">1218000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000712"
      unitRef="USD">2254000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000714"
      unitRef="USD">974000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000716"
      unitRef="USD">1014000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2026-01-01to2026-09-30" id="Fact000718">&lt;p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zH33xsSUkx71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_861_zlbzXbzLi5hf"&gt;Concentration of Credit
Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company
believes it is not exposed to any significant credit risk because of any non-performance by the financial institutions. As of September
30, 2026, one customer accounted for approximately &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgGwQYYT16mh" title="Concentration of credit risk percentage"&gt;28&lt;/span&gt;% of our consolidated revenue and two customers accounted for approximately &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zM3EVaNwNMkf" title="Concentration of credit risk percentage"&gt;14&lt;/span&gt;%,
and &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20260101__20260930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVIn90Mi9RSd" title="Concentration of credit risk percentage"&gt;14&lt;/span&gt;% of our trade accounts receivable balance. As of September 30, 2025, one customer accounted for approximately &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUJ7JF9us3H9" title="Concentration of credit risk percentage"&gt;25&lt;/span&gt;% of our consolidated
revenue and two customers accounted for approximately &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF5OhVb7alEd" title="Concentration of credit risk percentage"&gt;36&lt;/span&gt;%, and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXJbPjr4iX3h" title="Concentration of credit risk percentage"&gt;10&lt;/span&gt;% of our trade accounts receivable balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, five
customers accounted for &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zz0j3yRN8D1"&gt;19&lt;/span&gt;%,
&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQ9T6xDAZa4a"&gt;18&lt;/span&gt;%,
&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbQzWmGVCYNg"&gt;13&lt;/span&gt;%,
&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z753kMts0Jel"&gt;12&lt;/span&gt;%
and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20251231__srt--MajorCustomersAxis__custom--CustomerFiveMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfz4kd32pyT5"&gt;11&lt;/span&gt;%
of our trade accounts receivable balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-09-30_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000720"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-09-30_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000722"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2026-01-012026-09-30_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000724"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000726"
      unitRef="Pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000728"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000730"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000731"
      unitRef="Pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000732"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000733"
      unitRef="Pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-12-31_custom_CustomerFourMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000734"
      unitRef="Pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-12-31_custom_CustomerFiveMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000735"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <DSS:NotesReceivableUnearnedInterestAndRelatedRecognitionPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000737">&lt;p id="xdx_844_ecustom--NotesReceivableUnearnedInterestAndRelatedRecognitionPolicyTextBlock_zg61RsELPAg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86C_z7U1FwcSM3h6"&gt;Notes receivable, unearned
interest, and related recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - The Company records all future payments of principal and interest on notes as notes receivable,
which are then offset by the amount of any related unearned interest income. For financial statement purposes, the Company reports the
net investment in the notes receivable on the consolidated balance sheet as current or long-term based on the maturity date of the underlying
notes. Such net investment is comprised of the amount advanced on the loans, adjusting for net deferred loan fees or costs incurred at
origination, amounts allocated to warrants received upon origination, and any payments received in advance. The unearned interest is recognized
over the term of the notes and the income portion of each note payment is calculated so as to generate a constant rate of return on the
net balance outstanding. Net deferred loan fees or costs, together with discounts recognized in connection with warrants acquired at origination,
are accreted as an adjustment to yield over the term of the loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</DSS:NotesReceivableUnearnedInterestAndRelatedRecognitionPolicyTextBlock>
    <DSS:AllowanceForLoansAndLeaseLossesPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000739">&lt;p id="xdx_846_ecustom--AllowanceForLoansAndLeaseLossesPolicyTextBlock_zMuEuPoPucp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_866_zKO3Ey4hO4ge"&gt;Allowance
For Loans Losses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - ASC Topic 326 which requires an allowance for credit losses to be deducted from the amortized cost
basis of financial assets to present the net carrying value at the amount that is expected to be collected over the contractual term
of the asset considering relevant information about past events, current conditions, and reasonable and supportable forecasts that
affect the collectability of the reported amount. In estimating expected losses in the loan portfolio, borrower-specific financial
data and macro-economic assumptions are utilized to project losses over a reasonable and supportable forecast period. Assumptions
and judgment are applied to measure amounts and timing of expected future cash flows, collateral values and other factors used to
determine the borrowers&#x2019; abilities to repay obligations. After the forecast period, the Company utilizes longer-term
historical loss experience to estimate losses over the remaining contractual life of the loans. At September 30, 2026 and December
31, 2025, the Company established a reserve for credit losses of approximately $&lt;span id="xdx_904_eus-gaap--AllowanceForLoanAndLeaseLossesRealEstate_iI_c20260930_zFCDGcHYqzl9" title="Allowance for loans losses"&gt;7,451,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AllowanceForLoanAndLeaseLossesRealEstate_iI_c20251231_z4JWW8djSfT5" title="Allowance for loans losses"&gt;7,478,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</DSS:AllowanceForLoansAndLeaseLossesPolicyTextBlock>
    <us-gaap:AllowanceForLoanAndLeaseLossesRealEstate
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000741"
      unitRef="USD">7451000</us-gaap:AllowanceForLoanAndLeaseLossesRealEstate>
    <us-gaap:AllowanceForLoanAndLeaseLossesRealEstate
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000743"
      unitRef="USD">7478000</us-gaap:AllowanceForLoanAndLeaseLossesRealEstate>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000745">&lt;p id="xdx_844_eus-gaap--InvestmentPolicyTextBlock_zhD4UHuIZrCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_869_zoH3S3ycKEph"&gt;Investments&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&#x2013;
Investments in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair
value with unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment
is recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings. For equity method investments, the investments are initially recorded at cost and
subsequently adjusted for the Company&#x2019;s proportionate share of the investee&#x2019;s earnings or losses and other comprehensive income
and reduced by any distributions received. Where an investee&#x2019;s financial information is not available in time for the Company&#x2019;s
reporting deadline, the Company records its share of the investee&#x2019;s results on a lag using the most recent financial information
available, and records adjustment as needed when more current investee financial information becomes available. The Company also regularly
reviews its equity method investments to determine whether there is a decline in fair value below book value. If there is a decline that
is other-than-temporary, the investment is written down to fair value. See Note 10 for further discussion on investments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2026-01-01to2026-09-30" id="Fact000747">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3IAcdUpfUQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86E_zqgno6e3C35c"&gt;Fair Value of Financial
Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; - &lt;/i&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) establishes a three-tier fair value hierarchy
which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
These tiers include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#x25cf; Level 1, defined as observable inputs such
as quoted prices for identical instruments in active markets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#x25cf; Level 2, defined as inputs other than quoted
prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets
or quoted prices for identical or similar instruments in markets that are not active; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#x25cf; Level 3, defined as unobservable inputs in
which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation
techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The carrying amounts reported
in the consolidated balance sheet for cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable and accrued expenses
approximate their fair values due primarily to the short-term nature of these instruments. The carrying amounts of notes receivable, notes
payable and long-term debt generally approximate their fair values based on the stated or discounted interest rates, contractual terms
and expected timing of cash flows. Investments are accounted for in accordance with the applicable U.S. GAAP guidance based on the nature
and classification of the investment. Investments for which fair value is not readily determined are measured in accordance with the applicable
measurement alternative, when eligible. Financial instruments measured at fair value are classified within the fair value hierarchy based
on the observability of the inputs used in the valuation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000749">&lt;p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zntvZnoi49c5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_861_zZm1kqI7dCtl"&gt;Inventory&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&#x2013;
Inventories consist primarily of paper, pre-printed security paper, paperboard, fully prepared packaging, air filtration systems,
and health and beauty products which and are stated at the lower of cost or net realizable value on the first-in, first-out
(&#x201c;FIFO&#x201d;) method. Packaging work-in-process and finished goods included the cost of materials, direct labor and overhead.
At the closing of each reporting period, the Company evaluates its inventory in order to adjust the inventory balance for obsolete
and slow-moving items. An allowance for obsolescence of approximately $&lt;span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_c20260930_zQLJ88qOF2x5" title="Inventory adjustments"&gt;134,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--InventoryAdjustments_iI_c20251231_z1CGcr21Ky0b" title="Inventory, allowance for obsolescence"&gt;53,000&lt;/span&gt;
associated with the inventory at our Premier Packaging subsidiary for September 30, 2026, and December 31, 2025, respectively.
Write-downs and write-offs are charged to cost of revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000751"
      unitRef="USD">134000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000753"
      unitRef="USD">53000</us-gaap:InventoryAdjustments>
    <us-gaap:RealEstatePolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000755">&lt;p id="xdx_846_eus-gaap--RealEstatePolicyTextBlock_zYnQMDVjgoR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_z9FHWVZSV2m3"&gt;Investments in real estate,
net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; &#x2013; Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition.
Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related to finding, analyzing
and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible
and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market
leases, in-place lease value (if applicable). Acquisition date fair values of assets and assumed liabilities are determined based on replacement
costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate
discount and/or capitalization rates and available market information. Depreciation and amortization is computed using the straight-line
method over the estimated useful lives of the assets. Depreciation, amortization, cost to maintain and secure the buildings as well as
interest incurred on the loans to procure the real estate are included in Cost of revenue on the accompanying Condensed consolidated statement
of operations. The Company&#x2019;s policy is to obtain an independent third-party valuation for each major project in the United States
as part of our assessment of identifying potential triggering events for impairment. Management may use the market comparison method to
value the investments. In addition to the annual assessment of potential triggering events in accordance with ASC 360 &#x2013; Property
Plant and Equipment (&#x201c;ASC 360&#x201d;), the Company applies a fair value-based impairment test to the net book value assets on an
annual basis and on an interim basis if certain events or circumstances indicate that an impairment loss may have occurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:RealEstatePolicyTextBlock>
    <DSS:ConvertibleBondInvestmentPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000757">&lt;p id="xdx_84F_ecustom--ConvertibleBondInvestmentPolicyTextBlock_zR7jNENWZKw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zRRF4kQ3m7Ea"&gt;Convertible bond investment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The Company accounts for its convertible bond investment as a financial asset measured at fair value. The Company has elected the fair
value option under ASC 825, Financial Instruments, and, accordingly, changes in the fair value of the investment are recognized in earnings
in the period of change. Interest income is recognized when earned in accordance with the contractual terms of the bond. Fair value is
determined in accordance with ASC 820, Fair Value Measurement, using valuation techniques appropriate for the instrument and available
market information. The valuation considers, among other factors, the stated interest rate, maturity date, conversion price, market price
of the underlying equity securities, foreign currency exchange rates, issuer credit risk, expected term, volatility, liquidity, and conversion
economics. The convertible bond investment is classified as a Level 3 financial asset because there is no quoted price in an active market
for the identical bond and the valuation requires significant unobservable inputs, including issuer credit risk, expected term, volatility,
liquidity, conversion probability, and conversion economics.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</DSS:ConvertibleBondInvestmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2026-01-01to2026-09-30" id="Fact000759">&lt;p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zpIPWkPVzJj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zaOoaV9Qkiv8"&gt;Intangible Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and
cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired
intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually or more frequently whenever
events or changes in circumstances indicate that the carrying amounts of those assets are below their estimated fair values. Impairment
is tested under ASC 350. No circumstances or events have occurred since the most recent analysis that would indicate the need for an impairment
is needed for the nine months ended September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2026-01-01to2026-09-30" id="Fact000761">&lt;p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zRBA8Jb0PKs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_866_zSn9jRugIKoi"&gt;Goodwill&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&#x2013;
Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed
in a business combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual
tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides
an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a
determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after completing
the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. The Company may also elect to perform a quantitative test instead of a qualitative test
for any or all of our reporting units. The test compares the fair value of an entity&#x2019;s reporting units to the carrying value of
those reporting units. This quantitative test requires various judgments and estimates. The Company estimates the fair value of the reporting
unit using a market approach in combination with a discounted operating cash flow approach. Impairment of goodwill is measured as the
excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting
unit. The Company performed its annual goodwill impairment test as of December 31, 2025, and no impairment was deemed necessary for the
goodwill associated with Premier Packaging Company of approximately $&lt;span id="xdx_90D_eus-gaap--Goodwill_iI_c20251231__dei--LegalEntityAxis__custom--ImpactBioMedicalMember_z9KYHpmwS1y1" title="Goodwill"&gt;1,769,000&lt;/span&gt;. No circumstances or events have occurred since the most
recent analysis that would indicate the need for an impairment is needed for the nine months ended September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill
      contextRef="AsOf2025-12-31_custom_ImpactBioMedicalMember"
      decimals="0"
      id="Fact000763"
      unitRef="USD">1769000</us-gaap:Goodwill>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000765">&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zY0CbuMwgARf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_zK9EQiR8iTK4"&gt;Impairment of Long-Lived
Assets and Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - The Company monitors the carrying value of long-lived assets for potential impairment and tests the recoverability
of such assets whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. If a change in circumstance
occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted
expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine
whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values
are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset
or asset group to its carrying value. No circumstances or events have occurred since the most recent analysis that would indicate the
need for an impairment is needed for the nine months ended September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <DSS:ConvertiblePromissoryNotePolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000767">&lt;p id="xdx_84F_ecustom--ConvertiblePromissoryNotePolicyTextBlock_zQ0YedYkpoK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_zt6w0UVj3n9a"&gt;Convertible Promissory Note&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The Company accounts for convertible promissory notes in accordance with ASU 2020-06 and evaluates embedded and freestanding features
under ASC 815. Convertible notes are initially recorded at principal amount, net of any original issue discount, debt issuance costs,
and discounts arising from the allocation of proceeds to detachable warrants or other freestanding instruments. When a financing transaction
includes multiple instruments, the Company allocates proceeds based on the relative fair values of the instruments, or, when required,
first records liability-classified instruments at fair value with residual proceeds allocated to the remaining instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company evaluates conversion
options, redemption provisions, down-round or anti-dilution features, most-favored-nation provisions, default rights, warrants, and other
terms to determine whether separate accounting is required. Embedded derivatives or liability-classified instruments are measured at fair
value, with changes in fair value recognized in earnings. Debt discounts, original issue discount, and issuance costs are amortized to
interest expense using the effective interest method over the contractual term. Convertible notes are classified as current or noncurrent
based on contractual maturity and settlement provisions. For diluted earnings per share, the Company applies the if-converted method in
accordance with ASC 260.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</DSS:ConvertiblePromissoryNotePolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2026-01-01to2026-09-30" id="Fact000769">&lt;p id="xdx_84D_eus-gaap--BusinessCombinationsPolicy_zOrW1WThyK14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zYtIwTVXoBQc"&gt;Business Combinations and
Acquisitions&lt;/span&gt; - &lt;/i&gt;&lt;/b&gt;Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations.
Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition and
all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill.
If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded.
The application of business combination accounting requires the use of significant estimates and assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Acquisition of assets are recorded
at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are expensed as incurred.
This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that
requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures
and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets
and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to
those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000771">&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zM5EnN4uRjC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_zcLNYV1XYHBi"&gt;Loss Per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share reflect the actual weighted average
of shares issued and outstanding during the period. Diluted (loss) earnings per share are computed including the number of additional
shares from outstanding warrants, stock options and preferred stock that would have been outstanding if dilutive potential shares had
been issued and is calculated utilizing the treasury stock method. In a loss period, the calculation for basic and diluted (loss) earnings
per share is the same, as the impact of potential common shares is anti-dilutive. For the nine months ended September 30, 2026 and 2025,
there were approximately &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260930_zxyOGqO5M7R8" title="Antidilutive securities"&gt;36,444,000&lt;/span&gt; and &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zyjqI24WbYza" title="Antidilutive securities"&gt;0&lt;/span&gt; potential dilutive instruments issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact000773"
      unitRef="Shares">36444000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30"
      decimals="INF"
      id="Fact000775"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2026-01-01to2026-09-30" id="Fact000777">&lt;p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zj1a6eCFHDdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zsnfwc1criq8"&gt;Share-Based Payments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- Compensation cost for stock awards are measured at fair value and the Company recognizes compensation expense over the service period
for which awards are expected to vest. For stock options and similar awards, fair value is estimated on the grant date using an appropriate
valuation model, such as the Black-Scholes option-pricing model, which requires management to make assumptions regarding expected volatility,
expected term, risk-free interest rate, expected dividends, and forfeitures. For restricted stock, restricted stock units, and common
stock awards, fair value is generally based on the market price of the Company&#x2019;s common stock on the grant date. For equity instruments
issued to consultants and vendors in exchange for goods and services the Company determines the measurement date for the fair value of
the equity instruments issued at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached
or (ii) the date at which the consultant or vendor&#x2019;s performance is complete. In the case of equity instruments issued to consultants,
the fair value of the equity instrument is recognized over the term of the consulting agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000779">&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zAAxUqd7l134" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_861_zH5EiJAg1nq5"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; - The
Company recognizes estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future
tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income items is based on enacted tax laws
including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.
We recognize penalties and accrued interest related to unrecognized tax benefits in income tax expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <DSS:GoingConcernPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000781">&lt;p id="xdx_843_ecustom--GoingConcernPolicyTextBlock_zXjoorXPbaX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zbQwrTuF7oj9"&gt;Going
Concern&lt;/span&gt;&lt;/i&gt;&lt;/b&gt; &#x2013; The accompanying consolidated financial statements have been prepared assuming that the Company will
continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in
the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and
classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. While the
Company has approximately $&lt;span id="xdx_90B_eus-gaap--Cash_iI_pn5n6_c20260930_z1vZkn4e0FJ2" title="Cash"&gt;3.3&lt;/span&gt; million in
cash, the Company has incurred operating losses as well as negative cash flows from operating and investing activities over the past
two years and as of September 30, 2026 has negative working capital of approximately $&lt;span id="xdx_905_ecustom--WorkingCapital_iI_pn5n6_c20260930_zS26XCi6JJW4" title="Working capital"&gt;42.8 &lt;/span&gt;million.
These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year of the date
that the financial statements are issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Aside from its $&lt;span id="xdx_906_eus-gaap--Cash_iI_pn5n6_c20260930_zCgn0sV4PYPa" title="Cash"&gt;3.3&lt;/span&gt; million in
cash as of September 30, 2026, to continue as a going concern, the Company can generate operating cash through the sale of its $&lt;span id="xdx_908_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20260101__20260930_zAxLIUy6TdYg" title="Sale of marketable securities"&gt;0.6&lt;/span&gt; million
of Marketable Securities. To continue as a going concern, historically, the Company has been able to obtain equity and/or debt-based financing
to meet its working capital needs. In addition, the Company has taken steps, and will continue to take measures, to materially reduce
the expenses and cash burn at all corporate and business line levels. Management believes that the combination of cash on hand, potential
proceeds from the sale of marketable securities and real estate, additional financing, and reductions in operating expenditures will provide
the Company with sufficient liquidity to fund its operations and meet its obligations as they become due. However, there can be no assurance
that the Company will be successful in completing asset sales, obtaining additional financing on acceptable terms, or achieving the anticipated
reductions in operating expenditures&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/b&gt; Accordingly, management&#x2019;s plans may not be sufficient to alleviate the substantial
doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</DSS:GoingConcernPolicyTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2026-09-30"
      decimals="-5"
      id="Fact000783"
      unitRef="USD">3300000</us-gaap:Cash>
    <DSS:WorkingCapital
      contextRef="AsOf2026-09-30"
      decimals="-5"
      id="Fact000785"
      unitRef="USD">42800000</DSS:WorkingCapital>
    <us-gaap:Cash
      contextRef="AsOf2026-09-30"
      decimals="-5"
      id="Fact000787"
      unitRef="USD">3300000</us-gaap:Cash>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2026-01-01to2026-09-30"
      decimals="-5"
      id="Fact000789"
      unitRef="USD">600000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <DSS:RelatedPartyTransactionsPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000791">&lt;p id="xdx_843_ecustom--RelatedPartyTransactionsPolicyTextBlock_zhfEN2oOjD9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86C_z92YHKfV02L"&gt;Related Party Transactions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;
- Transactions with affiliates and other parties that meet the definition of a related party under ASC 850, Related Party Disclosures
are reflected in the accompanying condensed consolidated financial statements. All related-party balances are recorded at the exchange
amounts established and agreed to by the parties. All material transaction not in the normal course of business operations are approved
by the Audit Committee of the Board of Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</DSS:RelatedPartyTransactionsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000793">&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zdZUFlcXTs58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zrkXyRD4CJfh"&gt;Recently Issued Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&#x2014; The Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to
the treatment and recording of certain accounting transactions. There are several new accounting pronouncements issued by FASB which are
not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In December 2023, the FASB issued
ASU 2023-09, &#x201c;Improvements to Income Tax Disclosures&#x201d; which is intended to simplify various aspects related to accounting
for income taxes and enhance the transparency of income tax disclosures by requiring additional information regarding income tax rate
reconciliations and income taxes paid, including disaggregation by jurisdiction. ASU 2023-09 removes certain exceptions to the general
principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The amendments in ASU 2023-09
are effective for public business entities for fiscal years beginning after December 15, 2024, including interim periods therein. Early
adoption of the standard is permitted, including adoption in interim or annual periods. The Company adopted the amendments for the year
ended December 31, 2025. The adoption did not have a material impact on the Company&#x2019;s consolidated financial position, results of operations,
or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In November 2024, the FASB issued
ASU No. 2024-03 (&#x201c;ASU 2024-03&#x201d;), &lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disaggregation of Income Statement Expenses (&#x201c;DISE&#x201d;)&lt;/i&gt;. ASU 2024-03 requires
disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03 does not change the expense captions an
entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories
in disclosures within the footnotes to the financial statements. As revised by ASU No. 2025-01, Income Statement&#x2014;Reporting Comprehensive
Income&#x2014;Expense Disaggregation Disclosures, the provisions of ASU 2024-03 are effective for fiscal years beginning after December
15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. With the exception
of expanding disclosures to include more granular income statement expense categories, we do not expect the adoption of ASU 2024-03 to
have a material effect on our consolidated financial statements taken as a whole.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In November 2024, the FASB issued
ASU 2024-04 (&#x201c;ASU 2024-04&#x201d;), &lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of
Convertible Debt Instruments&lt;/i&gt;, which clarifies the requirements for determining whether certain settlements of convertible debt instruments
should be accounted for as induced conversions or as extinguishments. The amendments in ASU 2024-04 are effective for annual reporting
periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted
for entities that have adopted ASU 2020-06. The Company adopted the amendments as effective January 1, 2026. The adoption of ASU 2024-04
did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In December 2025, the
Financial Accounting Standards Board issued Accounting Standards Update No. 2025-11, &lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interim
Reporting (Topic 270)&lt;/i&gt;. The amendments are intended to improve interim financial reporting disclosures and clarify the
application of Topic 270. The amendments in ASU 2025-11 are effective for annual reporting periods beginning January 1, 2028, and
interim reporting periods within those annual reporting periods. The Company is currently evaluating the provisions of ASU 2025-11,
including the timing of adoption and the potential impact on its interim financial statement presentation and related disclosures.
The Company does not currently expect the adoption of ASU 2025-11 to have a material impact on its consolidated financial position,
results of operations, or cash flows.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000795">&lt;p id="xdx_803_eus-gaap--RevenueFromContractWithCustomerTextBlock_z9u6Y1rgyIK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3. &lt;span id="xdx_82B_zcTDOdzjz2a5"&gt;Revenue&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes its revenue
based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the
amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed
and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, net of amortization
of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual fixed increases attributable to
operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. The Company
recognizes net investment income from its investment banking line of business as interest and management fees related to loans managed
for third parties owed to the Company occurs. The Company generates revenue from its direct marketing line of business primarily through
internet sales and recognizes revenue as items are shipped.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2026, the
Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant
to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of
revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient
allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost
of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the
asset that the Company would have otherwise recognized is one year or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs of revenue&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Costs of revenue includes all
direct cost of the Company&#x2019;s packaging, commercial and security printing sales, primarily, paper, inks, dies, and other consumables,
and direct labor, transportation, amortization, deprecation, and manufacturing facility costs. In addition, this category includes all
direct costs associated with the manufacturing and procurement of the products sold in the Company&#x2019;s technology sales, services
and licensing including hardware and software that is resold, third-party fees, and fees paid to inventors or others as a result of technology
licenses or settlements, if any. Cost of revenue for our REIT line of business includes all direct cost associated with the maintenance
and upkeep of the related facilities, depreciation, amortization and the costs to acquire the facilities. Our Commercial Lending operating
segment has costs of revenue associated with the impairment of notes receivable for those amounts at risk of collection. Costs of revenue
do not include expenses related to product development, integration, and support. These costs are included in research and development,
which is a component of selling, general and administrative expenses on the consolidated statement of operations. Legal costs are included
in selling, general and administrative.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales Commissions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Sales commissions are expensed
as incurred for contracts with an expected duration of one year or less. There were &lt;span id="xdx_904_ecustom--SalesCommissionsCapitalized_iI_do_c20260930_zdktSdLYM2X6" title="Sales commissions"&gt;&lt;span id="xdx_90E_ecustom--SalesCommissionsCapitalized_iI_do_c20250930_zhV52EpuhZy" title="Sales commissions"&gt;no&lt;/span&gt;&lt;/span&gt; sales commissions capitalized as of September 30,
2026 or September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shipping and Handling Costs&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Costs incurred by the Company
related to shipping and handling are included in cost of products sold. Amounts charged to customers relating to these costs are reflected
as revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;See Note 16 for disaggregated revenue information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <DSS:SalesCommissionsCapitalized
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000797"
      unitRef="USD">0</DSS:SalesCommissionsCapitalized>
    <DSS:SalesCommissionsCapitalized
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000799"
      unitRef="USD">0</DSS:SalesCommissionsCapitalized>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000801">&lt;p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zkglRUk6jtV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4. &lt;span id="xdx_82B_z4wxjxFhN94f"&gt;Inventory&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zhrtCwap8p83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Inventory consisted of the following as of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zwcI8EJeNCrf" style="display: none"&gt;Schedule of Inventory&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20260930_z2lDXinkct79" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20251231_z0PaEsTcJgE5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maIGzONj_zgRYE4Mg7Ts6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Finished Goods&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;900,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;807,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_pp0p0_maIGzONj_zVZLYzNk1eX9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in Process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;358,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InventoryRawMaterialsAndSupplies_iI_pp0p0_maIGzONj_zR5h9nKEQZP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Raw Materials&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,081,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;746,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryGross_iTI_pp0p0_mtIGzONj_maINzNJB_zsyC3dvNStEi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,339,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,051,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryAdjustments_iNI_pp0p0_di_msINzNJB_zq3FMCFTGaph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less allowance for obsolescence&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(134,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryNet_iTI_pp0p0_mtINzNJB_zXlBhmDFTAb1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,205,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,998,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zcgE9zefOBT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000803">&lt;p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zhrtCwap8p83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Inventory consisted of the following as of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zwcI8EJeNCrf" style="display: none"&gt;Schedule of Inventory&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20260930_z2lDXinkct79" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20251231_z0PaEsTcJgE5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maIGzONj_zgRYE4Mg7Ts6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Finished Goods&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;900,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;807,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryWorkInProcess_iI_pp0p0_maIGzONj_zVZLYzNk1eX9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in Process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;358,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InventoryRawMaterialsAndSupplies_iI_pp0p0_maIGzONj_zR5h9nKEQZP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Raw Materials&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,081,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;746,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryGross_iTI_pp0p0_mtIGzONj_maINzNJB_zsyC3dvNStEi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,339,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,051,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryAdjustments_iNI_pp0p0_di_msINzNJB_zq3FMCFTGaph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less allowance for obsolescence&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(134,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryNet_iTI_pp0p0_mtINzNJB_zXlBhmDFTAb1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,205,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,998,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000805"
      unitRef="USD">900000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000806"
      unitRef="USD">807000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000808"
      unitRef="USD">358000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000809"
      unitRef="USD">498000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000811"
      unitRef="USD">1081000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000812"
      unitRef="USD">746000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryGross
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000814"
      unitRef="USD">2339000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000815"
      unitRef="USD">2051000</us-gaap:InventoryGross>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000817"
      unitRef="USD">134000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000818"
      unitRef="USD">53000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryNet
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact000820"
      unitRef="USD">2205000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000821"
      unitRef="USD">1998000</us-gaap:InventoryNet>
    <us-gaap:FinancingReceivablesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000823">&lt;p id="xdx_807_eus-gaap--FinancingReceivablesTextBlock_z0NYUCXQObu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5. &lt;span id="xdx_82F_zAovAc3haKTb"&gt;Notes Receivable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On May 14, 2021, DSS Pure Air,
Inc. a subsidiary of the Company entered a convertible promissory note (&#x201c;Note 1&#x201d;) with Puradigm, Inc. (&#x201c;Puradigm&#x201d;),
a company registered in the state of Texas. Note 1 has an aggregate principal balance up to $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20210514__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember__srt--RangeAxis__srt--MaximumMember_z4TM4PYqWXPf" title="Debt instrument face amount"&gt;5,000,000&lt;/span&gt;, to be funded at the request of
Puradigm. Note 1, which incurs interest at a rate of &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210514__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zwPEchiOcR3" title="Interest rate"&gt;6.65&lt;/span&gt;% due quarterly, had a maturity date of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210514__20210514__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zR27zbngFW62" title="Maturity date"&gt;May 1, 2023&lt;/span&gt;. &lt;span id="xdx_907_eus-gaap--DebtConversionDescription_c20210514__20210514__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zoptlHmFGuTd" title="Debt conversion description"&gt;Note 1 contains an optional
conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Puradigm with the maximum
principal amount equal to 18% of the total equity position of Puradigm at conversion.&lt;/span&gt; The outstanding principal and interest as of September
30, 2026 and December 31, 2025, approximated $&lt;span id="xdx_908_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zwPN8JcgBn39" title="Notes and loans receivable net current"&gt;&lt;span id="xdx_901_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zQTyv5sFWj5l" title="Notes and loans receivable net current"&gt;5,544,000&lt;/span&gt;&lt;/span&gt;. As of September 30, 2026 and December 31, 2025 this note is in default and the
Company has a reserve of $&lt;span id="xdx_90E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_znNHGKR29G81" title="Reserve amount"&gt;&lt;span id="xdx_907_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteOneMember_zCqejLpToush" title="Reserve amount"&gt;5,544,000&lt;/span&gt;&lt;/span&gt; against the principal and interest outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 2&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 2, 2022, APF and WUURII
Commerce, Inc. (&#x201c;WUURII&#x201d;), a corporation organized under the laws of the Republic of Korea entered into a promissory note
(&#x201c;WUURII Note&#x201d;). Under the terms of WUURRI Note, APF at its discretion, may lend up to the principal sum of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20220302__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zUvLckNzRVu6" title="Debt instrument face amount"&gt;893,000&lt;/span&gt; with
an interest rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220302__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_z3sPiMCld4Pa" title="Interest rate"&gt;8&lt;/span&gt;%, and matured in &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20220302__20220302__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zvAZUi8mjFHh" title="Maturity date description"&gt;March 2024&lt;/span&gt; and was extended to April 2025, with interest payable quarterly. The outstanding principal
and interest at September 30, 2026, and December 31, 2025 is $&lt;span id="xdx_900_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zgJJCaHyUXI5" title="Notes and loans receivable gross current"&gt;465,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_zncWTohoOFA2" title="Notes and loans receivable gross current"&gt;465,000&lt;/span&gt;, respectively. This loan is currently in default and
as of September 30, 2026 the Company has a reserve of $&lt;span id="xdx_90E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwoMember_z9dSPrQPmYti" title="Reserve amount against principal and interest outstanding"&gt;465,000&lt;/span&gt; against the principal and interest outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 3&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On May 9, 2022, DSS PureAir and
Puradigm entered into a promissory note (&#x201c;Puradigm Note 1&#x201d;) in the principal sum of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20220509__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zLmRva1DsPT" title="Debt instrument face amount"&gt;210,000&lt;/span&gt; with interest of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220509__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zH8xRzmILHK" title="Interest rate"&gt;10&lt;/span&gt;%, is due
in three quarterly installments beginning on August 9, 2022, with the first two payment consisting of interest only. All unpaid principal
and interest are due on &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20220509__20220509__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zVfT99nkNBxa" title="Debt instrument maturity date"&gt;February 9, 2023&lt;/span&gt;. This loan is currently in default. The outstanding principal and interest at September 30, 2026
and December 31, 2025 approximates $&lt;span id="xdx_90E_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zvy9Dj52h1Gj" title="Notes and loans receivable net current"&gt;&lt;span id="xdx_90E_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteThreeMember_zTrRJy4Bhqpi" title="Notes and loans receivable net current"&gt;224,000&lt;/span&gt;&lt;/span&gt;. This note was fully reserved for as of September 30, 2026 and December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 4, related party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;BMI Capital International LLC.
(&#x201c;BMIC LLC&#x201d;), a related party, entered into a promissory note (&#x201c;BMIC Note 1&#x201d;) in the principal sum of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20220829__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_z6icjsBP37Vh" title="Debt instrument, face amount"&gt;100,000&lt;/span&gt;
with interest of &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220829__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_zoHmpXIqsuq" title="Debt instrument, interest rate"&gt;8&lt;/span&gt;%, is due in three quarterly installments beginning on September 14, 2022. All unpaid principal and interest was due
on &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220829__20220829__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_zYXLxlitYD8i" title="Maturity date"&gt;August 29, 2025&lt;/span&gt;. The outstanding principal and interest at September 30, 2026 and December 31, 2025 approximated $ &lt;span id="xdx_90F_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_zztYsn2ygZXe" title="Notes and loans receivable gross current"&gt;83,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_z2epK895t5Lc" title="Notes and loans receivable gross current"&gt;86,000&lt;/span&gt;
respectively, and was fully reserved for as of September 30, 2026 and December 31, 2025. DSS owns &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BMICapitalInternationalLLCMember_zfpADF13xj2b" title="Ownership percentage"&gt;24.9&lt;/span&gt;% of the outstanding common shares
of BMIC LLC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 5, related party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On May 8, 2023, DSS Financial
Management Inc and BMIC LLC entered into a promissory note (&#x201c;BMIC Note 2&#x201d;) in the principal sum of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230508__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_zyw9IuwkIE08" title="Debt instrument face amount"&gt;102,000&lt;/span&gt; with interest
at the prime rate plus &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230508__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_zfvDC6FloRkj" title="Interest rate"&gt;2&lt;/span&gt;% with a maturity date of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20230508__20230508__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_zuCPkmok2Ixc" title="Debt instrument maturity date"&gt;May 7, 2026&lt;/span&gt;. The outstanding principal and interest at September 30, 2026, and December
31, 2025 approximated $&lt;span id="xdx_905_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_z8X2g1ZvRAp1" title="Notes and loans receivable gross current"&gt;&lt;span id="xdx_900_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_zu5RP2rwaMZa" title="Notes and loans receivable gross current"&gt;110,000&lt;/span&gt;&lt;/span&gt;, and was fully reserved for as of September 30, 2026 and December 31, 2025. DSS owns &lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BMICapitalInternationalLLCMember_zoeUJXW2ftxj" title="Ownership percentage"&gt;24.9&lt;/span&gt;% of the outstanding
common shares of BMIC LLC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 6, related party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On July 26, 2022, APF and VEII,
Inc. (&#x201c;VEII&#x201d;) entered into a promissory note (&#x201c;Note 6&#x201d;) in the principal sum of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20220726__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_zrtZos6wQ93f" title="Principal amount"&gt;1,000,000&lt;/span&gt; with interest of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220726__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_zdnfAmy8gmZ5" title="Interest rate"&gt;8&lt;/span&gt;%
with all unpaid principal and interest due on &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220725__20220726__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_zx9EgJH6Sz37" title="Debt instrument maturity date"&gt;July 26, 2024&lt;/span&gt;. This note was amended so that all unpaid principal and interest is due July
26, 2025. The outstanding principal and interest as of September 30, 2026 and December 31, 2025 approximates $&lt;span id="xdx_907_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_z6k8Y3Wya8mh" title="Notes and loans receivable gross current"&gt;890,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_z5KslpDH0hDb" title="Notes and loans receivable gross current"&gt;917,000&lt;/span&gt;, respectively.
This note was fully reserved for as of September 30, 2026 and December 31, 2025. Heng Fai Ambrose Chan, the Chairman of DSS, Inc is also
the on the board of directors of VEII.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 7&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On February 19, 2021,
Impact BioMedical, Inc, entered into a promissory note (&#x201c;Note 7&#x201d;) with an individual. The Company loaned the principal
sum of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20210219__us-gaap--ShortTermDebtTypeAxis__custom--NoteSevenMember_znCswrRyKeEj" title="Principal amount"&gt;206,000&lt;/span&gt;,
with interest at a rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210219__us-gaap--ShortTermDebtTypeAxis__custom--NoteSevenMember_z6UEBnhliEp" title="Debt instrument interest percentage"&gt;6.5&lt;/span&gt;%,
and maturity date of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210219__20210219__us-gaap--ShortTermDebtTypeAxis__custom--NoteSevenMember_zPzVEnux2Hjk" title="Maturity date"&gt;August
19, 2022&lt;/span&gt; later amended to February 19, 2029. Monthly payments are due on the twenty-first day of each month and continuing
each month thereafter until February 19, 2026. This note is secured by certain real property situated in Collier County, Florida.
The outstanding principal and interest as of September 30, 2026, and December 31, 2025 was approximately $&lt;span id="xdx_902_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteSevenMember_zFu0RBLCSle8" title="Outstanding principal and interest"&gt;199,000&lt;/span&gt;
and $&lt;span id="xdx_904_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteSevenMember_zdDyR3qdm04f" title="Outstanding principal and interest"&gt;198,000&lt;/span&gt;,
respectively. As of September 30, 2026, approximately $&lt;span id="xdx_90A_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteSevenMember_zEMrnvc4GI31" title="Notes receivable current"&gt;14,000&lt;/span&gt;
is classified in Current notes receivable. As of December 31, 2025, $&lt;span id="xdx_90D_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteSevenMember_zj7uJ6zpnGE9" title="Notes receivable"&gt;185,000&lt;/span&gt;
is classified in Current notes receivable and the remaining $185,000 is classified as Notes receivable on the accompanying
consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 8&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 31, 2023, DSS Biohealth
Security, Inc and an individual entered into a promissory note (&#x201c;Note 8&#x201d;) in the principal sum of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NoteEightMember_zYl91nhxOKV6" title="Debt instrument face amount"&gt;140,000&lt;/span&gt; and interest rate
floating daily to Wall Street Journal Prime rate per annum with the total outstanding principal and interest due at the maturity date
of &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20230331__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NoteEightMember_z9z3HDaTxQ74" title="Debt instrument maturity date"&gt;March 31, 2025&lt;/span&gt;. As of September 30, 2026 and December 31, 2025, the outstanding principal and interest approximated $&lt;span id="xdx_909_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteEightMember_zGKixFMgrbIk" title="Notes receivable noncurrent"&gt;&lt;span id="xdx_902_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteEightMember_zjnIAIytAU65" title="Notes receivable noncurrent"&gt;135,000&lt;/span&gt;&lt;/span&gt;. This
balance was fully reserved for as of September 30, 2026 and December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 9, related party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On August 29, 2024, APF entered
into a promissory note (&#x201c;Note 9&#x201d;) with WestPark. Note has a principal balance of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240829__us-gaap--ShortTermDebtTypeAxis__custom--NoteNineMember_zN6S1cwr7ND4" title="Principal balance"&gt;459,000&lt;/span&gt;. Note 9, which incurs interest at
a rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240829__us-gaap--ShortTermDebtTypeAxis__custom--NoteNineMember_zQSVTiUU3Q11" title="Interest rate"&gt;10.0&lt;/span&gt;% with principal and interest due at the maturity date of &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20240829__20240829__us-gaap--ShortTermDebtTypeAxis__custom--NoteNineMember_zJC6YmKE51nh" title="Maturity date"&gt;April 27, 2026&lt;/span&gt;. As of September 30, 2026, the outstanding principal
and interest approximates $&lt;span id="xdx_90E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteNineMember_z3CRFqobJGh1" title="Outstanding principal and interest"&gt;194,000&lt;/span&gt;, which is classified as Current notes receivable on the accompanying consolidated balance sheet. As
of December 31, 2025, the outstanding principal and interest approximates $&lt;span id="xdx_904_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteNineMember_zFaSwOeNgf2h" title="Outstanding principal and interest"&gt;237,000&lt;/span&gt;, which is classified as Current notes receivable, related party on
the accompanying consolidated balance sheet. The maturity date of this note is currently being renegotiated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 10&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On April 16, 2026, the
Company, entered into a promissory note (&#x201c;Note 10&#x201d;) with an individual. The Company loaned the principal sum of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20260416__us-gaap--ShortTermDebtTypeAxis__custom--NoteTenMember_zvfwcUfWRz7b"&gt;25,000&lt;/span&gt;,
with interest at a rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260416__us-gaap--ShortTermDebtTypeAxis__custom--NoteTenMember_zxH6fF0KdRli"&gt;6.75&lt;/span&gt;%,
and maturity date of &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20260416__20260416__us-gaap--ShortTermDebtTypeAxis__custom--NoteTenMember_zGcgEk375Fkh"&gt;April
16, 2027&lt;/span&gt; at which time all outstanding principal and interest is due. This loan is secured by certain stock in BMI Financial
Group, Inc. The outstanding principal and interest as of September 30, 2026, and December 31, 2025 was approximately $&lt;span id="xdx_90D_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteTenMember_zQO97XwfbwR6"&gt;26,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteTenMember_zIeRJ1ILNDj1"&gt;0&lt;/span&gt;,
respectively. As of September 30, 2026, $&lt;span id="xdx_906_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteTenMember_z3pMmzYvAMXh" title="Current notes receivable"&gt;26,000&lt;/span&gt;
is classified in Current notes receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 11&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On June 23, 2026, the Company,
entered into a promissory note (&#x201c;Note 11&#x201d;) with an individual. The Company loaned the principal sum of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20260623__us-gaap--ShortTermDebtTypeAxis__custom--NoteElevenMember_zLYLHLMyb9di" title="Note principal amount"&gt;25,000&lt;/span&gt;, with interest
at a rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260623__us-gaap--ShortTermDebtTypeAxis__custom--NoteElevenMember_zOLsxUMuMWr8" title="Note interest rate"&gt;6.75&lt;/span&gt;%, and maturity date of &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20260623__20260623__us-gaap--ShortTermDebtTypeAxis__custom--NoteElevenMember_zBlYcEbeFrH9" title="Note maturity date"&gt;June 23, 2027&lt;/span&gt; at which time all outstanding principal and interest is due. This loan is secured
by certain stock in BMI Financial Group, Inc. The outstanding principal and interest as of September 30, 2026, and December 31, 2025 was
approximately $&lt;span id="xdx_904_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteElevenMember_zLt3hlg4PrX5"&gt;25,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteElevenMember_zvv2ZOmzbcYf" title="Note principal and interest outstanding"&gt;0&lt;/span&gt;, respectively. As of September 30, 2026, the $&lt;span id="xdx_900_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteElevenMember_z0iomNPl3hTe" title="Current notes receivable"&gt;25,000&lt;/span&gt; is classified in Current notes receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 12&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On August 26, 2026, the Company,
entered into a promissory note (&#x201c;Note 12&#x201d;) with an individual. The Company loaned the principal sum of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20260826__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwelveMember_zxf70V68ImSf" title="Note principal amount"&gt;20,000&lt;/span&gt;, with interest
at a rate of &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260826__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwelveMember_zd4MtunEGps2" title="Note interest rate"&gt;6.75&lt;/span&gt;%, and maturity date of &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20260826__20260826__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwelveMember_z8mjnncUmUGk" title="Note maturity date"&gt;August 26, 2027&lt;/span&gt; at which time all outstanding principal and interest is due. This loan is secured
by certain stock in BMI Financial Group, Inc. The outstanding principal and interest as of September 30, 2026, and December 31, 2025 was
approximately $&lt;span id="xdx_90C_eus-gaap--NotesReceivableNet_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwelveMember_zGHvqJcdPXj9"&gt;20,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--NotesReceivableNet_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwelveMember_zVrN6Ffxznfh" title="Note principal and interest outstanding"&gt;0&lt;/span&gt;, respectively. As of September 30, 2026, the $&lt;span id="xdx_909_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteTwelveMember_z8Nh3rx9JEL7" title="Current notes receivable"&gt;20,000&lt;/span&gt; is classified in Current notes receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:FinancingReceivablesTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-05-14_custom_NoteOneMember_srt_MaximumMember"
      decimals="0"
      id="Fact000825"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-05-14_custom_NoteOneMember"
      decimals="INF"
      id="Fact000827"
      unitRef="Pure">0.0665</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2021-05-142021-05-14_custom_NoteOneMember"
      id="Fact000829">2023-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionDescription
      contextRef="From2021-05-142021-05-14_custom_NoteOneMember"
      id="Fact000831">Note 1 contains an optional
conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Puradigm with the maximum
principal amount equal to 18% of the total equity position of Puradigm at conversion.</us-gaap:DebtConversionDescription>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteOneMember"
      decimals="0"
      id="Fact000833"
      unitRef="USD">5544000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteOneMember"
      decimals="0"
      id="Fact000835"
      unitRef="USD">5544000</us-gaap:NotesReceivableNet>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="AsOf2026-09-30_custom_NoteOneMember"
      decimals="0"
      id="Fact000837"
      unitRef="USD">5544000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="AsOf2025-12-31_custom_NoteOneMember"
      decimals="0"
      id="Fact000839"
      unitRef="USD">5544000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-03-02_custom_NoteTwoMember"
      decimals="0"
      id="Fact000841"
      unitRef="USD">893000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-03-02_custom_NoteTwoMember"
      decimals="INF"
      id="Fact000843"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2022-03-022022-03-02_custom_NoteTwoMember"
      id="Fact000845">March 2024</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteTwoMember"
      decimals="0"
      id="Fact000847"
      unitRef="USD">465000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteTwoMember"
      decimals="0"
      id="Fact000849"
      unitRef="USD">465000</us-gaap:NotesReceivableNet>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="AsOf2026-09-30_custom_NoteTwoMember"
      decimals="0"
      id="Fact000851"
      unitRef="USD">465000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-05-09_custom_NoteThreeMember"
      decimals="0"
      id="Fact000853"
      unitRef="USD">210000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-05-09_custom_NoteThreeMember"
      decimals="INF"
      id="Fact000855"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-05-092022-05-09_custom_NoteThreeMember"
      id="Fact000857">2023-02-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteThreeMember"
      decimals="0"
      id="Fact000859"
      unitRef="USD">224000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteThreeMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">224000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-08-29_custom_NoteFourMember"
      decimals="0"
      id="Fact000863"
      unitRef="USD">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-08-29_custom_NoteFourMember"
      decimals="INF"
      id="Fact000865"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-08-292022-08-29_custom_NoteFourMember"
      id="Fact000867">2025-08-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteFourMember"
      decimals="0"
      id="Fact000869"
      unitRef="USD">83000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteFourMember"
      decimals="0"
      id="Fact000871"
      unitRef="USD">86000</us-gaap:NotesReceivableNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-09-30_custom_BMICapitalInternationalLLCMember"
      decimals="INF"
      id="Fact000873"
      unitRef="Pure">0.249</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-08_custom_NoteFiveMember"
      decimals="0"
      id="Fact000875"
      unitRef="USD">102000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-05-08_custom_NoteFiveMember"
      decimals="INF"
      id="Fact000877"
      unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-05-082023-05-08_custom_NoteFiveMember"
      id="Fact000879">2026-05-07</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteFiveMember"
      decimals="0"
      id="Fact000881"
      unitRef="USD">110000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteFiveMember"
      decimals="0"
      id="Fact000883"
      unitRef="USD">110000</us-gaap:NotesReceivableNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-09-30_custom_BMICapitalInternationalLLCMember"
      decimals="INF"
      id="Fact000885"
      unitRef="Pure">0.249</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-07-26_custom_NoteSixMember"
      decimals="0"
      id="Fact000887"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-07-26_custom_NoteSixMember"
      decimals="INF"
      id="Fact000889"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-07-252022-07-26_custom_NoteSixMember"
      id="Fact000891">2024-07-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteSixMember"
      decimals="0"
      id="Fact000893"
      unitRef="USD">890000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteSixMember"
      decimals="0"
      id="Fact000895"
      unitRef="USD">917000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-02-19_custom_NoteSevenMember"
      decimals="0"
      id="Fact000897"
      unitRef="USD">206000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-02-19_custom_NoteSevenMember"
      decimals="INF"
      id="Fact000899"
      unitRef="Pure">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2021-02-192021-02-19_custom_NoteSevenMember"
      id="Fact000901">2022-08-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteSevenMember"
      decimals="0"
      id="Fact000903"
      unitRef="USD">199000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteSevenMember"
      decimals="0"
      id="Fact000905"
      unitRef="USD">198000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2026-09-30_custom_NoteSevenMember"
      decimals="0"
      id="Fact000907"
      unitRef="USD">14000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2025-12-31_custom_NoteSevenMember"
      decimals="0"
      id="Fact000909"
      unitRef="USD">185000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-03-31_custom_NoteEightMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">140000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-03-312023-03-31_custom_NoteEightMember"
      id="Fact000913">2025-03-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteEightMember"
      decimals="0"
      id="Fact000915"
      unitRef="USD">135000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteEightMember"
      decimals="0"
      id="Fact000917"
      unitRef="USD">135000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-08-29_custom_NoteNineMember"
      decimals="0"
      id="Fact000919"
      unitRef="USD">459000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-08-29_custom_NoteNineMember"
      decimals="INF"
      id="Fact000921"
      unitRef="Pure">0.100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-08-292024-08-29_custom_NoteNineMember"
      id="Fact000923">2026-04-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2026-09-30_custom_NoteNineMember"
      decimals="0"
      id="Fact000925"
      unitRef="USD">194000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2025-12-31_custom_NoteNineMember"
      decimals="0"
      id="Fact000927"
      unitRef="USD">237000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-04-16_custom_NoteTenMember"
      decimals="0"
      id="Fact000928"
      unitRef="USD">25000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-04-16_custom_NoteTenMember"
      decimals="INF"
      id="Fact000929"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2026-04-162026-04-16_custom_NoteTenMember"
      id="Fact000930">2027-04-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteTenMember"
      decimals="0"
      id="Fact000931"
      unitRef="USD">26000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteTenMember"
      decimals="0"
      id="Fact000932"
      unitRef="USD">0</us-gaap:NotesReceivableNet>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2026-09-30_custom_NoteTenMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">26000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-06-23_custom_NoteElevenMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">25000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-06-23_custom_NoteElevenMember"
      decimals="INF"
      id="Fact000938"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2026-06-232026-06-23_custom_NoteElevenMember"
      id="Fact000940">2027-06-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteElevenMember"
      decimals="0"
      id="Fact000941"
      unitRef="USD">25000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteElevenMember"
      decimals="0"
      id="Fact000943"
      unitRef="USD">0</us-gaap:NotesReceivableNet>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2026-09-30_custom_NoteElevenMember"
      decimals="0"
      id="Fact000945"
      unitRef="USD">25000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-08-26_custom_NoteTwelveMember"
      decimals="0"
      id="Fact000947"
      unitRef="USD">20000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-08-26_custom_NoteTwelveMember"
      decimals="INF"
      id="Fact000949"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2026-08-262026-08-26_custom_NoteTwelveMember"
      id="Fact000951">2027-08-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2026-09-30_custom_NoteTwelveMember"
      decimals="0"
      id="Fact000952"
      unitRef="USD">20000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2025-12-31_custom_NoteTwelveMember"
      decimals="0"
      id="Fact000954"
      unitRef="USD">0</us-gaap:NotesReceivableNet>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2026-09-30_custom_NoteTwelveMember"
      decimals="0"
      id="Fact000956"
      unitRef="USD">20000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:InvestmentHoldingsTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact000958">&lt;p id="xdx_804_eus-gaap--InvestmentHoldingsTextBlock_zim8C4hL7F6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6. &lt;span id="xdx_82D_zVmcP7iKTpi7"&gt;Convertible Bond Investment &#x2013; related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 27, 2026, the Company
received a convertible bond investment from True Partners Capital Holding Limited (&#x201c;True Partners&#x201d;), a publicly listed company
on the Hong Kong Stock Exchange and a related party of the Company. The bond has a face value of $&lt;span id="xdx_907_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20260327__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zVvVMDl81o8a" title="Bond face value"&gt;2,450,000&lt;/span&gt;, bears interest at &lt;span id="xdx_909_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_uPure_c20260327__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zYiJS8JncoQ" title="Bears interest rate"&gt;3.0&lt;/span&gt;% per
annum, was registered on March 27, 2026, and matures on &lt;span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20260327__20260327__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_z8lYmNwdryBl" title="Maturity date"&gt;March 26, 2028&lt;/span&gt;, unless earlier converted, redeemed, or otherwise settled in accordance
with its terms. Interest accrues daily on a 365-day basis and is payable annually in cash. At maturity, the outstanding principal balance
is mandatorily and automatically convertible into ordinary shares of True Partners.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;True Partners is considered a
related party because the Company holds a significant equity investment in True Partners and has determined that it has the ability to
exercise significant influence over True Partners. This determination is based on the Company&#x2019;s equity ownership, and the election
of the Company&#x2019;s Executive Chairman and significant stockholder, Heng Fai Ambrose Chan, to True Partners&#x2019; board of directors.
Accordingly, the Company&#x2019;s receipt of the convertible bond is considered a related party transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The bond is convertible into ordinary
shares of True Partners at a conversion price of HKD $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uHKDPShares_c20260327__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_z1iDwhJDbMfi" title="Conversion price per share"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uHKDPShares_c20260326__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zfybuo72BNfi" title="Conversion price per share"&gt;0.10&lt;/span&gt;&lt;/span&gt; per share, which was approximately USD $&lt;span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20260327__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zVrOBbz3EAl2" title="Conversion price per share"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20260630__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zP52o9JsThzc" title="Conversion price per share"&gt;0.01&lt;/span&gt;&lt;/span&gt; per share as of both March 27,
2026 and March 31, 2026, based on the applicable exchange rate or rounded U.S. dollar equivalent used by the Company. Based on the bond&#x2019;s
fixed currency conversion rate, the bond is convertible into approximately &lt;span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20260327__20260327__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zMWy0jwbiKt7" title="Convertible shares"&gt;190,684,000&lt;/span&gt; ordinary shares of True Partners.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for the convertible
bond investment at fair value and has elected the fair value option under ASC 825, Financial Instruments. Based on a valuation performed
as of March 27, 2026, the estimated fair value of the convertible bond was approximately $&lt;span id="xdx_906_eus-gaap--InvestmentsFairValueDisclosure_iI_c20260327__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zNHCuueDCkf1" title="Estimated fair value of convertible bond"&gt;8,648,000&lt;/span&gt;, consisting of a $&lt;span id="xdx_90F_eus-gaap--TradingSecuritiesDebt_iI_c20260327__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zvoHhJO9TcXh" title="Debt component"&gt;127,000&lt;/span&gt; debt-like
component related to the present value of contractual cash interest payments and an $&lt;span id="xdx_903_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260327__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zpeyhOACKgl3" title="Equity conversion amount"&gt;8,521,000&lt;/span&gt; equity-like conversion feature related
to the value of the shares issuable upon conversion of principal. Based on a valuation performed as of March 31, 2026, the estimated fair
value of the convertible bond was approximately $&lt;span id="xdx_904_eus-gaap--InvestmentsFairValueDisclosure_iI_c20260331__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zNvoe0JrHzB2" title="Estimated fair value of convertible bond"&gt;8,520,000&lt;/span&gt;, consisting of a $&lt;span id="xdx_902_eus-gaap--TradingSecuritiesDebt_iI_c20260331__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zfradUFumYo9" title="Fair value of debt-like component"&gt;129,000&lt;/span&gt; debt-like component and an $&lt;span id="xdx_901_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260331__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zmnzYxp1QPXe" title="Fair value of equity-like conversion feature"&gt;8,391,000&lt;/span&gt; equity-like
conversion feature. The Company recorded the convertible bond investment at March 31, 2026 estimated fair value of approximately $&lt;span id="xdx_904_eus-gaap--InvestmentsFairValueDisclosure_iI_c20260331__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zwX6Ao9y3oYi" title="Estimated fair value of convertible bond"&gt;8,520,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of the convertible
bond investment was determined in accordance with ASC 820, Fair Value Measurement. The valuation considered, among other factors, the
contractual interest rate, maturity date, mandatory conversion terms, conversion price, market price of the underlying True Partners ordinary
shares, foreign currency exchange rates, issuer credit risk, expected term, liquidity, discount rates, and conversion economics. The investment
is classified as a Level 3 asset within the fair value hierarchy because there is no quoted price in an active market for the identical
convertible bond and the valuation requires significant unobservable inputs, including issuer credit risk, expected term, liquidity assumptions,
discount rates, and conversion economics.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Because the convertible bond was
received from a related party, the Company evaluated the substance of the transaction, including the relationship between the parties,
the nature of the consideration exchanged, and whether the fair value of the bond exceeded the stated face amount or consideration transferred.
Because the convertible bond was issued in connection with the Company&#x2019;s additional investment in True Capital Holdings and the
parties are related, the Company evaluated the difference between the fair value of the convertible bond and the consideration transferred
in accordance with the applicable U.S. GAAP guidance. Based on the Company&#x2019;s assessment of the economic substance of the transaction,
the Company determined that the excess of the fair value of the convertible bond over the consideration transferred represented a capital
contribution and recorded approximately $&lt;span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_c20260101__20260930__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zjC9TDgAMcn5" title="Additional paid-in capital"&gt;6,198,000&lt;/span&gt; in additional paid-in capital. Subsequent changes in fair value are recognized in earnings
in accordance with the Company&#x2019;s election of the fair value option under ASC 825. As of March 31, 2026 the Company recognized a
loss of approximately $&lt;span id="xdx_901_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20260331__20260331__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zE98suiA1OJ6" title="Convertible bond recognized loss"&gt;128,000 &lt;/span&gt;on the condensed consolidated statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On April 29, 2026, True Partner
International Limited, a subsidiary of the Company, delivered a conversion notice to True Partners to convert the full outstanding principal
amount of the $&lt;span id="xdx_900_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20260429__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zX9lVhUcbW17"&gt;2,450,000&lt;/span&gt;,
&lt;span id="xdx_907_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_uPure_c20260429__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zJOmRfKXJZL6"&gt;3.0&lt;/span&gt;%
convertible bond. Pursuant to the notice, the bond was converted at a conversion price of HKD $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uHKDPShares_c20260429__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zfoi6XwlbMtg"&gt;0.10&lt;/span&gt;
per share, resulting in the issuance of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20260429__20260429__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zCNPlk0gez5a"&gt;190,683,500&lt;/span&gt;
ordinary shares of True Partners. Immediately prior to conversion, the Company remeasured the convertible bond to fair value. Based on
a valuation performed as of April 29, 2026, the estimated fair value of the convertible bond was approximately $&lt;span id="xdx_90F_eus-gaap--InvestmentsFairValueDisclosure_iI_c20260429__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zxDvvqvaoSJ"&gt;8,647,000&lt;/span&gt;,
consisting of a $&lt;span id="xdx_90A_eus-gaap--TradingSecuritiesDebt_iI_c20260429__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zGfuSGHgBg9k"&gt;131,000&lt;/span&gt;
debt-like component and an $&lt;span id="xdx_901_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20260429__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_z6cm08GdtuM8"&gt;8,516,000&lt;/span&gt;
equity-like conversion feature. The Company recognized an increase in fair value of approximately $&lt;span id="xdx_909_eus-gaap--AssetsFairValueAdjustment_c20260429__20260429__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zJ2TQNljCeP7"&gt;127,000&lt;/span&gt;
from March 31, 2026 through the conversion date in the condensed consolidated statement of operations. Upon conversion, the Company derecognized
the convertible bond investment and recorded the ordinary shares received as part of its equity method investment in True Partners. Following
the conversion, the Company owned approximately &lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20260429__20260429__us-gaap--FinancialInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TruePartnersCapitalHoldingLimitedMember_zfu6gK47qCs9"&gt;45&lt;/span&gt;%
of the issued and outstanding shares of True Partners and continues to account for its investment in True Partners under the equity method
of accounting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:InvestmentHoldingsTextBlock>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000960"
      unitRef="USD">2450000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact000962"
      unitRef="Pure">0.030</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2026-03-272026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      id="Fact000964">2028-03-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact000966"
      unitRef="HKDPShares">0.10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2026-03-26_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact000968"
      unitRef="HKDPShares">0.10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact000970"
      unitRef="USDPShares">0.01</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2026-06-30_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact000972"
      unitRef="USDPShares">0.01</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2026-03-272026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact000974"
      unitRef="Shares">190684000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000976"
      unitRef="USD">8648000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:TradingSecuritiesDebt
      contextRef="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000978"
      unitRef="USD">127000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000980"
      unitRef="USD">8521000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2026-03-31_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000982"
      unitRef="USD">8520000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:TradingSecuritiesDebt
      contextRef="AsOf2026-03-31_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000984"
      unitRef="USD">129000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="AsOf2026-03-31_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000986"
      unitRef="USD">8391000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2026-03-31_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000988"
      unitRef="USD">8520000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2026-01-012026-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000990"
      unitRef="USD">6198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="From2026-03-312026-03-31_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000992"
      unitRef="USD">128000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="AsOf2026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000993"
      unitRef="USD">2450000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="AsOf2026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact000994"
      unitRef="Pure">0.030</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact000995"
      unitRef="HKDPShares">0.10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2026-04-292026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact000996"
      unitRef="Shares">190683500</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000997"
      unitRef="USD">8647000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:TradingSecuritiesDebt
      contextRef="AsOf2026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000998"
      unitRef="USD">131000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="AsOf2026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact000999"
      unitRef="USD">8516000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="From2026-04-292026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact001000"
      unitRef="USD">127000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2026-04-292026-04-29_custom_ConvertibleBondInvestmentMember_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact001001"
      unitRef="Pure">0.45</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001003">&lt;p id="xdx_80A_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zFyoivEE2Tml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7. &lt;span id="xdx_825_zxhg4KSeYQC4"&gt;Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash, Cash Equivalents, Restricted Cash and Marketable
Securities&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_ze4TJBcJUgKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The following tables show the Company&#x2019;s cash,
cash equivalents, restricted cash, and marketable securities by significant investment category as of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zhz3O98SOhwi" style="display: none"&gt;Schedule of Cash and Marketable Securities by Significant Investment Category&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unrealized&lt;br/&gt; Gain/(Loss)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair &lt;br/&gt; Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and&lt;br/&gt; Cash&lt;br/&gt; Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;Marketable&lt;br/&gt; Securities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zVfNShMmrToh" style="width: 9%; text-align: right" title="Cost"&gt;3,220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--UnrealizedGainLossOnInvestments_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zyuvUEQHqYr1" style="width: 9%; text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zJU9GMXHVNTd" style="width: 9%; text-align: right" title="Fair Value"&gt;3,220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zeSQSMnco9T7" style="width: 9%; text-align: right" title="Cash and Cash Equivalents"&gt;3,220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zvconnp0k7Vk" style="width: 9%; text-align: right" title="Current marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Level 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Money Market Funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zS8EAkKtUR5d" style="text-align: right" title="Cost"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--UnrealizedGainLossOnInvestments_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjXh1wzThJoi" style="text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx6xST6aC9g3" style="text-align: right" title="Fair Value"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4OsumbuyFR" style="text-align: right" title="Current marketable securities"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--MarketableSecurities_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5PWO6i8mQ07" style="text-align: right" title="Convertible bond investment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1025"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Marketable Securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTc0tF40bFN5" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"&gt;16,120,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--UnrealizedGainLossOnInvestments_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1381cP52q1" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized Gain/(Loss)"&gt;(14,077,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgSSq8rXXJ6b" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value"&gt;2,043,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z87odJnJsUta" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and Cash Equivalents"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--MarketableSecurities_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zhCHJVCb76I5" style="border-bottom: Black 1pt solid; text-align: right" title="Current marketable securities"&gt;2,043,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20260101__20260930_zJNnrHc0tb8l" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;19,395,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--UnrealizedGainLossOnInvestments_c20260101__20260930_ziqCPqQesCn1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized Gain/(Loss)"&gt;(14,077,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20260930_zseuni3erRie" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value"&gt;5,318,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20260930_zYmCgq5OrVE5" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents"&gt;3,275,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pp0p0_c20260930_zbxmHQCKZsge" style="border-bottom: Black 2.5pt double; text-align: right" title="Current marketable securities"&gt;2,043,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjusted&lt;br/&gt; Cost&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unrealized&lt;br/&gt; Gain/(Loss)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair &lt;br/&gt; Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and&lt;br/&gt; Cash&lt;br/&gt; Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;Marketable&lt;br/&gt; Securities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_ze3IWUISr9J3" style="width: 9%; text-align: right" title="Cost"&gt;4,981,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--UnrealizedGainLossOnInvestments_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zwegX8VCpeZd" style="width: 9%; text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_ziR5q9ZtTQm1" style="width: 9%; text-align: right" title="Fair Value"&gt;4,981,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zfAKK9k2frNa" style="width: 9%; text-align: right" title="Cash and Cash Equivalents"&gt;4,981,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zBnrA5XOLWni" style="width: 9%; text-align: right" title="Current marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zNHF8GpiLfAg" style="text-align: right" title="Cost"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--UnrealizedGainLossOnInvestments_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zIOwDZIqyenb" style="text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zkXaj4wtrFqe" style="text-align: right" title="Fair Value"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zXNEdqVoClrj" style="text-align: right" title="Cash and Cash Equivalents"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zDiarxvJHhcc" style="text-align: right" title="Current marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Level 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Money Market Funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVizXK2j8RX2" style="text-align: right" title="Cost"&gt;1,233,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--UnrealizedGainLossOnInvestments_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpqgsT1pQ7e2" style="text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1069"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHl5N9nx9Tbc" style="text-align: right" title="Fair Value"&gt;1,233,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zvzBLMbOW1P4" style="text-align: right" title="Cash and Cash Equivalents"&gt;1,233,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfupYdYACJF2" style="text-align: right" title="Current marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Marketable Securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z76bHQZsm3Ck" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"&gt;26,383,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--UnrealizedGainLossOnInvestments_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOWAXKBjCwO8" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized Gain/(Loss)"&gt;(17,172,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPFOfbo7ZUC5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value"&gt;9,211,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHn4Y2s5Sdi9" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and Cash Equivalents"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1083"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zSgJPlZA0uDl" style="border-bottom: Black 1pt solid; text-align: right" title="Current marketable securities"&gt;9,211,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231_z3xVX4EoAdef" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;32,697,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--UnrealizedGainLossOnInvestments_c20250101__20251231_zLsPmZankK" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized Gain/(Loss)"&gt;(17,172,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231_zPUW1pxy6yik" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value"&gt;15,525,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231_zaoucdMhIae2" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents"&gt;6,314,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231_zyUIZqJQXgol" style="border-bottom: Black 2.5pt double; text-align: right" title="Current marketable securities"&gt;9,211,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z3lGWJNKYz9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company typically invests
with the primary objective of minimizing the potential risk of principal loss. The Company&#x2019;s investment policy generally requires
securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual
security in the investment portfolio.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001005">&lt;p id="xdx_897_eus-gaap--ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_ze4TJBcJUgKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The following tables show the Company&#x2019;s cash,
cash equivalents, restricted cash, and marketable securities by significant investment category as of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zhz3O98SOhwi" style="display: none"&gt;Schedule of Cash and Marketable Securities by Significant Investment Category&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unrealized&lt;br/&gt; Gain/(Loss)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair &lt;br/&gt; Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and&lt;br/&gt; Cash&lt;br/&gt; Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;Marketable&lt;br/&gt; Securities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zVfNShMmrToh" style="width: 9%; text-align: right" title="Cost"&gt;3,220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--UnrealizedGainLossOnInvestments_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zyuvUEQHqYr1" style="width: 9%; text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zJU9GMXHVNTd" style="width: 9%; text-align: right" title="Fair Value"&gt;3,220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zeSQSMnco9T7" style="width: 9%; text-align: right" title="Cash and Cash Equivalents"&gt;3,220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zvconnp0k7Vk" style="width: 9%; text-align: right" title="Current marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Level 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Money Market Funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zS8EAkKtUR5d" style="text-align: right" title="Cost"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--UnrealizedGainLossOnInvestments_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjXh1wzThJoi" style="text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx6xST6aC9g3" style="text-align: right" title="Fair Value"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4OsumbuyFR" style="text-align: right" title="Current marketable securities"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--MarketableSecurities_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5PWO6i8mQ07" style="text-align: right" title="Convertible bond investment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1025"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Marketable Securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTc0tF40bFN5" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"&gt;16,120,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--UnrealizedGainLossOnInvestments_pp0p0_c20260101__20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1381cP52q1" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized Gain/(Loss)"&gt;(14,077,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgSSq8rXXJ6b" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value"&gt;2,043,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z87odJnJsUta" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and Cash Equivalents"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--MarketableSecurities_iI_pp0p0_c20260930__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zhCHJVCb76I5" style="border-bottom: Black 1pt solid; text-align: right" title="Current marketable securities"&gt;2,043,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20260101__20260930_zJNnrHc0tb8l" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;19,395,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--UnrealizedGainLossOnInvestments_c20260101__20260930_ziqCPqQesCn1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized Gain/(Loss)"&gt;(14,077,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20260930_zseuni3erRie" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value"&gt;5,318,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20260930_zYmCgq5OrVE5" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents"&gt;3,275,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pp0p0_c20260930_zbxmHQCKZsge" style="border-bottom: Black 2.5pt double; text-align: right" title="Current marketable securities"&gt;2,043,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjusted&lt;br/&gt; Cost&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unrealized&lt;br/&gt; Gain/(Loss)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair &lt;br/&gt; Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and&lt;br/&gt; Cash&lt;br/&gt; Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;Marketable&lt;br/&gt; Securities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_ze3IWUISr9J3" style="width: 9%; text-align: right" title="Cost"&gt;4,981,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--UnrealizedGainLossOnInvestments_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zwegX8VCpeZd" style="width: 9%; text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_ziR5q9ZtTQm1" style="width: 9%; text-align: right" title="Fair Value"&gt;4,981,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zfAKK9k2frNa" style="width: 9%; text-align: right" title="Cash and Cash Equivalents"&gt;4,981,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zBnrA5XOLWni" style="width: 9%; text-align: right" title="Current marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zNHF8GpiLfAg" style="text-align: right" title="Cost"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--UnrealizedGainLossOnInvestments_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zIOwDZIqyenb" style="text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zkXaj4wtrFqe" style="text-align: right" title="Fair Value"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zXNEdqVoClrj" style="text-align: right" title="Cash and Cash Equivalents"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--RestrictedCashMember_zDiarxvJHhcc" style="text-align: right" title="Current marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Level 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Money Market Funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVizXK2j8RX2" style="text-align: right" title="Cost"&gt;1,233,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--UnrealizedGainLossOnInvestments_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpqgsT1pQ7e2" style="text-align: right" title="Unrealized Gain/(Loss)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1069"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHl5N9nx9Tbc" style="text-align: right" title="Fair Value"&gt;1,233,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zvzBLMbOW1P4" style="text-align: right" title="Cash and Cash Equivalents"&gt;1,233,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfupYdYACJF2" style="text-align: right" title="Current marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Marketable Securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z76bHQZsm3Ck" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"&gt;26,383,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--UnrealizedGainLossOnInvestments_pp0p0_c20250101__20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOWAXKBjCwO8" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized Gain/(Loss)"&gt;(17,172,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPFOfbo7ZUC5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value"&gt;9,211,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHn4Y2s5Sdi9" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and Cash Equivalents"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1083"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231__us-gaap--CashAndCashEquivalentsAxis__custom--MarketableSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zSgJPlZA0uDl" style="border-bottom: Black 1pt solid; text-align: right" title="Current marketable securities"&gt;9,211,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_pp0p0_c20250101__20251231_z3xVX4EoAdef" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;32,697,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--UnrealizedGainLossOnInvestments_c20250101__20251231_zLsPmZankK" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized Gain/(Loss)"&gt;(17,172,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20251231_zPUW1pxy6yik" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value"&gt;15,525,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pp0p0_c20251231_zaoucdMhIae2" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash and Cash Equivalents"&gt;6,314,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20251231_zyUIZqJQXgol" style="border-bottom: Black 2.5pt double; text-align: right" title="Current marketable securities"&gt;9,211,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="From2026-01-012026-09-30_us-gaap_CashMember"
      decimals="0"
      id="Fact001007"
      unitRef="USD">3220000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2026-09-30_us-gaap_CashMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">3220000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_CashMember"
      decimals="0"
      id="Fact001013"
      unitRef="USD">3220000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="From2026-01-012026-09-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001017"
      unitRef="USD">55000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2026-09-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001021"
      unitRef="USD">55000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2026-09-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001023"
      unitRef="USD">55000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="From2026-01-012026-09-30_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001027"
      unitRef="USD">16120000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2026-01-012026-09-30_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001029"
      unitRef="USD">-14077000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2026-09-30_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001031"
      unitRef="USD">2043000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2026-09-30_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001035"
      unitRef="USD">2043000</us-gaap:MarketableSecurities>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001037"
      unitRef="USD">19395000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001039"
      unitRef="USD">-14077000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001041"
      unitRef="USD">5318000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001043"
      unitRef="USD">3275000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001045"
      unitRef="USD">2043000</us-gaap:MarketableSecurities>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="From2025-01-012025-12-31_us-gaap_CashMember"
      decimals="0"
      id="Fact001047"
      unitRef="USD">4981000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_CashMember"
      decimals="0"
      id="Fact001051"
      unitRef="USD">4981000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_CashMember"
      decimals="0"
      id="Fact001053"
      unitRef="USD">4981000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="From2025-01-012025-12-31_custom_RestrictedCashMember"
      decimals="0"
      id="Fact001057"
      unitRef="USD">100000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2025-12-31_custom_RestrictedCashMember"
      decimals="0"
      id="Fact001061"
      unitRef="USD">100000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_RestrictedCashMember"
      decimals="0"
      id="Fact001063"
      unitRef="USD">100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="From2025-01-012025-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001067"
      unitRef="USD">1233000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001071"
      unitRef="USD">1233000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001073"
      unitRef="USD">1233000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="From2025-01-012025-12-31_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001077"
      unitRef="USD">26383000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2025-01-012025-12-31_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001079"
      unitRef="USD">-17172000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2025-12-31_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001081"
      unitRef="USD">9211000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2025-12-31_custom_MarketableSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001085"
      unitRef="USD">9211000</us-gaap:MarketableSecurities>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact001087"
      unitRef="USD">32697000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact001089"
      unitRef="USD">-17172000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001091"
      unitRef="USD">15525000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001093"
      unitRef="USD">6314000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">9211000</us-gaap:MarketableSecurities>
    <us-gaap:CreditLossFinancialInstrumentTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001097">&lt;p id="xdx_805_eus-gaap--CreditLossFinancialInstrumentTextBlock_z2LjyrWUccC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8. &lt;span id="xdx_828_zXAouAH2gl9f"&gt;Provision for Credit Losses&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;ASC Topic 326 for the measurement
of credit losses on financial instruments and other financial assets. That guidance requires an allowance for credit losses to be deducted
from the amortized cost basis of financial assets to present the net carrying value that is expected to be collected over the contractual
term of the assets considering relevant information about past events, current conditions, and reasonable and supportable forecasts that
affect the collectability of the reported amount. The guidance replaced the previous incurred loss model for determining the allowance
for credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Accounts receivable are stated
at the amount owed by the customer. The Company maintains an allowance for credit losses for accounts receivable and unbilled receivables,
based on expected credit losses resulting from the inability of our customers to make required payments. The allowance for credit losses
is estimated based on historical experience, current economic conditions and the creditworthiness of customers. Receivables are charged
to the allowance when determined to be no longer collectible. The Company regularly monitors and assesses its risk of not collecting amounts
owed by customers and records its allowance for credit losses based on the results of this analysis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2026 and December
31, 2025, we have reviewed the entire loan portfolio as well as all financial assets of the Company for the purpose of evaluating the
loan portfolio and the loan balances, including a review of individual and collective portfolio loan quality, loan(s) performance, including
past due status and covenant defaults, assessment of the ability of the borrower to repay the loan on the loan terms, whether any loans
should be placed on nonaccrual or returned to accrual, any concentrations in any single borrower and/or industry that we might need to
further manage, and if any specific or general loan loss reserve should be established for the entire loan portfolio or for any specific
loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;We analyzed the loan loss reserve
from three basis: general loan portfolio reserves; industry portfolio reserves, and specific loan loss reserves. For the nine months ended
September 30, 2026, and year ended December 31, 2025, the Company recorded a Loan loss reserve of approximately $&lt;span id="xdx_908_eus-gaap--ProvisionForLoanLossesExpensed_c20260101__20260930__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__custom--LoanMember_z5CgV0Vf1lGb" title="Loan loss reserve"&gt;7,451,000&lt;/span&gt;, and $&lt;span id="xdx_909_eus-gaap--ProvisionForLoanLossesExpensed_pp0p0_c20250101__20251231__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__custom--LoanMember_zu3rtES79Pql" title="Loan loss reserve"&gt;7,478,000&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General Loan Portfolio Reserve
- &lt;/b&gt;Based upon the review of our loan portfolio, we do not believe that a substantial general loan portfolio reserve is due at this
time. However, we do recognize that some inherent risks are in all loan portfolios, thus we recorded a general contingent portfolio reserve
of $&lt;span id="xdx_90A_ecustom--BusinessCombinationConsiderationTransferredLoanLossReverves_c20260101__20260930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--GeneralLoanPortfolioReserveMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember_zam866bc0ED7" title="Portfolio reserve"&gt;0&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--BusinessCombinationConsiderationTransferredLoanLossReverves_c20250101__20251231__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--GeneralLoanPortfolioReserveMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember_zHVkgjZmGgZ5" title="Portfolio reserve"&gt;0&lt;/span&gt; of the loan portfolio loan balance as of September 30, 2026 and December 31, 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Industry Portfolio Reserves
- &lt;/b&gt;Given the relatively diversification of the portfolio over several different loan products, this risk
is reduced. Accordingly, we have not recorded a discretionary reserve as of September 30, 2026 and December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Specific
Loan Reserves &lt;/b&gt;- The Company had previously identified credit weakness in Puradigm and has placed a reserve approximating $&lt;span id="xdx_900_eus-gaap--ConvertibleDebt_iI_c20241231__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiliLLCMember_z372nX4zfFtj" title="Outstanding principal and interest"&gt;5,768,000&lt;/span&gt;
against the outstanding principal and interest as of December 31, 2024 of their two loans. During the first quarter of 2024, the
Company identified credit weakness in VEII and an individual and has placed a reserve approximating $&lt;span id="xdx_904_eus-gaap--ConvertibleDebt_iI_c20240331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VEIIIncMember_zM3FOxEW51w3" title="Outstanding principal and interest"&gt;959,000&lt;/span&gt;
against the outstanding principal and interest as of March 31, 2024. This was later adjusted to $&lt;span id="xdx_906_eus-gaap--ConvertibleDebt_iI_c20260930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VEIIIncMember_zGmDE2kwOgek" title="Outstanding principal and interest"&gt;890,000&lt;/span&gt;
as of September 30, 2026. Also, during the first quarter of 2024, the Company identified credit weakness in BMIC LLC., a related
party, and has placed a reserve approximating $&lt;span id="xdx_908_eus-gaap--ConvertibleDebt_iI_c20240331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BMICapitalIncMember_z9ry08twDVZg" title="Outstanding principal and interest"&gt;211,000&lt;/span&gt;
against the outstanding principal and interest as of March 31, 2024, later adjusted to $&lt;span id="xdx_907_eus-gaap--ConvertibleDebt_iI_c20241231__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BMICapitalIncMember_z72bMTVWdbEe" title="Outstanding principal and interest"&gt;196,000&lt;/span&gt;
as of December 31, 2024 and $&lt;span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_c20260930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BMICapitalIncMember_zO0Cz0M4SSia" title="Outstanding principal and interest"&gt;192,000&lt;/span&gt;
as of September 30, 2026. The Company identified credit weakness with WUURII and has placed a $&lt;span id="xdx_906_eus-gaap--ConvertibleDebt_iI_c20241231__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WUURIICommerceIncMember_zX09Tpx8WJrd" title="Outstanding principal and interest"&gt;234,000&lt;/span&gt;
reserve against the outstanding principal and interest as of December 31, 2024 and reserved for the remaining outstanding balance of
approximately $&lt;span id="xdx_90E_eus-gaap--ConvertibleDebt_iI_c20251231__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WUURIICommerceIncMember_z6ifgGaqG1J3" title="Outstanding principal and interest"&gt;233,000&lt;/span&gt;
as of December 31, 2025 for a total of $&lt;span id="xdx_909_eus-gaap--ConvertibleDebt_iI_c20251231__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WUURIICommerceIncMember_zy6lE92viAIf" title="Outstanding principal and interest"&gt;467,000&lt;/span&gt; December 31, 2025. This was later adjusted to $&lt;span id="xdx_905_eus-gaap--ConvertibleDebt_iI_c20260930__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WUURIICommerceIncMember_zwQh93n6fZc5" title="Outstanding principal and interest"&gt;465,000&lt;/span&gt; at September 30, 2026. The
Company has also identified credit weakness with an individual and has placed a $&lt;span id="xdx_90B_eus-gaap--ConvertibleDebt_iI_c20241231__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--IndividualMember_zPTzqPDpIBCe" title="Outstanding principal and interest"&gt;135,000&lt;/span&gt;
reserve against the outstanding principal and interest as of December 31, 2024, and reserved for an approximate $&lt;span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_c20251231__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--SpecificLoanReservesMember__us-gaap--BusinessAcquisitionAxis__custom--AmericanPacificBancorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--IndividualMember_zz0BTGehmQPc" title="Outstanding principal and interest"&gt;17,000&lt;/span&gt;
against the outstanding principal and interest for another individual as of December 31, 2025. No additional reserves were deemed
necessary as of September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="From2026-01-012026-09-30_custom_LoanMember"
      decimals="0"
      id="Fact001099"
      unitRef="USD">7451000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="From2025-01-012025-12-31_custom_LoanMember"
      decimals="0"
      id="Fact001101"
      unitRef="USD">7478000</us-gaap:ProvisionForLoanLossesExpensed>
    <DSS:BusinessCombinationConsiderationTransferredLoanLossReverves
      contextRef="From2026-01-012026-09-30_custom_GeneralLoanPortfolioReserveMember_custom_AmericanPacificBancorpMember"
      decimals="0"
      id="Fact001103"
      unitRef="USD">0</DSS:BusinessCombinationConsiderationTransferredLoanLossReverves>
    <DSS:BusinessCombinationConsiderationTransferredLoanLossReverves
      contextRef="From2025-01-012025-12-31_custom_GeneralLoanPortfolioReserveMember_custom_AmericanPacificBancorpMember"
      decimals="0"
      id="Fact001105"
      unitRef="USD">0</DSS:BusinessCombinationConsiderationTransferredLoanLossReverves>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_AsiliLLCMember"
      decimals="0"
      id="Fact001107"
      unitRef="USD">5768000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-03-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_VEIIIncMember"
      decimals="0"
      id="Fact001109"
      unitRef="USD">959000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2026-09-30_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_VEIIIncMember"
      decimals="0"
      id="Fact001111"
      unitRef="USD">890000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-03-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_BMICapitalIncMember"
      decimals="0"
      id="Fact001113"
      unitRef="USD">211000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_BMICapitalIncMember"
      decimals="0"
      id="Fact001115"
      unitRef="USD">196000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2026-09-30_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_BMICapitalIncMember"
      decimals="0"
      id="Fact001117"
      unitRef="USD">192000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_WUURIICommerceIncMember"
      decimals="0"
      id="Fact001119"
      unitRef="USD">234000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2025-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_WUURIICommerceIncMember"
      decimals="0"
      id="Fact001121"
      unitRef="USD">233000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2025-12-31_custom_SpecificLoanReservesMember_custom_WUURIICommerceIncMember"
      decimals="0"
      id="Fact001123"
      unitRef="USD">467000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2026-09-30_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_custom_WUURIICommerceIncMember"
      decimals="0"
      id="Fact001125"
      unitRef="USD">465000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_us-gaap_IndividualMember"
      decimals="0"
      id="Fact001127"
      unitRef="USD">135000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2025-12-31_custom_SpecificLoanReservesMember_custom_AmericanPacificBancorpMember_us-gaap_IndividualMember"
      decimals="0"
      id="Fact001129"
      unitRef="USD">17000</us-gaap:ConvertibleDebt>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001131">&lt;p id="xdx_807_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zj3piQ0ay9I7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9. &lt;span id="xdx_823_zhB0ZN5iH0H9"&gt;Disposal of assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 27, 2025, the
Company finalized the sale of its Plano, Tx. Facility for a gross sales price of $&lt;span id="xdx_907_eus-gaap--ProceedsFromSaleOfOtherAssets1_c20250327__20250327_zNkzJQaUVBV9" title="Sale of retail space"&gt;9,500,000&lt;/span&gt;.
The associated asset was previously classified as held for sale in the amount of $&lt;span id="xdx_907_ecustom--AssetsHeldForSales_c20250327__20250327_zfz1YE9ddsTg" title="Assets held for sales"&gt;9,750,000&lt;/span&gt;,
resulting in a loss on the sale of approximately $&lt;span id="xdx_90F_eus-gaap--GainsLossesOnSalesOfAssets_c20250327__20250327_z5Qlcjm39Tte" title="Gain on the sale of assets"&gt;727,000&lt;/span&gt;
after related expenses. On July 24, 2026, Premier Packaging entered into an agreement to sell a 2008 Heidelberg CD102-5+L press for the sum
of $&lt;span id="xdx_909_ecustom--AssetsHeldForSales_c20260724__20260724_zZb3anctwcPg" title="Assets held for sales"&gt;350,000&lt;/span&gt; resulting in a loss on the sale of approximately $&lt;span id="xdx_901_eus-gaap--GainsLossesOnSalesOfAssets_c20260724__20260724_zyxGmOBPqO7" title="Gain on the sale of assets"&gt;35,000&lt;/span&gt; after related expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfOtherAssets1
      contextRef="From2025-03-272025-03-27"
      decimals="0"
      id="Fact001133"
      unitRef="USD">9500000</us-gaap:ProceedsFromSaleOfOtherAssets1>
    <DSS:AssetsHeldForSales
      contextRef="From2025-03-272025-03-27"
      decimals="0"
      id="Fact001135"
      unitRef="USD">9750000</DSS:AssetsHeldForSales>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2025-03-272025-03-27"
      decimals="0"
      id="Fact001137"
      unitRef="USD">727000</us-gaap:GainsLossesOnSalesOfAssets>
    <DSS:AssetsHeldForSales
      contextRef="From2026-07-242026-07-24"
      decimals="0"
      id="Fact001139"
      unitRef="USD">350000</DSS:AssetsHeldForSales>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2026-07-242026-07-24"
      decimals="0"
      id="Fact001141"
      unitRef="USD">35000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:InvestmentTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001143">&lt;p id="xdx_80F_eus-gaap--InvestmentTextBlock_zi957poR8rWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10. &lt;span id="xdx_826_zeeAJUdsHUm3"&gt;Investments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Alset International Limited&lt;/b&gt;, &lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;related party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company owns &lt;span id="xdx_90C_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20260930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zbgZsmKHqf8i" title="Investment owned"&gt;127,179,291&lt;/span&gt; shares
or approximately &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20260101__20260930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zdloMZXc3Ap3" title="Percentage of outstanding shares"&gt;4&lt;/span&gt;% of the outstanding shares of Alset International Limited (&#x201c;Alset Intl&#x201d;), a company incorporated in Singapore
and publicly listed on the Singapore Exchange Limited. This investment is classified as a marketable security and is classified as long-term
assets on the consolidated balance sheets as the Company has the intent and ability to hold the investments for a period of at least one
year. The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of Alset Intl. Mr.
Chan is also the majority shareholder of Alset Intl as well as the largest shareholder of the Company. The fair value of the marketable
security as of September 30, 2026 and December 31, 2025, was approximately $&lt;span id="xdx_903_eus-gaap--MarketableSecurities_iI_c20260930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zsGnUshaGJTe" title="Marketable securities"&gt;1,399,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--MarketableSecurities_iI_c20251231__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zdbkp19esMHf" title="Marketable securities"&gt;2,277,000&lt;/span&gt;, respectively. During the nine months
ended September 30, 2026 and 2025, the Company recorded unrealized loss of approximately $&lt;span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20260101__20260930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zC2f4P4MWZf3" title="Unrealized loss on investments"&gt;877,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--UnrealizedGainLossOnInvestments_c20250101__20250930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_z4qegipqmkz8" title="Unrealized loss on investments"&gt;51,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;True Partners Capital Holding Limited&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company owns &lt;span id="xdx_900_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20260930__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zg1e03gFpI87"&gt;272,520,408&lt;/span&gt; shares
or approximately &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20260101__20260930__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zxV2qTs9YVt7" title="Percentage of outstanding shares"&gt;44.66&lt;/span&gt;% of True Partners Capital Holding Limited (&#x201c;True Partners&#x201d;. &#x201c;TPCH&#x201d;), a publicly listed
company on the Hong Kong Stock Exchange. On February 28, 2022, the Company entered into a Stock Purchase Agreement with Alset EHome International
Inc. (&#x201c;AEI&#x201d;), pursuant to which AEI has agreed to sell a subsidiary holding &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220228__20220228__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zv4zmN2dIvwl"&gt;62,336,908&lt;/span&gt; shares of stock of True Partner Capital
Holding Limited exchange for &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220228__20220228__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zMSWxiV5KRwa" title="Issuance of common stock for bonus, shares"&gt;17,570,948&lt;/span&gt; shares of common stock of the Company (the &#x201c;DSS Shares&#x201d;). The Company&#x2019;s Executive
Chairman and a significant stockholder, Heng Fai Ambrose Chan is the Chairman, Chief Executive Officer and largest shareholder of AEI.
Further, on February 20, 2025, the Company acquired an additional &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20250220__20250220__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zU4QTjlVqBod" title="Number of shares acquired"&gt;19,500,000&lt;/span&gt; shares of True Partners. The fair value of the marketable
security as of December 31, 2025, was approximately $&lt;span id="xdx_900_eus-gaap--MarketableSecurities_iI_c20251231__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zYCCzgRV67Bf" title="Fair value of marketable securities"&gt;4,206,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 27, 2026, the Company
acquired or received a convertible bond investment issued by True Partners with an initial fair value of approximately $&lt;span id="xdx_901_eus-gaap--Investments_iI_c20260327__us-gaap--DebtInstrumentAxis__custom--ConvertibleBondInvestmentMember_zFpxWMORqLnc" title="Convertible bond investment"&gt;8,648,000&lt;/span&gt;, which
was adjusted to $&lt;span id="xdx_903_ecustom--EstimatedFairValueOfDebt_c20260327__20260327__us-gaap--DebtInstrumentAxis__custom--ConvertibleBondInvestmentMember_zi1E0ZcInfee" title="Estimated fair value of debt"&gt;8,520,000&lt;/span&gt; as of March 31, 2026. During the three months ended March 31, 2026, in connection with the Company&#x2019;s
additional investment in True Partners through the convertible bond and the election of Mr. Chan to the board of directors of True Partners,
the Company determined that it has the ability to exercise significant influence over True Partners. Accordingly, beginning on March 27,
2026, the Company began accounting for its investment in True Partners under the equity method of accounting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As a result of the change to equity
method accounting, the Company reclassified its investment in True Partners from Investment in equity securities to Investment, equity
method on the consolidated balance sheet. On April 29, 2026, the convertible bond was converted into approximately &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260429__20260429__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zH7OkF1gka5l" title="Shares new issues"&gt;190,683,500&lt;/span&gt; ordinary
shares of TPCH increasing its total ownership to &lt;span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20260429__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zwaOrXdEsCA7" title="Ownership shares"&gt;272,520,408&lt;/span&gt; shares or approximately &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20260429__20260429__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_z9IJEbdcMwP4" title="Percentage of outstanding shares"&gt;44.66&lt;/span&gt;%. Immediately prior to conversion the fair
value of convertible bond approximately $&lt;span id="xdx_90F_ecustom--ConvertibleBondInvestment_iI_c20260428__us-gaap--DebtInstrumentAxis__custom--ConvertibleBondInvestmentMember_zf2XuKwJxQR3" title="Convertible bond investment fair value"&gt;8,647,000&lt;/span&gt;, resulting in an approximate $&lt;span id="xdx_905_ecustom--ChangeInFairValueOfConvertibleBondInvestmentRelatedParty_c20260428__20260428_zQCKVdDUGSFf" title="Gain from change in fair value of convertible bond"&gt;127,000&lt;/span&gt; gain on the change in fair value. As of September
30, 2026, the carrying value of the Company&#x2019;s investment in True Partners, was approximately $&lt;span id="xdx_908_eus-gaap--MarketableSecurities_iI_c20260930__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zRgp7l27D2Aj" title="Fair value of marketable securities"&gt;11,410,000&lt;/span&gt;. Prior to the ability to
exercise significant influence, the Company recognized an unrealized loss of approximately $&lt;span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20260101__20260331__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zckmAfHGrrbc" title="Marketable securities unrealized gain loss"&gt;606,000&lt;/span&gt; during the three months ended March
31, 2026 related to the change in fair value of True Partners&#x2019; marketable equity securities. During the nine months ended September
30, 2025, the Company recognized an unrealized loss of approximately $&lt;span id="xdx_906_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20250101__20250930__dei--LegalEntityAxis__custom--TruePartnersCapitalHoldingLimitedMember_zhZ7ldj9EdE5" title="Marketable securities unrealized gain loss"&gt;613,000 &lt;/span&gt;related to the investment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;WestPark Capital Group, LLC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On December 30, 2020, the Company
signed a binding letter of intent with WestPark Capital Group, LLC. (&#x201c;WestPark&#x201d;) and Century TBD, Inc. (&#x201c;TBD&#x201d;)
where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to WestPark and WestPark
shall issue to DSS a stock certificate reflecting &lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20201229__20201230__dei--LegalEntityAxis__custom--WestParkCapitalGroupLLCMember_zgZxCZowVgr6" title="Debt instrument convertible threshold percentage of stock price trigger"&gt;7.5&lt;/span&gt;% of the issued and outstanding shares of West Park. This note and stock exchange
agreement was finalized during the first quarter 2022 and valued at approximately $&lt;span id="xdx_900_eus-gaap--Investments_iI_c20260930__dei--LegalEntityAxis__custom--WestParkCapitalIncMember_zBL5Y0Wv739e" title="Investments"&gt;&lt;span id="xdx_900_eus-gaap--Investments_iI_c20251231__dei--LegalEntityAxis__custom--WestParkCapitalIncMember_zNNdT7Ieqlvh" title="Investments"&gt;500,000&lt;/span&gt;&lt;/span&gt; and is included in Investments on the consolidated
balance sheet on September 30, 2026 and December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BMI Capital International LLC, related party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On September 10, 2020, the Company&#x2019;s
wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware
corporation (&#x201c;BMIF&#x201d;) and BMI Capital International LLC, a Texas limited liability company (&#x201c;BMIC&#x201d;) whereas DSS
Securities, Inc. purchased &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200910__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DSSSecuritiesIncMember_zOv4P1z5AUfh" title="Membership interests percentage"&gt;14.9&lt;/span&gt;% membership interests in BMIC for $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200909__20200910__dei--LegalEntityAxis__custom--DSSSecuritiesIncMember_zh5HZQ7zvNbh" title="Number of shares purchased, value"&gt;100,000&lt;/span&gt;. DSS Securities also had the option to purchase an additional
&lt;span id="xdx_90A_ecustom--OutstandingMembershipInterest_pid_dp_uPure_c20210101__20210131__dei--LegalEntityAxis__custom--DSSSecuritiesIncMember_z2o1ah5Dr753"&gt;10&lt;/span&gt;% of the outstanding membership interest which it exercised for $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210131__us-gaap--BusinessAcquisitionAxis__custom--BMICapitalInternationalLLCMember_zEhAHhyESec1" title="Number of shares issued"&gt;100,000&lt;/span&gt; in January of 2021 and increased its ownership to &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BMICapitalInternationalLLCMember_zq7Zq95pQIf7" title="Ownership percentage"&gt;24.9&lt;/span&gt;%. The
Company is currently accounting for this investment under the equity method of accounting per ASC 323. The Company&#x2019;s portion of
net loss in BMIC during the nine months ended September 30, 2026 and 2025, approximated $&lt;span id="xdx_906_ecustom--EquityMethodInvestment_c20260101__20260930__us-gaap--BusinessAcquisitionAxis__custom--BMICapitalInternationalLLCMember_zcU0pyj7kLZ5" title="Equity method investment"&gt;13,000&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--EquityMethodInvestment_c20250101__20250930__us-gaap--BusinessAcquisitionAxis__custom--BMICapitalInternationalLLCMember_zgX6fl2Ukgs8" title="Equity method investment"&gt;4,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;BMIC is a broker-dealer registered
with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (&#x201c;FINRA&#x201d;), and
is a member of the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;). The Company&#x2019;s chairman of the board and another
independent board member of the Company also have ownership interest in BMIC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:InvestmentTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2026-09-30_custom_AlsetInternationalLimitedMember"
      decimals="INF"
      id="Fact001145"
      unitRef="Shares">127179291</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2026-01-012026-09-30_custom_AlsetInternationalLimitedMember"
      decimals="INF"
      id="Fact001147"
      unitRef="Pure">0.04</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2026-09-30_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact001149"
      unitRef="USD">1399000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2025-12-31_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact001151"
      unitRef="USD">2277000</us-gaap:MarketableSecurities>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2026-01-012026-09-30_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact001153"
      unitRef="USD">877000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2025-01-012025-09-30_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact001155"
      unitRef="USD">51000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2026-09-30_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">272520408</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2026-01-012026-09-30_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact001158"
      unitRef="Pure">0.4466</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-282022-02-28_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact001159"
      unitRef="Shares">62336908</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-02-282022-02-28_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact001161"
      unitRef="Shares">17570948</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2025-02-202025-02-20_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact001163"
      unitRef="Shares">19500000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2025-12-31_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact001165"
      unitRef="USD">4206000</us-gaap:MarketableSecurities>
    <us-gaap:Investments
      contextRef="AsOf2026-03-27_custom_ConvertibleBondInvestmentMember"
      decimals="0"
      id="Fact001167"
      unitRef="USD">8648000</us-gaap:Investments>
    <DSS:EstimatedFairValueOfDebt
      contextRef="From2026-03-272026-03-27_custom_ConvertibleBondInvestmentMember"
      decimals="0"
      id="Fact001169"
      unitRef="USD">8520000</DSS:EstimatedFairValueOfDebt>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2026-04-292026-04-29_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact001171"
      unitRef="Shares">190683500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2026-04-29_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact001173"
      unitRef="Shares">272520408</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2026-04-292026-04-29_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="INF"
      id="Fact001175"
      unitRef="Pure">0.4466</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <DSS:ConvertibleBondInvestment
      contextRef="AsOf2026-04-28_custom_ConvertibleBondInvestmentMember"
      decimals="0"
      id="Fact001177"
      unitRef="USD">8647000</DSS:ConvertibleBondInvestment>
    <DSS:ChangeInFairValueOfConvertibleBondInvestmentRelatedParty
      contextRef="From2026-04-282026-04-28"
      decimals="0"
      id="Fact001179"
      unitRef="USD">127000</DSS:ChangeInFairValueOfConvertibleBondInvestmentRelatedParty>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2026-09-30_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact001181"
      unitRef="USD">11410000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2026-01-012026-03-31_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact001183"
      unitRef="USD">606000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-012025-09-30_custom_TruePartnersCapitalHoldingLimitedMember"
      decimals="0"
      id="Fact001185"
      unitRef="USD">613000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2020-12-292020-12-30_custom_WestParkCapitalGroupLLCMember"
      decimals="INF"
      id="Fact001187"
      unitRef="Pure">0.075</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:Investments
      contextRef="AsOf2026-09-30_custom_WestParkCapitalIncMember"
      decimals="0"
      id="Fact001189"
      unitRef="USD">500000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2025-12-31_custom_WestParkCapitalIncMember"
      decimals="0"
      id="Fact001191"
      unitRef="USD">500000</us-gaap:Investments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-09-10_custom_DSSSecuritiesIncMember"
      decimals="INF"
      id="Fact001193"
      unitRef="Pure">0.149</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-09-092020-09-10_custom_DSSSecuritiesIncMember"
      decimals="0"
      id="Fact001195"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <DSS:OutstandingMembershipInterest
      contextRef="From2021-01-012021-01-31_custom_DSSSecuritiesIncMember"
      decimals="INF"
      id="Fact001196"
      unitRef="Pure">0.10</DSS:OutstandingMembershipInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-01-31_custom_BMICapitalInternationalLLCMember"
      decimals="0"
      id="Fact001198"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-01-31_custom_BMICapitalInternationalLLCMember"
      decimals="INF"
      id="Fact001200"
      unitRef="Pure">0.249</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <DSS:EquityMethodInvestment
      contextRef="From2026-01-012026-09-30_custom_BMICapitalInternationalLLCMember"
      decimals="0"
      id="Fact001202"
      unitRef="USD">13000</DSS:EquityMethodInvestment>
    <DSS:EquityMethodInvestment
      contextRef="From2025-01-012025-09-30_custom_BMICapitalInternationalLLCMember"
      decimals="0"
      id="Fact001204"
      unitRef="USD">4000</DSS:EquityMethodInvestment>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001206">&lt;p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zxV2wliXhyY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11. &lt;span id="xdx_820_zZiIZTjH5WXa"&gt;Short-Term and Long-Term Debt&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Promissory Notes -&lt;/i&gt;&lt;/b&gt;
On May 20, 2021, Premier Packaging entered into master loan and security agreement (&#x201c;BOA Note&#x201d;) with Bank of America, N.A.
(&#x201c;BOA&#x201d;) to secure financing approximating $&lt;span id="xdx_903_ecustom--DebtFinancingAmount_iI_pp0p0_c20210520__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_zabb6Io9NTSd" title="Debt financing amount"&gt;3,710,000&lt;/span&gt; to purchase and use as collateral, a new Heidelberg XL 106-7+L printing
press. The aggregate principal balance outstanding under the BOA Note shall bear interest at a variable rate on or before the loan closing.
As of September 30, 2026, and December 31, 2025, the outstanding principal on the BOA Note was $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20260930__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_zaXl9bLk3jll" title="Debt instrument, face amount"&gt;1,511,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20251231__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_ziVzXF8syzmj" title="Debt instrument, face amount"&gt;1,916,000&lt;/span&gt;, respectively
and had an interest rate of &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210520__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_zKO2cFGqhWW7" title="Debt interest rate percentage"&gt;4.63&lt;/span&gt;%. As of September 30, 2026, $&lt;span id="xdx_90D_eus-gaap--LongTermDebtCurrent_iI_c20260930__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_zwDJCh1F3Y8j" title="Long term debt current"&gt;563,000&lt;/span&gt; was included in the Current portion of long-term debt, net, and
the remaining balance of approximately $&lt;span id="xdx_909_eus-gaap--LongTermDebt_iI_c20260930__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_zjFknJhTMqQ6" title="Long term debt"&gt;947,000&lt;/span&gt; is recorded as Long-term debt. As of December 31, 2025, $&lt;span id="xdx_909_eus-gaap--LongTermDebtCurrent_iI_c20251231__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_zGfHfCDyt77e" title="Long term debt current"&gt;544,000&lt;/span&gt; was included in the current
portion of long-term debt, net, and the remaining balance of approximately $&lt;span id="xdx_90B_eus-gaap--LongTermDebt_iI_c20251231__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_zdvRoPAMAiV7" title="Long term debt"&gt;1,372,000&lt;/span&gt; recorded as long-term debt. This note matures in
April of 2029. Interest expense for the nine months ended September 30, 2026 and 2025 approximated $&lt;span id="xdx_90C_eus-gaap--InterestExpense_c20260101__20260930__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_zElg8BYK2l29" title="Interest expense"&gt;60,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--InterestExpense_c20250101__20250930__dei--LegalEntityAxis__custom--PremierPackagingBankOfAmericaNAMember_zWljqtW5uHl9" title="Interest expense"&gt;79,000&lt;/span&gt;, respectively.
The BOA Note contains certain covenants that are analyzed annually. As of September 30, 2026, Premier is in compliance with these covenants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On August 1, 2021, AMRE Shelton,
LLC., (&#x201c;AMRE Shelton&#x201d;) a subsidiary of AMRE, entered into a loan agreement (&#x201c;Shelton Agreement&#x201d;) with Patriot
Bank, N.A. (&#x201c;Patriot Bank&#x201d;) in an amount up to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20210801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_z7c66vGcVjKf" title="Debt instrument face amount"&gt;6,155,000&lt;/span&gt;, with the amount financed approximating $&lt;span id="xdx_90E_eus-gaap--LongTermDebtCurrent_iI_c20210801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zCfWpzVvA197" title="Current portion of long-term debt, net"&gt;5,105,000&lt;/span&gt;. The Shelton
Agreement contains monthly payments of principal and an initial interest of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210801__dei--LegalEntityAxis__custom--AMRESheltonLLCMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zOXVpRIFRWTg" title="Debt instrument interest rate"&gt;4.25&lt;/span&gt;%. &lt;span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20210729__20210801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_ztk1jeQ4Z7De" title="Debt instrument description"&gt;The interest will be adjusted commencing on July 1,
2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date and shall be an interest
rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but
in no event less than &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_z0NxmbUIxJP4" title="Debt instrument, interest rate, effective percentage"&gt;4.25&lt;/span&gt;% for the term of 120 months&lt;/span&gt; with a balloon payment approximating $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20210801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_z3SjUqab9Ajd" title="Debt instrument balloon payment"&gt;2,829,000&lt;/span&gt; due at term end. The funds borrowed
were used to purchase a 40,000 square foot, 2.0 story, Class A+ multi-tenant medical office building located on a 13.62-acre site, which
serves as collateral for the Shelton Agreement. The purchase price has been allocated as $&lt;span id="xdx_90B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210729__20210801__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zXiyNzBstWWe" title="Payments to acquire property plant and equipment"&gt;4,640,000&lt;/span&gt;, $&lt;span id="xdx_90C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210729__20210801__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zRo6b87ZbwQ8" title="Payments to acquire property plant and equipment"&gt;1,600,000&lt;/span&gt;, and $&lt;span id="xdx_905_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210729__20210801__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TenantImprovementsMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zKnGXu2fLYt4" title="Payments to acquire property plant and equipment"&gt;325,000&lt;/span&gt; for the
facility, land, and tenant improvements, respectively. Also included in the value of the property is $&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquireIntangibleAssets_c20210729__20210801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zmQ3Ag0H3pcb" title="Payments to intangible assets"&gt;585,000&lt;/span&gt; of intangible assets with
an estimated useful life of approximating &lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20210801__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zgtLanXCQSy1" title="Estimated useful life"&gt;3&lt;/span&gt; years. The net book value of these assets as of September 30, 2026, and December 31, 2025,
approximated $&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zxcGPfSWvEij" title="Net book value of assets"&gt;6,157,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zWsAU9nBsgKc" title="Net book value of assets"&gt;6,231,000&lt;/span&gt;, respectively. As of September 30, 2026, the outstanding principal and interest of approximately
$&lt;span id="xdx_90F_eus-gaap--LongTermDebt_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zHz9Ww2Z66Ba" title="Long term debt"&gt;4,075,000&lt;/span&gt;, net of $&lt;span id="xdx_907_eus-gaap--DeferredFinanceCostsNet_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zPND9I6SI3Ak" title="Deferred finance costs net"&gt;2,000&lt;/span&gt; in deferred financing costs. As of September 30, 2026, approximately $&lt;span id="xdx_909_eus-gaap--LongTermDebt_iI_c20260930__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zsu3WKHwEtT9" title="Long-term debt"&gt;381,000&lt;/span&gt; is classified as Current portion
of long-term debt, net with the remaining $&lt;span id="xdx_906_eus-gaap--OtherLiabilitiesNoncurrent_iI_c20260930__dei--LegalEntityAxis__custom--AMRESheltonLLCMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zQWIao7rkJLf" title="Non-current liabilities held for sale assets"&gt;3,694,000&lt;/span&gt; classified as long-term debt, net on the consolidated balance sheet. Interest expense
for the nine months ended September 30, 2026 and 2025 approximated $&lt;span id="xdx_905_eus-gaap--InterestExpense_c20260101__20260930__dei--LegalEntityAxis__custom--AMRESheltonLLCMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zL7rm3PNtfPk" title="Interest expense"&gt;89,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--InterestExpense_c20250101__20250930__dei--LegalEntityAxis__custom--AMRESheltonLLCMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zZ3EnvuYpgd8" title="Interest expense"&gt;93,000&lt;/span&gt;, respectively. As of December 31, 2025 approximately
$&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zPiHjJACKoA7" title="Outstanding principal and interest"&gt;226,000&lt;/span&gt; of principal and accrued interest is classified as current portion of long-term debt, net, and the remaining balance of approximately
$&lt;span id="xdx_90E_eus-gaap--LongTermDebt_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zytGfeek8VA7" title="Long term debt"&gt;4,001,000&lt;/span&gt; recorded as long-term debt, net of $&lt;span id="xdx_900_eus-gaap--DeferredFinanceCostsNet_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__dei--LegalEntityAxis__custom--AMRESheltonLLCMember_zOFUl005EEDh" title="Deferred finance costs net"&gt;4,000&lt;/span&gt; in deferred financing costs. This agreement matures in July of 2031.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On October 13, 2021, LVAM entered
into loan agreement with BMIC (&#x201c;BMIC Loan&#x201d;), a related party, whereas LVAM borrowed the principal amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20211013__us-gaap--DebtInstrumentAxis__custom--BMICLoanMember_zL6yTKHi790h" title="Debt instrument, face amount"&gt;3,000,000&lt;/span&gt;, with
interest to be charged at a variable rate to be adjusted at the maturity date. The BMIC loan contains an auto renewal period of three
months, with a current maturity date of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_c20211013__20211013__us-gaap--DebtInstrumentAxis__custom--BMICLoanMember_z6MbQOn0Ulv1" title="Maturity date"&gt;October 2026&lt;/span&gt;. As of September 30, 2026, and December 31, 2025, the outstanding principal and interest
of approximately $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--BMICLoanMember_zJnwwwbFKeMh" title="Debt instrument, face amount"&gt;33,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--BMICLoanMember_zmtyswOaqeBd" title="Debt instrument, face amount"&gt;33,000&lt;/span&gt;, respectively, are included in Current portion of long-term debt &#x2013; related party, net on the
consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On October 13, 2021, LVAM entered
into a loan agreement with Lee Wilson Tsz Kin (&#x201c;Wilson Loan&#x201d;), a related party, whereas LVAM borrowed the principal amount
of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20211013__us-gaap--DebtInstrumentAxis__custom--WilsonLoanMember_znk1WdJMOZab" title="Debt instrument face amount"&gt;3,000,000&lt;/span&gt;, with interest to be charged at a variable rate to be calculated at the maturity date. The Wilson Loan matures on October
12, 2022, and contains an auto renewal period of three months with a current maturity date of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDateDescription_c20211013__20211013__us-gaap--DebtInstrumentAxis__custom--WilsonLoanMember_z5wNt8OR7CRa" title="Maturity date"&gt;October 2026&lt;/span&gt;. As of September 30, 2026, and
December 31, 2025, the outstanding principal and interest of approximately $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--WilsonLoanMember_zqN7uopaDOm4" title="Debt instrument face amount"&gt;145,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--WilsonLoanMember_z0k1AUwEFtWf" title="Debt instrument face amount"&gt;145,000&lt;/span&gt;, respectively, are included in Current
portion of long-term debt &#x2013; related party, net on the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On November 2, 2021, AMRE LifeCare
entered into a loan agreement (&#x201c;LifeCare Agreement&#x201d;) with Pinnacle Bank, (&#x201c;Pinnacle Bank&#x201d;) in the amount of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211102__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zO8SuGoOvfpc" title="Debt instrument face amount"&gt;40,300,000&lt;/span&gt;.
The LifeCare Agreement supported the acquisition of three medical facilities located in Fort Worth, Texas (sold in December 2025), Plano,
Texas (sold in March 2025), and Pittsburgh, Pennsylvania for a purchase price of $&lt;span id="xdx_90B_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20211101__20211102__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zTpUcm9uEq5" title="Payments to acquire business"&gt;62,000,000&lt;/span&gt;.
These assets are classified as investments, real estate on the consolidated balance sheet, and serves as collateral for the LifeCare
Agreement. The purchase price has been allocated as $&lt;span id="xdx_907_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20211101__20211102__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember__dei--LegalEntityAxis__custom--PinnacleBankMember_zI6uVYG2o1Hf" title="Payments to acquire assets"&gt;32,100,000&lt;/span&gt;,
$&lt;span id="xdx_906_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20211101__20211102__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember__dei--LegalEntityAxis__custom--PinnacleBankMember_zSyGh6m5zb27" title="Payments to acquire assets"&gt;12,100,000&lt;/span&gt;,
and $&lt;span id="xdx_90B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20211101__20211102__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--SiteImprovementsMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember__dei--LegalEntityAxis__custom--PinnacleBankMember_zWqcrJlu67n2" title="Payments to acquire assets"&gt;1,500,000
&lt;/span&gt;for the facility, land and site improvements, respectively. Also included in the value of the property is $&lt;span id="xdx_90C_eus-gaap--PaymentsToAcquireIntangibleAssets_c20211101__20211102__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember__dei--LegalEntityAxis__custom--PinnacleBankMember_zzzMRt9QbGna" title="Payments to acquire intangible assets"&gt;15,901,000&lt;/span&gt;
of intangible assets with estimated useful lives ranging from &lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20211102__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember__dei--LegalEntityAxis__custom--PinnacleBankMember__srt--RangeAxis__srt--MinimumMember_zLgbSs8oEfal" title="Estimated useful life"&gt;1&lt;/span&gt;
to &lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20211102__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember__dei--LegalEntityAxis__custom--PinnacleBankMember__srt--RangeAxis__srt--MaximumMember_zhsVhlrWpH9b" title="Estimated useful life"&gt;11&lt;/span&gt;
years. The net book value of the assets acquired as of September 30, 2026 is approximately $&lt;span id="xdx_90A_eus-gaap--RealEstateAssetsHeldForDevelopmentAndSale_iI_c20260930__dei--LegalEntityAxis__custom--AMRELifeCarePortfolioLLCMember_zjEz7AEPib5k" title="Net book value of assets"&gt;10,060,000&lt;/span&gt;.
The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly instalments based upon a twenty-five (25)
year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate
determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20220729__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zReHYlYzzITg" title="Debt instrument interest rate"&gt;4.28&lt;/span&gt;%,
with the first such instalment being payable on August 29, 2022 and subsequent instalments being payable on the first day of each succeeding
month thereafter until the maturity date, at which time any outstanding principal and interest is due in full. The affective interest
rate at September 30, 2026 was &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20260930__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zQol1Ehiw4p2" title="Interest rate"&gt;8.0&lt;/span&gt;%.
As of September 30, 2026, and December 31, 2025, the outstanding principal and interest of the LifeCare agreement approximates $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20260930__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zGwCu35aA4ea" title="Principal amount"&gt;39,102,000&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zu21ZUaqfSzk" title="Principal amount"&gt;37,401,000&lt;/span&gt;,
respectively. As September 30, 2026, $&lt;span id="xdx_906_eus-gaap--LongTermDebtCurrent_iI_c20260930__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zaDv1N8OFQ21" title="Long term debt current"&gt;29,419,000&lt;/span&gt;
is included Current portion of long-term debt, net, $&lt;span id="xdx_903_eus-gaap--InterestReceivable_iI_c20260930__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zwVAntQxdB6l" title="Accrued interest"&gt;8,916,000&lt;/span&gt;
is included in Accrued interest on long-term debt, and $&lt;span id="xdx_90B_eus-gaap--OtherNotesPayable_iI_c20260930__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zYrb24Jw15t2" title="Other payables"&gt;768,000&lt;/span&gt; of other costs are included in Other payables on the accompanying balance sheet. As December 31, 2025, $&lt;span id="xdx_909_eus-gaap--LongTermDebtCurrent_iI_c20251231__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zncOKHIfd169" title="Long term debt current"&gt;30,254,000&lt;/span&gt;
is included Current portion of long-term debt, net and $&lt;span id="xdx_90E_eus-gaap--InterestReceivable_iI_c20251231__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zbtXSTZmm4Ma" title="Accrued interest"&gt;7,147,000&lt;/span&gt;
is included in Accrued interest on long-term debt on the accompanying balance sheet. Interest expense for the nine months ended September
30, 2026 and 2025 approximated $&lt;span id="xdx_90B_eus-gaap--InterestExpense_c20260101__20260930__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_zxUkevmyZmff" title="Interest expense"&gt;1,769,000&lt;/span&gt;
and $&lt;span id="xdx_90A_eus-gaap--InterestExpense_c20250101__20250930__dei--LegalEntityAxis__custom--PinnacleBankMember__us-gaap--TypeOfArrangementAxis__custom--LifeCareAgreementMember_znupZt2ZqCa7" title="Interest expense"&gt;2,278,000&lt;/span&gt;,
respectively. This note is in default and demand was made for final payment to be made by December 22, 2023. As of September 30, 2026,
this amount is past due.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 30, 2023, Premier Packaging,
a subsidiary of the Company entered into a loan and security agreement with Union Bank &amp;amp; Trust Company for the principal amount of
$&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230330__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember_z0I6ZKHMPPRl" title="Debt instrument face amount"&gt;790,000&lt;/span&gt; and shall accrued interest at the rate of &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230330__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember_zu01EfNO95Ql" title="Principal interest percentage"&gt;7.44&lt;/span&gt;%. Principal and interest shall be repaid in the approximate amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_c20230330__20230330__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember_zbVAkZ08s6Vb" title="Principal and interest payable"&gt;14,000&lt;/span&gt;
through March 2029. This loan is collateralized by a Bobst Model Novacut and is guaranteed by DSS, Inc. As of September 30, 2026, the
outstanding principal and interest approximates $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember_zvcm8BQV7F29" title="Debt instrument, face amount"&gt;384,000&lt;/span&gt; of which $&lt;span id="xdx_90B_eus-gaap--LongTermDebtCurrent_iI_pp0p0_c20260930__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember_zp4sDUvgLPik" title="Long term debt current"&gt;140,000&lt;/span&gt; was included in the current portion of long-term debt, net,
and the remaining balance of approximately $&lt;span id="xdx_907_eus-gaap--LongTermDebt_iI_pp0p0_c20260930__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember_z8H5jhStJKIb" title="Long term debt current"&gt;244,000&lt;/span&gt; recorded as long-term debt. As of December 31, 2025, the outstanding principal and
interest approximates $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember_zZfnVhxg6ZT" title="Debt instrument, face amount"&gt;482,000&lt;/span&gt; of which $&lt;span id="xdx_90F_eus-gaap--LongTermDebtCurrent_iI_pp0p0_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember_zZdV1KLdfXu2" title="Long term debt current"&gt;132,000&lt;/span&gt; was included in the current portion of long-term debt, net, and the remaining balance
of approximately $&lt;span id="xdx_901_eus-gaap--LongTermDebt_iI_pp0p0_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember_zJ7Yz0jt2NM" title="Long term debt"&gt;350,000&lt;/span&gt; recorded as long-term debt. Interest expense for the nine months ended September 30, 2026 and 2025 approximated
$&lt;span id="xdx_904_eus-gaap--InterestExpense_c20260101__20260930__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zwTBKVS1PQyh" title="Interest expense"&gt;25,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--InterestExpense_c20250101__20250930__dei--LegalEntityAxis__custom--UnionBankAndTrustCompanyMember__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_z0B1kOjkzfod" title="Interest expense"&gt;32,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In August of 2025, DSS issued
a $&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_c20250831__dei--LegalEntityAxis__custom--AlsetIncMember_zaqzbkvT8wU1" title="Convertible promissory note"&gt;500,000&lt;/span&gt; convertible promissory note to Alset, Inc. (&#x201c;holder&#x201d;), the Company&#x2019;s largest shareholder and a related party,
bearing interest at Prime (&lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260930__dei--LegalEntityAxis__custom--AlsetIncMember_z9c3oJsvAFw5" title="Interest rate"&gt;6.75&lt;/span&gt;% at September 30, 2026). The first 12 months&#x2019; interest is to be paid in shares of the Company; thereafter,
interest is prepaid annually in cash or shares at the holder&#x2019;s election. The note is convertible at the holder&#x2019;s option at
a fixed $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250831__dei--LegalEntityAxis__custom--AlsetIncMember_zfqvTVMdjDll" title="Debt conversion price per share"&gt;0.86&lt;/span&gt; per share, is payable on demand (or July 31, 2028 if not demanded), and may be redeemed by the Company on or after the first
anniversary. The Company is required to reserve sufficient authorized shares and maintain the listing/quotation of its common stock. Under
ASU 2020-06 and ASC 815-40, the debt host&#x2019;s embedded conversion feature is indexed to the Company&#x2019;s own stock and is equity-classified;
accordingly, no embedded derivative is bifurcated and the instrument is accounted for as single-unit debt using the effective interest
method. Interest is recognized in interest expense; when settled in shares, a credit to APIC is recorded at the fair value of shares on
settlement, and any prepaid interest is recorded as a discount/prepaid and amortized to expense over the related period. The outstanding
principal and interest, approximates $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20260930__dei--LegalEntityAxis__custom--AlsetIncMember_zrs6APDdQ4Hk" title="Principal amount"&gt;538,000&lt;/span&gt; and is included in Convertible note payable, related party on the accompanying consolidated
balance sheet at September 30, 2026. The outstanding principal and interest, approximates $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__dei--LegalEntityAxis__custom--AlsetIncMember_zXOwXPyubVma" title="Principal amount"&gt;512,000&lt;/span&gt; and is included in Convertible note
payable, related party on the accompanying consolidated balance sheet at December 31, 2025. Interest expense for the nine months ended
September 30, 2026 and 2025 approximated $&lt;span id="xdx_903_eus-gaap--InterestExpense_c20260101__20260930__dei--LegalEntityAxis__custom--AlsetIncMember_zg2eW43gyOOb" title="Interest expense"&gt;36,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--InterestExpense_c20250101__20250930__dei--LegalEntityAxis__custom--AlsetIncMember_zHX7YZ3kXNkc" title="Interest expense"&gt;3,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 26, 2026, the Company
issued a $&lt;span id="xdx_902_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20260326__us-gaap--DebtInstrumentAxis__custom--ConvertibleBondInvestmentMember_zCb7pW8AvsPa" title="Convertible bond investment fair value"&gt;2,450,000&lt;/span&gt; convertible promissory note to Alset International Limited (&#x201c;AIL&#x201d;), a related party. The note bears interest
at &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260326__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zfNYRiI5Cz29" title="Simple interest rate"&gt;3.0&lt;/span&gt;% per annum, is payable on demand by Alset International Limited, or if the demand is not sooner made, is payable on the earliest
to occur of (i) five years from issuance; (ii) the acceleration of the note upon occurrence of an event of default; (iii) upon full conversion
of the note; or (iv) upon repurchase of the note by the Company. This note is convertible at any time into shares of the Company&#x2019;s
common stock at a conversion price of $&lt;span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260326__20260326__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zEJqDmsxXak5" title="Converted outstanding price"&gt;0.74&lt;/span&gt; per share. Interest is payable at maturity either in cash or shares of common stock, at the
holder&#x2019;s election. The note also contains a most favored nation provision allowing AIL to exchange the note for a subsequent convertible
instrument issued by the Company if AIL determines that such instrument contains more favorable terms. AIL is a related party because
the Company owns approximately 4% of AIL&#x2019;s outstanding shares, and the Company&#x2019;s Chairman is the Executive Director, Chief
Executive Officer, majority shareholder of AIL, and the largest shareholder of the Company. In connection with the note, the Company issued
AIL a warrant to purchase up to &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20260326__20260326__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrTaKgE4G9a7" title="Purchase of warrant"&gt;16,554,055&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260326__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zD6V0aGBSv7h" title="Exercise price"&gt;0.93&lt;/span&gt; per share. The warrant
expires five years from the issuance date. The Company evaluated the conversion feature, most favored nation provision, and warrant under
ASC 815, ASC 815-40, and ASC 480 and concluded that no derivative liability was required. The conversion feature qualified for the scope
exception for instruments indexed to and classified in the Company&#x2019;s own equity, and the warrant was classified as equity because
it is share-settled, contains a fixed share limit, does not require net cash settlement, and the Company has sufficient authorized and
unissued shares to settle the warrant. &lt;span id="xdx_90E_ecustom--BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zMzTOv7fztgd" title="Allocated description"&gt;The Company allocated the $2,450,000 proceeds between the convertible note and warrant based on
their relative fair values. The warrant valuation was determined using a Black-Scholes option-pricing model. Significant valuation inputs
included the Company&#x2019;s common stock price of $0.91 per share, exercise price of $0.93 per share, expected term of 5.0 years, risk-free
rate of 4.0%, selected volatility of 85.0%, expected dividend rate of 0.0%, and 16,554,055 warrants outstanding. Based on these inputs,
the calculated warrant value was $0.63 per warrant, resulting in an indicated fair value of $10,368,000. The fair value of the convertible
note was determined using valuation techniques that considered the contractual note terms, conversion feature, most favored nation provision,
Company-specific credit risk, market interest rates, expected volatility, and probability-weighted conversion scenarios. The valuation
considered two scenarios: a no subsequent convertible instrument issuance before expiration scenario, with an indicated value of $3,418,000.
For purposes of allocating the $2,450,000 proceeds at issuance, the Company used the relative fair values of the warrant and convertible
note. Accordingly, $1,843,000 was allocated to the warrant and recorded in additional paid-in capital, and $607,000 was allocated to the
note. The allocation resulted in a debt discount of $1,843,000, which will be amortized to interest expense over the five-year term of
the note using the effective interest method. As of September 30, 2026, the note had a principal amount of $2,450,000, unamortized debt
discount of approximately $1,776,000 and a net carrying amount of approximately $674,000.&lt;/span&gt; The debt discount is being amortized to interest
expense over the five-year contractual term of the note using the effective interest method. Interest expense for the nine months ended September 30, 2026 and 2025 approximated $38,000 and $0, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On June 23, 2026, the Company
issued a $&lt;span id="xdx_907_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z68dM8t0OFJa" title="Convertible bond investment fair value"&gt;1,000,000&lt;/span&gt;
convertible promissory note to Alset, Inc. (&#x201c;Alset&#x201d;), a related party, and received aggregate proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_c20260623__20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zOuzFTwmpiEg" title="Proceeds from issuance of convertible promissory note"&gt;1,000,000&lt;/span&gt;.
The note bears interest at &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zkRLTym6Vexc" title="Interest rate"&gt;3.0&lt;/span&gt;%
per annum, calculated based on the actual number of days elapsed over a 360-day year, is payable on demand by Alset, and otherwise matures
on &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20260623__20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zvho7CTnwVxh" title="Maturity date"&gt;June
23, 2031&lt;/span&gt;. The outstanding principal and accrued interest are convertible into shares of the Company&#x2019;s common stock at a
conversion price of $&lt;span id="xdx_903_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260623__20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z4DT1LdmY579" title="Converted outstanding price"&gt;0.45&lt;/span&gt;
per share, subject to required stockholder approval and customary anti-dilution adjustments. Interest is payable at maturity either in
cash or shares of common stock, at the holder&#x2019;s election. Beginning June 23, 2027, the Company may redeem all or a portion of the
outstanding principal without penalty. Alset is a related party due to common control and overlapping directors and officers, and the
transaction is disclosed in accordance with ASC 850-10-50. In connection with the note, the Company issued Alset warrants to purchase
up to &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20260623__20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z5I3EoQpmjjh" title="Purchase of warrant"&gt;17,777,776&lt;/span&gt;
shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zNCQlw3uSZY2" title="Exercise price"&gt;0.50&lt;/span&gt;
per share. The warrants are immediately exercisable and expire on June 23, 2029. The Company evaluated the conversion feature, holder
demand provision, issuer redemption provision, and warrants under ASC 470-20, ASC 815-15, ASC 815-40, and ASC 480 and concluded that
no derivative liability was required. The conversion feature qualified for the scope exception for instruments indexed to and classified
in the Company&#x2019;s own equity. The holder demand and issuer redemption provisions were determined to be clearly and closely related
to the debt host. The warrants were classified as equity because they are share-settled, have a fixed exercise price and fixed share
limit, do not require net cash settlement, and the Company has sufficient authorized and unissued shares to settle the warrants. Accordingly,
the warrants were recorded in additional paid-in capital and are not subsequently remeasured while they continue to qualify for equity
classification. &lt;span id="xdx_900_ecustom--BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_zZGEDcyzCJB4" title="Allocated description"&gt;The
Company allocated the $1,000,000 of proceeds between the convertible note and warrants based on their relative fair values in accordance
with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined using a Black-Scholes option-pricing model. Significant
valuation inputs included the Company&#x2019;s common stock price of $0.61 per share, exercise price of $0.50 per share, expected term
of 3.0 years, risk-free interest rate of 4.2%, selected volatility of 85.0%, expected dividend rate of 0.0%, and 17,777,776 warrants
outstanding. Based on these inputs, the calculated warrant value was $0.37 per warrant, resulting in an indicated fair value of $6,651,000.
The fair value of the convertible note at issuance was determined using a binomial lattice model that considered the contractual note
terms, conversion feature, Company-specific credit risk, market interest rates, expected volatility, and the Company&#x2019;s redemption
right. Significant valuation inputs included the Company&#x2019;s common stock price of $0.61 per share, conversion price of $0.45 per
share, contractual term of 5.0 years, risk-free interest rate of 4.2%, selected volatility of 85.0%, and discount rate of 13.25%. Based
on these inputs, the indicated fair value of the convertible note at issuance was $1,531,000. For purposes of allocating the $1,000,000
of proceeds at issuance, the Company used the relative fair values of the warrants and convertible note. Accordingly, $813,000 was allocated
to the warrants and recorded in additional paid-in capital, and $187,000 was allocated to the note. The allocation resulted in an initial
debt discount of $813,000, which is being amortized to interest expense over the five-year contractual term of the note using the effective
interest method. As of September 30, 2026, the note had a principal amount of $1,000,000, an unamortized debt discount of approximately
$802,000, and a net carrying amount of approximately $198,000. &lt;/span&gt;Interest expense for the nine months ended September 30, 2026 and
2025 approximated $&lt;span id="xdx_906_eus-gaap--InterestExpense_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_zz1PaJsdxmV1" title="Interest expense"&gt;8,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--InterestExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_zgBHGNfSaZL4" title="Interest expense"&gt;0&lt;/span&gt;, respectively.&#160;The note is classified as a current liability under ASC 470-10-45 because it is payable
on demand.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On August 17, 2026, the Company
issued a $&lt;span id="xdx_90B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20260817__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zHKavnnCM6C6" title="Convertible bond investment fair value"&gt;600,000&lt;/span&gt; convertible promissory note to Alset, Inc. (&#x201c;Alset&#x201d;), a related party, and received aggregate proceeds of
$&lt;span id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_c20260817__20260817__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_ztfUFSXVQbpc" title="Proceeds from issuance of convertible promissory note"&gt;600,000&lt;/span&gt;. The note bears interest at &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260817__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zqW2vsHkuB39" title="Interest rate"&gt;3.0&lt;/span&gt;% per annum, calculated based on the actual number of days elapsed over a 360-day year, is payable
on demand by Alset, and otherwise matures on &lt;span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20260817__20260817__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zZemshiMRhB3" title="Maturity date"&gt;August 17, 2031&lt;/span&gt;. The outstanding principal and accrued interest are convertible into shares
of the Company&#x2019;s common stock at a conversion price of $&lt;span id="xdx_902_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260817__20260817__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zf11TEOYAjRj" title="Converted outstanding price"&gt;0.45&lt;/span&gt; per share, subject to required stockholder approval and customary anti-dilution
adjustments. Interest is payable at maturity either in cash or shares of common stock, at the holder&#x2019;s election. Beginning August
17, 2027, the Company may redeem all or a portion of the outstanding principal without penalty. Alset is a related party due to common
control and overlapping directors and officers, and the transaction is disclosed in accordance with ASC 850-10-50. In connection with
the note, the Company issued Alset warrants to purchase up to &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20260817__20260817__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember_z3EugDr4pv7k" title="Purchase of warrant"&gt;10,666,667&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price
of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260817__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember_zOs1RJDG6EL3" title="Exercise price"&gt;0.50&lt;/span&gt; per share. The warrants are immediately exercisable and expire on August 17, 2031. The Company evaluated the conversion feature,
holder demand provision, issuer redemption provision and warrants under ASC 470-20, ASC 815-15, ASC 815-40 and ASC 480 and concluded that
no derivative liability was required. The conversion feature qualified for the scope exception for instruments indexed to and classified
in the Company&#x2019;s own equity. The holder demand and issuer redemption provisions were determined to be clearly and closely related
to the debt host. The warrants were classified as equity because they are share-settled, have a fixed exercise price and fixed share limit,
do not require net cash settlement, and the Company has sufficient authorized and unissued shares to settle the warrants. Accordingly,
the warrants were recorded in additional paid-in capital and are not subsequently remeasured while they continue to qualify for equity
classification. &lt;span id="xdx_90E_ecustom--BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteOneMember_zyvZ3QsaQGSb" title="Allocated description"&gt;The Company allocated the $600,000 of proceeds between the convertible note and warrants based on their relative fair
values in accordance with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined using a Black-Scholes option-pricing
model. Significant valuation inputs included the Company&#x2019;s common stock price of $0.5615 per share, exercise price of $0.50 per
share, expected term of 5.0 years, risk-free interest rate of 4.38%, selected volatility of 85.0%, expected dividend rate of 0.0%, and
10,666,667 warrants outstanding. Based on these inputs, the calculated warrant value was approximately $0.40 per warrant, resulting in
an indicated fair value of approximately $4,271,000. The fair value of the convertible note at issuance was determined using a valuation
approach that combined a discounted cash-flow analysis of the straight-debt component with an option-pricing analysis of the embedded
conversion feature. The valuation considered the contractual note terms, conversion feature, Company-specific credit risk, market interest
rates, expected volatility and the Company&#x2019;s redemption right. Significant valuation inputs included the Company&#x2019;s common
stock price of $0.56per share, conversion price of $0.45 per share, contractual term of 5.0 years, risk-free interest rate of 4.38%, selected
volatility of 85.0%, and a credit-adjusted discount rate of 14.43%. Based on these inputs, the indicated fair value of the convertible
note at issuance was approximately $898,000. For purposes of allocating the $600,000 of proceeds at issuance, the Company used the relative
fair values of the warrants and convertible note. Accordingly, approximately $496,000 was allocated to the warrants and recorded in additional
paid-in capital, and approximately $104,000 was allocated to the note. The allocation resulted in an initial debt discount of approximately
$496,000, which is being amortized to interest expense over the five-year contractual term of the note using the effective interest method
pursuant to ASC 835-30-35. As of September 30, 2026, the note had a principal amount of $600,000, an unamortized debt discount of approximately
$493,000, a net carrying amount of approximately $107,000 and accrued interest of approximately $2,000. Interest expense associated with
the note for the three and nine months ended September 30, 2026 was approximately $5,000, including approximately $3,000 of debt-discount
amortization.&lt;/span&gt; No corresponding interest expense was recognized during the comparable 2025 periods. The note is classified as a current
liability under ASC 470-10-45 because it is payable on demand.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On September 15, 2026, the Company
issued a $&lt;span id="xdx_90A_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20260915__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zOBYBoqn7BE1" title="Convertible bond investment fair value"&gt;500,000&lt;/span&gt; convertible promissory note to Alset, Inc. (&#x201c;Alset&#x201d;), a related party, and received aggregate proceeds of
$&lt;span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20260915__20260915__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z9MYiGWH3Iof" title="Proceeds from issuance of convertible promissory note"&gt;500,000&lt;/span&gt;. The note bears interest at &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260915__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zDTbXO7mxg8l" title="Interest rate"&gt;3.0&lt;/span&gt;% per annum, calculated based on the actual number of days elapsed over a 360-day year, is payable
on demand by Alset, and otherwise matures on &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateDescription_c20260915__20260915__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zcP6MCBbr58g" title="Maturity date"&gt;September 15, 2031&lt;/span&gt;. Following receipt of required stockholder approval, the outstanding principal
and accrued interest are convertible into shares of the Company&#x2019;s common stock at a conversion price of $&lt;span id="xdx_905_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260915__20260915__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zosUqo8Qf2ra" title="Converted outstanding price"&gt;0.50&lt;/span&gt; per share, subject
to customary anti-dilution adjustments. Interest is payable at maturity either in cash or shares of common stock, at the holder&#x2019;s
election. Beginning September 15, 2027, the Company may redeem all or a portion of the outstanding principal without penalty. Alset is
a related party due to common control and overlapping directors and officers, and the transaction is disclosed in accordance with ASC
850-10-50. In connection with the note, the Company issued Alset warrants to purchase up to &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20260915__20260915__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember_zdeElsL2FWvl" title="Purchase of warrant"&gt;8,000,000&lt;/span&gt; shares of the Company&#x2019;s common
stock at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260915__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember_zcdWhpelhYl" title="Exercise price"&gt;0.55&lt;/span&gt; per share. The warrants are immediately exercisable and expire on September 15, 2031. The Company
evaluated the conversion feature, holder demand provision, issuer redemption provision, and warrants under ASC 470-20, ASC 815-15, ASC
815-40, and ASC 480 and concluded that no separate derivative liability was required. The conversion feature was determined to qualify
for the scope exception applicable to instruments indexed to and classified in the Company&#x2019;s own equity. The holder demand and issuer
redemption provisions remain embedded in the debt host. The warrants were classified as equity because they are share-settled, have a
fixed exercise price and fixed maximum share amount, do not require net cash settlement, and otherwise meet the applicable equity-classification
requirements of ASC 815-40. Accordingly, the warrants were recorded in additional paid-in capital and are not subsequently remeasured
while they continue to qualify for equity classification. &lt;span id="xdx_900_ecustom--BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteTwoMember_zcPkUWbZx6Y2" title="Allocated description"&gt;The Company allocated the $500,000 of proceeds between the convertible note
and warrants based on their relative fair values in accordance with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined
using a Black-Scholes-Merton option-pricing model. Significant valuation inputs included the Company&#x2019;s common stock price of $0.7411
per share, exercise price of $0.55 per share, expected term of 5.0 years, risk-free interest rate of 4.83%, selected volatility of 85.0%,
expected dividend rate of 0.0%, and 8,000,000 warrants outstanding. Based on these inputs, the calculated warrant value was approximately
$0.55154 per warrant, resulting in an indicated fair value of approximately $4,412,000. The fair value of the convertible note at issuance
was determined using a component valuation approach consisting of a discounted cash flow analysis of the straight-debt component and a
Black-Scholes approximation of the embedded conversion feature. The straight-debt analysis considered the contractual cash flows, five-year
expected term, Company-specific credit risk and market interest rates. Significant valuation inputs included a principal amount of $500,000,
contractual interest rate of 3.0%, five-year term, and a credit-adjusted market yield of 15.55%. The indicated fair value of the straight-debt
component was approximately $280,000. The embedded conversion feature was valued using the Company&#x2019;s common stock price of $0.7411
per share, conversion price of $0.50 per share, expected term of 5.0 years, risk-free interest rate of 4.83%, selected volatility of 85.0%,
and expected dividend rate of 0.0%. The indicated value of the conversion feature was approximately $562,000, resulting in an indicated
stand-alone fair value of the convertible note of approximately $841,000. For purposes of allocating the $500,000 of proceeds at issuance,
the Company used the relative fair values of the warrants and convertible note. Accordingly, approximately $420,000 was allocated to the
warrants and recorded in additional paid-in capital, and approximately $80,000 was allocated to the note. The allocation resulted in an
initial debt discount of approximately $420,000, which is being amortized to interest expense over the five-year contractual term of the
note using the effective interest method in accordance with ASC 835-30. The resulting effective interest rate is approximately 47.55%.
As of September 30, 2026, the note had a principal amount of $500,000, an unamortized debt discount of approximately $419,000, and a net
carrying amount of approximately $81,000, exclusive of accrued contractual interest.&lt;/span&gt; For the period from September 15, 2026 through September
30, 2026, the Company recognized approximately $&lt;span id="xdx_90D_eus-gaap--InterestExpense_c20260915__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_zjET2Hxx4Su5" title="Interest expense"&gt;1,000&lt;/span&gt; of interest expense. Because the note is payable on demand, it is classified as
a current related-party liability under ASC 470-10-45.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_znZ9vN05X0i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;A summary of scheduled principal
payments of long-term and current debt, convertible notes and notes payable &#x2013; related party
as of September 30, 2026, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_z1X67xTxO1Ni" style="display: none"&gt;Schedule
of Long-Term And Current Debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zhQklFqFuMQ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Notes
    payable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConvertibleNotePayableRelatedPartyMember_zLMwjjPN10Ad" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible note payable &lt;br/&gt; - related party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z95qioaFILF" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Notes payable &lt;br/&gt; - related party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260930_zBoaUXSMge8l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pp0p0_maLTDztfD_z63j2H0xKSLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;30,503,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,598,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;178,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;32,279,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_maLTDztfD_zSNwLnOgG4cf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,091,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1439"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,091,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDztfD_zul7LMu9o3Oj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1444"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDztfD_zzqAZpzTkPVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1449"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDztfD_z0Z86Ps6X88g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1453"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1454"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearAfterYearFour_iI_pp0p0_maLTDztfD_zShupBCA7xt3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,649,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1459"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,649,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDztfD_z61JNjhqPDIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="display: none; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,389,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,598,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;178,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;37,165,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <DSS:DebtFinancingAmount
      contextRef="AsOf2021-05-20_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="0"
      id="Fact001208"
      unitRef="USD">3710000</DSS:DebtFinancingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="0"
      id="Fact001210"
      unitRef="USD">1511000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="0"
      id="Fact001212"
      unitRef="USD">1916000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-05-20_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="INF"
      id="Fact001214"
      unitRef="Pure">0.0463</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2026-09-30_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="0"
      id="Fact001216"
      unitRef="USD">563000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-09-30_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="0"
      id="Fact001218"
      unitRef="USD">947000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2025-12-31_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="0"
      id="Fact001220"
      unitRef="USD">544000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="AsOf2025-12-31_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="0"
      id="Fact001222"
      unitRef="USD">1372000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="0"
      id="Fact001224"
      unitRef="USD">60000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_custom_PremierPackagingBankOfAmericaNAMember"
      decimals="0"
      id="Fact001226"
      unitRef="USD">79000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001228"
      unitRef="USD">6155000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001230"
      unitRef="USD">5105000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="INF"
      id="Fact001232"
      unitRef="Pure">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2021-07-292021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      id="Fact001234">The interest will be adjusted commencing on July 1,
2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date and shall be an interest
rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but
in no event less than 4.25% for the term of 120 months</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="INF"
      id="Fact001236"
      unitRef="Pure">0.0425</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="AsOf2021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001238"
      unitRef="USD">2829000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-07-292021-08-01_custom_FacilityMember_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001240"
      unitRef="USD">4640000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-07-292021-08-01_us-gaap_LandMember_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001242"
      unitRef="USD">1600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-07-292021-08-01_custom_TenantImprovementsMember_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001244"
      unitRef="USD">325000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-07-292021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001246"
      unitRef="USD">585000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2021-08-01_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      id="Fact001248">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-09-30_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001250"
      unitRef="USD">6157000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001252"
      unitRef="USD">6231000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-09-30_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001254"
      unitRef="USD">4075000</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2026-09-30_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001256"
      unitRef="USD">2000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-09-30_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001258"
      unitRef="USD">381000</us-gaap:LongTermDebt>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2026-09-30_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001260"
      unitRef="USD">3694000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_custom_AMRESheltonLLCMember_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001262"
      unitRef="USD">89000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_custom_AMRESheltonLLCMember_custom_LoanAgreementMember"
      decimals="0"
      id="Fact001264"
      unitRef="USD">93000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001266"
      unitRef="USD">226000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt
      contextRef="AsOf2025-12-31_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001268"
      unitRef="USD">4001000</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2025-12-31_custom_LoanAgreementMember_custom_AMRESheltonLLCMember"
      decimals="0"
      id="Fact001270"
      unitRef="USD">4000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-10-13_custom_BMICLoanMember"
      decimals="0"
      id="Fact001272"
      unitRef="USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2021-10-132021-10-13_custom_BMICLoanMember"
      id="Fact001274">October 2026</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_custom_BMICLoanMember"
      decimals="0"
      id="Fact001276"
      unitRef="USD">33000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_BMICLoanMember"
      decimals="0"
      id="Fact001278"
      unitRef="USD">33000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-10-13_custom_WilsonLoanMember"
      decimals="0"
      id="Fact001280"
      unitRef="USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2021-10-132021-10-13_custom_WilsonLoanMember"
      id="Fact001282">October 2026</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_custom_WilsonLoanMember"
      decimals="0"
      id="Fact001284"
      unitRef="USD">145000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_WilsonLoanMember"
      decimals="0"
      id="Fact001286"
      unitRef="USD">145000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-11-02_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001288"
      unitRef="USD">40300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2021-11-012021-11-02_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001290"
      unitRef="USD">62000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-11-012021-11-02_custom_FacilityMember_custom_LifeCareAgreementMember_custom_PinnacleBankMember"
      decimals="0"
      id="Fact001292"
      unitRef="USD">32100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-11-012021-11-02_us-gaap_LandMember_custom_LifeCareAgreementMember_custom_PinnacleBankMember"
      decimals="0"
      id="Fact001294"
      unitRef="USD">12100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-11-012021-11-02_custom_SiteImprovementsMember_custom_LifeCareAgreementMember_custom_PinnacleBankMember"
      decimals="0"
      id="Fact001296"
      unitRef="USD">1500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-11-012021-11-02_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001298"
      unitRef="USD">15901000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2021-11-02_custom_LifeCareAgreementMember_custom_PinnacleBankMember_srt_MinimumMember"
      id="Fact001300">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2021-11-02_custom_LifeCareAgreementMember_custom_PinnacleBankMember_srt_MaximumMember"
      id="Fact001302">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:RealEstateAssetsHeldForDevelopmentAndSale
      contextRef="AsOf2026-09-30_custom_AMRELifeCarePortfolioLLCMember"
      decimals="0"
      id="Fact001304"
      unitRef="USD">10060000</us-gaap:RealEstateAssetsHeldForDevelopmentAndSale>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2022-07-29_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="INF"
      id="Fact001306"
      unitRef="Pure">0.0428</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2026-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="INF"
      id="Fact001308"
      unitRef="Pure">0.080</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001310"
      unitRef="USD">39102000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001312"
      unitRef="USD">37401000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2026-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001314"
      unitRef="USD">29419000</us-gaap:LongTermDebtCurrent>
    <us-gaap:InterestReceivable
      contextRef="AsOf2026-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001316"
      unitRef="USD">8916000</us-gaap:InterestReceivable>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2026-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001318"
      unitRef="USD">768000</us-gaap:OtherNotesPayable>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2025-12-31_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001320"
      unitRef="USD">30254000</us-gaap:LongTermDebtCurrent>
    <us-gaap:InterestReceivable
      contextRef="AsOf2025-12-31_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001322"
      unitRef="USD">7147000</us-gaap:InterestReceivable>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001324"
      unitRef="USD">1769000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_custom_PinnacleBankMember_custom_LifeCareAgreementMember"
      decimals="0"
      id="Fact001326"
      unitRef="USD">2278000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-03-30_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember"
      decimals="0"
      id="Fact001328"
      unitRef="USD">790000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-03-30_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember"
      decimals="INF"
      id="Fact001330"
      unitRef="Pure">0.0744</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-03-302023-03-30_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember"
      decimals="0"
      id="Fact001332"
      unitRef="USD">14000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember"
      decimals="0"
      id="Fact001334"
      unitRef="USD">384000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2026-09-30_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember"
      decimals="0"
      id="Fact001336"
      unitRef="USD">140000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-09-30_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember"
      decimals="0"
      id="Fact001338"
      unitRef="USD">244000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember"
      decimals="0"
      id="Fact001340"
      unitRef="USD">482000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2025-12-31_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember"
      decimals="0"
      id="Fact001342"
      unitRef="USD">132000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="AsOf2025-12-31_custom_SecurityAgreementMember_custom_UnionBankAndTrustCompanyMember"
      decimals="0"
      id="Fact001344"
      unitRef="USD">350000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_custom_UnionBankAndTrustCompanyMember_custom_SecurityAgreementMember"
      decimals="0"
      id="Fact001346"
      unitRef="USD">25000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_custom_UnionBankAndTrustCompanyMember_custom_SecurityAgreementMember"
      decimals="0"
      id="Fact001348"
      unitRef="USD">32000</us-gaap:InterestExpense>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-08-31_custom_AlsetIncMember"
      decimals="0"
      id="Fact001350"
      unitRef="USD">500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-09-30_custom_AlsetIncMember"
      decimals="INF"
      id="Fact001352"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-08-31_custom_AlsetIncMember"
      decimals="INF"
      id="Fact001354"
      unitRef="USDPShares">0.86</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_custom_AlsetIncMember"
      decimals="0"
      id="Fact001356"
      unitRef="USD">538000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_AlsetIncMember"
      decimals="0"
      id="Fact001358"
      unitRef="USD">512000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_custom_AlsetIncMember"
      decimals="0"
      id="Fact001360"
      unitRef="USD">36000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_custom_AlsetIncMember"
      decimals="0"
      id="Fact001362"
      unitRef="USD">3000</us-gaap:InterestExpense>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2026-03-26_custom_ConvertibleBondInvestmentMember"
      decimals="0"
      id="Fact001364"
      unitRef="USD">2450000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-03-26_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001366"
      unitRef="Pure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2026-03-262026-03-26_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001368"
      unitRef="USDPShares">0.74</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2026-03-262026-03-26_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">16554055</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-26_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001372"
      unitRef="USDPShares">0.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementMember"
      id="Fact001374">The Company allocated the $2,450,000 proceeds between the convertible note and warrant based on
their relative fair values. The warrant valuation was determined using a Black-Scholes option-pricing model. Significant valuation inputs
included the Company&#x2019;s common stock price of $0.91 per share, exercise price of $0.93 per share, expected term of 5.0 years, risk-free
rate of 4.0%, selected volatility of 85.0%, expected dividend rate of 0.0%, and 16,554,055 warrants outstanding. Based on these inputs,
the calculated warrant value was $0.63 per warrant, resulting in an indicated fair value of $10,368,000. The fair value of the convertible
note was determined using valuation techniques that considered the contractual note terms, conversion feature, most favored nation provision,
Company-specific credit risk, market interest rates, expected volatility, and probability-weighted conversion scenarios. The valuation
considered two scenarios: a no subsequent convertible instrument issuance before expiration scenario, with an indicated value of $3,418,000.
For purposes of allocating the $2,450,000 proceeds at issuance, the Company used the relative fair values of the warrant and convertible
note. Accordingly, $1,843,000 was allocated to the warrant and recorded in additional paid-in capital, and $607,000 was allocated to the
note. The allocation resulted in a debt discount of $1,843,000, which will be amortized to interest expense over the five-year term of
the note using the effective interest method. As of September 30, 2026, the note had a principal amount of $2,450,000, unamortized debt
discount of approximately $1,776,000 and a net carrying amount of approximately $674,000.</DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2026-06-23_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001376"
      unitRef="USD">1000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001378"
      unitRef="USD">1000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-06-23_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001380"
      unitRef="Pure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember"
      id="Fact001382">June
23, 2031</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001384"
      unitRef="USDPShares">0.45</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001386"
      unitRef="Shares">17777776</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-06-23_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001388"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember"
      id="Fact001390">The
Company allocated the $1,000,000 of proceeds between the convertible note and warrants based on their relative fair values in accordance
with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined using a Black-Scholes option-pricing model. Significant
valuation inputs included the Company&#x2019;s common stock price of $0.61 per share, exercise price of $0.50 per share, expected term
of 3.0 years, risk-free interest rate of 4.2%, selected volatility of 85.0%, expected dividend rate of 0.0%, and 17,777,776 warrants
outstanding. Based on these inputs, the calculated warrant value was $0.37 per warrant, resulting in an indicated fair value of $6,651,000.
The fair value of the convertible note at issuance was determined using a binomial lattice model that considered the contractual note
terms, conversion feature, Company-specific credit risk, market interest rates, expected volatility, and the Company&#x2019;s redemption
right. Significant valuation inputs included the Company&#x2019;s common stock price of $0.61 per share, conversion price of $0.45 per
share, contractual term of 5.0 years, risk-free interest rate of 4.2%, selected volatility of 85.0%, and discount rate of 13.25%. Based
on these inputs, the indicated fair value of the convertible note at issuance was $1,531,000. For purposes of allocating the $1,000,000
of proceeds at issuance, the Company used the relative fair values of the warrants and convertible note. Accordingly, $813,000 was allocated
to the warrants and recorded in additional paid-in capital, and $187,000 was allocated to the note. The allocation resulted in an initial
debt discount of $813,000, which is being amortized to interest expense over the five-year contractual term of the note using the effective
interest method. As of September 30, 2026, the note had a principal amount of $1,000,000, an unamortized debt discount of approximately
$802,000, and a net carrying amount of approximately $198,000.</DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001392"
      unitRef="USD">8000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001394"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001398"
      unitRef="USD">600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001400"
      unitRef="Pure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember"
      id="Fact001402">August 17, 2031</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2026-08-172026-08-17_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001404"
      unitRef="USDPShares">0.45</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember108129671"
      decimals="INF"
      id="Fact001406"
      unitRef="Shares">10666667</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember108129671"
      decimals="INF"
      id="Fact001408"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteOneMember"
      id="Fact001410">The Company allocated the $600,000 of proceeds between the convertible note and warrants based on their relative fair
values in accordance with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined using a Black-Scholes option-pricing
model. Significant valuation inputs included the Company&#x2019;s common stock price of $0.5615 per share, exercise price of $0.50 per
share, expected term of 5.0 years, risk-free interest rate of 4.38%, selected volatility of 85.0%, expected dividend rate of 0.0%, and
10,666,667 warrants outstanding. Based on these inputs, the calculated warrant value was approximately $0.40 per warrant, resulting in
an indicated fair value of approximately $4,271,000. The fair value of the convertible note at issuance was determined using a valuation
approach that combined a discounted cash-flow analysis of the straight-debt component with an option-pricing analysis of the embedded
conversion feature. The valuation considered the contractual note terms, conversion feature, Company-specific credit risk, market interest
rates, expected volatility and the Company&#x2019;s redemption right. Significant valuation inputs included the Company&#x2019;s common
stock price of $0.56per share, conversion price of $0.45 per share, contractual term of 5.0 years, risk-free interest rate of 4.38%, selected
volatility of 85.0%, and a credit-adjusted discount rate of 14.43%. Based on these inputs, the indicated fair value of the convertible
note at issuance was approximately $898,000. For purposes of allocating the $600,000 of proceeds at issuance, the Company used the relative
fair values of the warrants and convertible note. Accordingly, approximately $496,000 was allocated to the warrants and recorded in additional
paid-in capital, and approximately $104,000 was allocated to the note. The allocation resulted in an initial debt discount of approximately
$496,000, which is being amortized to interest expense over the five-year contractual term of the note using the effective interest method
pursuant to ASC 835-30-35. As of September 30, 2026, the note had a principal amount of $600,000, an unamortized debt discount of approximately
$493,000, a net carrying amount of approximately $107,000 and accrued interest of approximately $2,000. Interest expense associated with
the note for the three and nine months ended September 30, 2026 was approximately $5,000, including approximately $3,000 of debt-discount
amortization.</DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001412"
      unitRef="USD">500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001414"
      unitRef="USD">500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001416"
      unitRef="Pure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember"
      id="Fact001418">September 15, 2031</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2026-09-152026-09-15_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001420"
      unitRef="USDPShares">0.50</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember108129687"
      decimals="INF"
      id="Fact001422"
      unitRef="Shares">8000000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember108129687"
      decimals="INF"
      id="Fact001424"
      unitRef="USDPShares">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteTwoMember"
      id="Fact001426">The Company allocated the $500,000 of proceeds between the convertible note
and warrants based on their relative fair values in accordance with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined
using a Black-Scholes-Merton option-pricing model. Significant valuation inputs included the Company&#x2019;s common stock price of $0.7411
per share, exercise price of $0.55 per share, expected term of 5.0 years, risk-free interest rate of 4.83%, selected volatility of 85.0%,
expected dividend rate of 0.0%, and 8,000,000 warrants outstanding. Based on these inputs, the calculated warrant value was approximately
$0.55154 per warrant, resulting in an indicated fair value of approximately $4,412,000. The fair value of the convertible note at issuance
was determined using a component valuation approach consisting of a discounted cash flow analysis of the straight-debt component and a
Black-Scholes approximation of the embedded conversion feature. The straight-debt analysis considered the contractual cash flows, five-year
expected term, Company-specific credit risk and market interest rates. Significant valuation inputs included a principal amount of $500,000,
contractual interest rate of 3.0%, five-year term, and a credit-adjusted market yield of 15.55%. The indicated fair value of the straight-debt
component was approximately $280,000. The embedded conversion feature was valued using the Company&#x2019;s common stock price of $0.7411
per share, conversion price of $0.50 per share, expected term of 5.0 years, risk-free interest rate of 4.83%, selected volatility of 85.0%,
and expected dividend rate of 0.0%. The indicated value of the conversion feature was approximately $562,000, resulting in an indicated
stand-alone fair value of the convertible note of approximately $841,000. For purposes of allocating the $500,000 of proceeds at issuance,
the Company used the relative fair values of the warrants and convertible note. Accordingly, approximately $420,000 was allocated to the
warrants and recorded in additional paid-in capital, and approximately $80,000 was allocated to the note. The allocation resulted in an
initial debt discount of approximately $420,000, which is being amortized to interest expense over the five-year contractual term of the
note using the effective interest method in accordance with ASC 835-30. The resulting effective interest rate is approximately 47.55%.
As of September 30, 2026, the note had a principal amount of $500,000, an unamortized debt discount of approximately $419,000, and a net
carrying amount of approximately $81,000, exclusive of accrued contractual interest.</DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription>
    <us-gaap:InterestExpense
      contextRef="From2026-09-152026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001428"
      unitRef="USD">1000</us-gaap:InterestExpense>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001430">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_znZ9vN05X0i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;A summary of scheduled principal
payments of long-term and current debt, convertible notes and notes payable &#x2013; related party
as of September 30, 2026, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_z1X67xTxO1Ni" style="display: none"&gt;Schedule
of Long-Term And Current Debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zhQklFqFuMQ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Notes
    payable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConvertibleNotePayableRelatedPartyMember_zLMwjjPN10Ad" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible note payable &lt;br/&gt; - related party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z95qioaFILF" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Notes payable &lt;br/&gt; - related party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260930_zBoaUXSMge8l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pp0p0_maLTDztfD_z63j2H0xKSLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;30,503,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,598,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;178,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;32,279,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_maLTDztfD_zSNwLnOgG4cf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,091,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1439"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,091,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDztfD_zul7LMu9o3Oj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1444"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDztfD_zzqAZpzTkPVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1449"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDztfD_z0Z86Ps6X88g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1453"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1454"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearAfterYearFour_iI_pp0p0_maLTDztfD_zShupBCA7xt3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,649,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1459"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,649,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDztfD_z61JNjhqPDIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="display: none; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,389,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,598,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;178,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;37,165,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="AsOf2026-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001432"
      unitRef="USD">30503000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="AsOf2026-09-30_custom_ConvertibleNotePayableRelatedPartyMember"
      decimals="0"
      id="Fact001433"
      unitRef="USD">1598000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001434"
      unitRef="USD">178000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001435"
      unitRef="USD">32279000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2026-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">1091000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001440"
      unitRef="USD">1091000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2026-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001442"
      unitRef="USD">1129000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001445"
      unitRef="USD">1129000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2026-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001447"
      unitRef="USD">638000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001450"
      unitRef="USD">638000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2026-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001452"
      unitRef="USD">379000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001455"
      unitRef="USD">379000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <DSS:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearAfterYearFour
      contextRef="AsOf2026-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001457"
      unitRef="USD">1649000</DSS:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearAfterYearFour>
    <DSS:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearAfterYearFour
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001460"
      unitRef="USD">1649000</DSS:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearAfterYearFour>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001462"
      unitRef="USD">35389000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-09-30_custom_ConvertibleNotePayableRelatedPartyMember"
      decimals="0"
      id="Fact001463"
      unitRef="USD">1598000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-09-30_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001464"
      unitRef="USD">178000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001465"
      unitRef="USD">37165000</us-gaap:LongTermDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001467">&lt;p id="xdx_80F_eus-gaap--LesseeOperatingLeasesTextBlock_zUr8Qqgusr0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12. &lt;span id="xdx_822_zAkkZxG6Mvae"&gt;Lease Liability&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company has operating leases
predominantly for operating facilities. As of September 30, 2026, the remaining lease terms on our operating leases range from less than
one to nine years. Renewal options to extend our leases have not been exercised due to uncertainty. Termination options are not reasonably
certain of exercise by the Company. There is no transfer of title or option to purchase the leased assets upon expiration. There are no
residual value guarantees or material restrictive covenants. There are no significant finance leases as of September 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLlQe2GHrKBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Future minimum lease payments as of September 30,
2026 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zCrYmbnm13gd" style="display: none"&gt;Schedule
of Future
Minimum Lease Payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Maturity of Lease Liability:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_496_20260930_zAlqFyxjfzDe" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzzH0_zp0fBLC3oj92" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: right"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;199,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzzH0_zyIjZWighT2b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzzH0_zCVdZGKaHkPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;824,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzzH0_zuGv4dnOLrW7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;840,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzzH0_z9TfWreW6eAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;857,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzzH0_zWo0txKar0gg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;After&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,216,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzzH0_zCLiKDvPhcqe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,744,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zujbDUO5vKJ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(912,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;Present value of remaining lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,832,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zsUklnxAt6cd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;598,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zPqM7cG516Wh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,234,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;Weighted average remaining lease term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260930_zDu0K55cLs54" title="Weighted average remaining lease term (years)"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zDkMeWVboNKb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zk0htO3oo1mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Total cash paid for leases during
the nine months ended September 30, 2026 and 2025 approximated $&lt;span id="xdx_904_eus-gaap--OperatingLeasePayments_c20260101__20260930_zGlREFeCLyd5" title="Operating lease, cash paid"&gt;640,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--OperatingLeasePayments_c20250101__20250930_zaNaQNGqWSoj" title="Operating lease, cash paid"&gt;651,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001469">&lt;p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLlQe2GHrKBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Future minimum lease payments as of September 30,
2026 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zCrYmbnm13gd" style="display: none"&gt;Schedule
of Future
Minimum Lease Payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Maturity of Lease Liability:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_496_20260930_zAlqFyxjfzDe" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzzH0_zp0fBLC3oj92" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: right"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;199,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzzH0_zyIjZWighT2b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzzH0_zCVdZGKaHkPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;824,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzzH0_zuGv4dnOLrW7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;840,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzzH0_z9TfWreW6eAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;857,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzzH0_zWo0txKar0gg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;After&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,216,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzzH0_zCLiKDvPhcqe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,744,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zujbDUO5vKJ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(912,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;Present value of remaining lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,832,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zsUklnxAt6cd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;598,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zPqM7cG516Wh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,234,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;Weighted average remaining lease term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260930_zDu0K55cLs54" title="Weighted average remaining lease term (years)"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zDkMeWVboNKb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001471"
      unitRef="USD">199000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001473"
      unitRef="USD">808000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001475"
      unitRef="USD">824000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001477"
      unitRef="USD">840000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001479"
      unitRef="USD">857000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <DSS:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001481"
      unitRef="USD">3216000</DSS:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001483"
      unitRef="USD">6744000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001485"
      unitRef="USD">912000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001487"
      unitRef="USD">5832000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001489"
      unitRef="USD">598000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001491"
      unitRef="USD">5234000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2026-09-30" id="Fact001493">P7Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2026-09-30"
      decimals="INF"
      id="Fact001495"
      unitRef="Pure">0.038</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001497"
      unitRef="USD">640000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact001499"
      unitRef="USD">651000</us-gaap:OperatingLeasePayments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001501">&lt;p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zssKTOeoqbTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13. &lt;span id="xdx_827_zSwpi4x4wUM4"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License Agreement&lt;/i&gt; &#x2013;
&lt;/b&gt;On March 19, 2022, Impact BioMedical entered into a License Agreement (&#x201c;Equivir License&#x201d;) with a third-party (&#x201c;Licensee&#x201d;)
where the Licensor is granted the right, amongst other things, to develop, commercialize, and sell the Company&#x2019;s Equivir technology.
&lt;span id="xdx_90A_eus-gaap--LossContingencyAllegations_c20220319__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--BioMedicalMember_z8SZZHgYY7R9" title="Loss contingency allegations"&gt;In exchange, the Licensee shall pay the Company a royalty of &lt;span id="xdx_909_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20220319__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zC9RmWwRRbR2" title="Sale of royalty percentage"&gt;5.5&lt;/span&gt;% of net sales. Under the terms of the Equivir Agreement, the Company
shall reimburse the Licensee for &lt;span id="xdx_90D_ecustom--DevelopmentCostPercent_pid_dp_uPure_c20220319__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zKIPaPMFyGX8" title="Development cost, percent"&gt;50&lt;/span&gt;% of the development costs provided that the development costs shall not exceed $&lt;span id="xdx_90E_eus-gaap--CostsIncurredDevelopmentCosts_c20220319__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zubVPNUPe6pj" title="Development costs"&gt;1,250,000&lt;/span&gt;. As of September
30, 2026 and December 31, 2025, a liability of $&lt;span id="xdx_90F_eus-gaap--CommitmentsAndContingencies_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zI8dLMEW7TRj" title="Commitments and Contingencies"&gt;&lt;span id="xdx_90E_eus-gaap--CommitmentsAndContingencies_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zvMZ2f3NkYGk" title="Commitments and Contingencies"&gt;0&lt;/span&gt;&lt;/span&gt; has been recorded in relation to the Equivir License.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Royalty Agreement&lt;/i&gt;&lt;/b&gt;
- On August 15, 2018, the Impact BioMedical entered into Royalty Agreement with Chemia Corporation (&#x201c;Chemia&#x201d;) pursuant to
which Chemia transferred to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and
is automatically renewed for a period of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral
formulations. Based on the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent application
and other intellectual property related to 3F. Chemia agreed to support the Company in efforts leading to development of 3F intellectual
property and it is licensing. Based on Royalty Agreement any payments received from development, sales, licensing or transfer of 3F technology
will be paid 50% to the Company and 50% to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (&#x201c;Addendum&#x201d;),
according to which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying
the 3F technology. Based on the Addendum, Chemia should pay the Company 5% of net sales in royalty. On November 8, 2019, both companies
entered into Amendment no.1 to Royalty Agreement, based on which certain expenses borne by the Company towards patent application and
licensing should be reimbursed to the Company before any royalty payments are made. For the nine months ended September 30, 2026 and 2025,
there were no reimbursements or royalties paid to the Company and the Company cannot be assured that Chemia&#x2019;s efforts will end up
in any future sales of the technology.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employment Agreements &#x2013;&lt;/i&gt;&lt;/b&gt;
Impact BioMedical has an employment agreement with it CEO Frank Heuszel in which Mr. Heuszel&#x2019;s agreement contains a mandatory bonus
clause of $&lt;span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--MrHeuszelsMember__us-gaap--AwardTypeAxis__custom--FirstYearMember_zVZrR0PbLHy8" title="Employment term bonus"&gt;150,000&lt;/span&gt; for the first year of the employment term, beginning September 2024, $&lt;span id="xdx_900_eus-gaap--SalariesWagesAndOfficersCompensation_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--MrHeuszelsMember__us-gaap--AwardTypeAxis__custom--SecondYearMember_zOktcquoSMI3" title="Employment term"&gt;100,000&lt;/span&gt; for the second year of the employment
term, beginning September 2025, and $&lt;span id="xdx_907_eus-gaap--SalariesWagesAndOfficersCompensation_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--MrHeuszelsMember__us-gaap--AwardTypeAxis__custom--ThirdYearMember_zqaCEC88Njf" title="Employment term bonus"&gt;100,000&lt;/span&gt; for the third year of the employment term, beginning September 2026. As of September 30,
2026, approximately $&lt;span id="xdx_90C_eus-gaap--AccruedBonusesCurrentAndNoncurrent_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--MrHeuszelsMember__us-gaap--AwardTypeAxis__custom--FirstYearMember_zJ2Y8gNK6Llj" title="Bonus"&gt;96,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AccruedBonusesCurrentAndNoncurrent_iI_c20260930__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--MrHeuszelsMember__us-gaap--AwardTypeAxis__custom--SecondYearMember_z26teokEhERh" title="Bonus"&gt;100,000&lt;/span&gt; is accrued for year one and year two of Mr. Heuszel&#x2019;s bonus, respectively. As of December
31, 2025, approximately $&lt;span id="xdx_90A_eus-gaap--AccruedBonusesCurrentAndNoncurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--MrHeuszelsMember__us-gaap--AwardTypeAxis__custom--FirstYearMember_zQVJJwYV2WQa" title="Accrued bonus"&gt;96,000&lt;/span&gt; is accrued for year one of Mr. Heuszel&#x2019;s bonus and $&lt;span id="xdx_907_eus-gaap--AccruedBonusesCurrentAndNoncurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember__srt--TitleOfIndividualAxis__custom--MrHeuszelsMember__us-gaap--AwardTypeAxis__custom--SecondYearMember_zG5j4jDNkyY9" title="Accrued bonus"&gt;25,000&lt;/span&gt; for the second year of Mr. Heuszel&#x2019;s
bonus.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contingent Litigation Payments
&lt;/i&gt;&lt;/b&gt;&#x2013; The Company retains the services of professional service providers, including law firms that specialize in intellectual
property licensing, enforcement and patent law. These service providers are often retained on an hourly, monthly, project, contingent
or a blended fee basis. In contingency fee arrangements, a portion of the legal fee is based on predetermined milestones or the Company&#x2019;s
actual collection of funds. The Company accrues contingent fees when it is probable that the milestones will be achieved, and the fees
can be reasonably estimated. As of September 30, 2026 and December 31, 2025, the Company had not accrued any contingent legal fees pursuant
to these arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 2, 2026, a putative securities class action lawsuit, Julianne Louie v. Picard Medical, Inc., et al., Case No. 3:26-cv-01024-RFL,
was filed in the United States District Court for the Northern District of California in connection with the initial public offering
of Picard Medical, Inc. Sentinel Brokers Company, Inc. (&#x201c;Sentinel&#x201d;), an indirectly majority-owned subsidiary of the Company,
was named as an underwriter defendant. Plaintiffs filed an amended complaint on July 28, 2026. On October 13, 2026, Sentinel and the
other underwriter defendants filed a motion to dismiss Count I of the amended complaint with prejudice. The motion remains pending. Based
on currently available information, management does not believe an unfavorable outcome is probable. However, the ultimate outcome of
the litigation remains uncertain, and the Company is unable to reasonably estimate a potential loss or range of loss at this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 13, 2026, a putative securities class action lawsuit, Leyber Gabriel Briones, et al. v. Syla Technologies Co., Ltd., et al., Index
No. 154747/2026, was filed in the Supreme Court of the State of New York, County of New York, in connection with certain initial public
offerings. Impact BioMedical Inc. (&#x201c;Impact&#x201d;), a majority-owned subsidiary of the Company, was named among numerous defendants.
As of the date of this filing, Impact has not been formally served with process. Based on currently available information, management
believes the allegations against Impact lack sufficient factual support and does not believe an unfavorable outcome is probable. However,
the ultimate outcome of the litigation remains uncertain, and the Company is unable to reasonably estimate a potential loss or range
of loss at this time.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAllegations
      contextRef="From2022-03-192022-03-19_custom_LicenseAgreementMember_custom_BioMedicalMember"
      id="Fact001503">In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company
shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $1,250,000. As of September
30, 2026 and December 31, 2025, a liability of $0 has been recorded in relation to the Equivir License.</us-gaap:LossContingencyAllegations>
    <DSS:SaleOfRoyaltyPercentage
      contextRef="From2022-03-192022-03-19_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Pure">0.055</DSS:SaleOfRoyaltyPercentage>
    <DSS:DevelopmentCostPercent
      contextRef="From2022-03-192022-03-19_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Pure">0.50</DSS:DevelopmentCostPercent>
    <us-gaap:CostsIncurredDevelopmentCosts
      contextRef="From2022-03-192022-03-19_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001509"
      unitRef="USD">1250000</us-gaap:CostsIncurredDevelopmentCosts>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-09-30_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001511"
      unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-12-31_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001513"
      unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2026-01-012026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_FirstYearMember"
      decimals="0"
      id="Fact001515"
      unitRef="USD">150000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2026-01-012026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_SecondYearMember"
      decimals="0"
      id="Fact001517"
      unitRef="USD">100000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2026-01-012026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_ThirdYearMember"
      decimals="0"
      id="Fact001519"
      unitRef="USD">100000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="AsOf2026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_FirstYearMember"
      decimals="0"
      id="Fact001521"
      unitRef="USD">96000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="AsOf2026-09-30_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_SecondYearMember"
      decimals="0"
      id="Fact001523"
      unitRef="USD">100000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_FirstYearMember"
      decimals="0"
      id="Fact001525"
      unitRef="USD">96000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_custom_EmploymentAgreementsMember_custom_MrHeuszelsMember_custom_SecondYearMember"
      decimals="0"
      id="Fact001527"
      unitRef="USD">25000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001529">&lt;p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z94D5BrIIG49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14. &lt;span id="xdx_822_zX6JiV9A5gLl"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;DSS, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity transactions&lt;/i&gt;&lt;/b&gt;
- On February 6, 2025, as a bonus for compensation awarded to Heng Fai Holdings Limited (&#x201c;HFHL&#x201d;), a Hong Kong Company, which
is beneficially owned by Mr. Heng Fai Ambrose Chan, Director of DSS, Inc., and pursuant to DSS, Inc&#x2019;s. 2020 Employee, Director and
Consultant Equity Incentive Plan (the &#x201c;Plan&#x201d;), HFHL was awarded &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250206__20250206__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zEYSGeSD3zwf" title="Common stock under the Plan, for services"&gt;1,000,000&lt;/span&gt; shares of the Company&#x2019;s common stock, approximating
$&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250206__20250206__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zIPLWM03ufAd" title="Common stock under the Plan, for services, value"&gt;870,000&lt;/span&gt;, under the Plan, for strategic planning and merger and acquisition services rendered at the beginning of 2025. The issuance was
approved by the board of directors on January 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 21, 2025, DSS, the parent
company of Impact Biomedical, Inc. completed the sale of &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250321__20250321__dei--LegalEntityAxis__custom--ImpactBioMedicalIncMember_zJLQeDvttpM6" title="Number of shares sold"&gt;499,800&lt;/span&gt; shares of Impact Biomedical common stock. These shares were acquired
by DSS during Impact&#x2019;s initial public offering on September 16, 2024. The sale of these shares, which were previously held by DSS
as part of its ownership interest in Impact, was completed for a total value of $&lt;span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250321__20250321__dei--LegalEntityAxis__custom--ImpactBioMedicalIncMember_zESitAnXCgOj" title="Value of shares sold"&gt;1,500,000&lt;/span&gt;, of which $&lt;span id="xdx_90E_eus-gaap--MinorityInterest_iI_c20260630__dei--LegalEntityAxis__custom--ImpactBioMedicalIncMember_zC1yKg0ZFEbc" title="Non controlling interest"&gt;205,000&lt;/span&gt; has been classified as non-controlling
interest in subsidiary, which represents the consideration received from the transaction. With this sale, the shares are now publicly
held and are no longer held by DSS.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On February 4, 2026, DSS entered
into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Aegis Capital Corp. (&#x201c;Aegis&#x201d;), which provided
for the issuance and sale by the Company and the purchase by the underwriter, in a firm commitment underwritten public offering of &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260204__20260204__dei--LegalEntityAxis__custom--AegisCapitalCorpMember_zYr0bUWpfaf3" title="Number of shares sold"&gt;900,000&lt;/span&gt;
shares of the Company&#x2019;s common stock. Subject to the terms and conditions contained in the Underwriting Agreement, the shares were
sold at a public offering price of $&lt;span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20260204__dei--LegalEntityAxis__custom--AegisCapitalCorpMember_zYSXpVqLwx01" title="Number of shares sold, per shares"&gt;1.00&lt;/span&gt; per share, less certain underwriting discounts and commissions. The Offering closed on February
5, 2026 and the Company received approximately $&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20260204__20260204__dei--LegalEntityAxis__custom--AegisCapitalCorpMember_zlrx3XWE1BPe" title="Net of expenses"&gt;657,000&lt;/span&gt;&lt;/span&gt;, net of expenses. Additionally, on
March 19, 2026, an additional &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260319__20260319__dei--LegalEntityAxis__custom--AegisCapitalCorpMember_zQ60XMPfkqJ8" title="Number of shares sold"&gt;50,000&lt;/span&gt; shares were issued under the Underwriting Agreement and the Company received approximately $&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20260319__20260319__dei--LegalEntityAxis__custom--AegisCapitalCorpMember_zTkp35KKXHi3" title="Net of expenses"&gt;46,000&lt;/span&gt;&lt;/span&gt;,
net of expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-Based Compensation
-&lt;/i&gt;&lt;/b&gt; The Company records stock-based payment expense related to options and warrants based on the grant date fair value in accordance
with FASB ASC 718. Stock-based compensation includes expense charges for all stock-based awards to employees, directors, and consultants.
Such awards include option grants, warrant grants, and restricted stock awards On February 6, 2025, as a bonus for compensation awarded
to Heng Fai Holdings Limited (&#x201c;HFHL&#x201d;), a Hong Kong Company, which is beneficially owned by Mr. Heng Fai Ambrose Chan, Director
of DSS, Inc., and pursuant to DSS, Inc&#x2019;s. 2020 Employee, Director and Consultant Equity Incentive Plan (the &#x201c;Plan&#x201d;),
HFHL was awarded &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250206__20250206__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zVwQBcoSPhCi" title="Common stock under the plan for services"&gt;1,000,000&lt;/span&gt; shares of the Company&#x2019;s common stock, approximating $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250206__20250206__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zEgqpedE7Qzg" title="Common stock under the plan for services, value"&gt;870,000&lt;/span&gt;, under the Plan, for strategic planning
and merger and acquisition services rendered at the beginning of 2025. The issuance was approved by the board of directors on January
31, 2025. During the three and nine months ended September 30, 2026 there were no such awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impact BioMedical, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Transaction -&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;On February 25, 2025, the Company completed the acquisition of certain assets owned by DSS Pure Air, Inc.
(DSS PureAir&#x201d;), a related party, for $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20250225__20250225__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ1A2tueoQzd"&gt;1,150,000&lt;/span&gt;
to be paid by &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250225__20250225__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaz3whBJW6na"&gt;43,189&lt;/span&gt;
shares of the Company&#x2019;s common stock calculated on a 10-day VWAP. Assets acquired included accounts receivable, inventory and intellectual
property of the Celios air purification system.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On February 26, 2025, the
Company issued &lt;span id="xdx_90B_eus-gaap--SharesIssued_iI_c20250226_zzyrFPeG9LEe" title="Shares issued"&gt;2,887&lt;/span&gt; shares of the
Company&#x2019;s common stock as payment of legal fees incurred associated with the Company&#x2019;s initial public offering
(&#x201c;IPO&#x201d;), registration of shares associated with its equity incentive plan as well as other related services. The legal fees received were valued at approximately $&lt;span id="xdx_903_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_c20250226_zBTiE3QmV7f" title="Legal fees received"&gt;29,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On June 23, 2025, the Company
issued &lt;span id="xdx_900_eus-gaap--SharesIssued_iI_c20250623_zA2IdnjuGuk9" title="Shares issued for payment of legal fees"&gt;7,924&lt;/span&gt; shares of the Company&#x2019;s common stock as payment of legal fees incurred associated with the Company&#x2019;s merger
and share exchange agreement with Dr. Ashleys Limited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On October 16, 2025, the Company
converted its Note payable, related party to &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20251016__20251016__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuRBEi02RfY" title="Stock issued for debt conversion"&gt;2,531,000&lt;/span&gt; shares common stock as agreed upon by the Company and DSS (lender).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On November
24, 2025, the Board of Directors of Impact BioMedical approved, subject to stockholder approval, a reverse stock split of the Company&#x2019;s
common stock at a ratio ranging from &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20251124__20251124__srt--RangeAxis__srt--MinimumMember_zbixjzwhiLr4" title="Reverse stock split"&gt;1-for-12.48&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20251124__20251124__srt--RangeAxis__srt--MaximumMember_zOYadbQ8KdF9" title="Reverse stock split"&gt;1-for-50&lt;/span&gt;. The reverse stock split was approved by the Company&#x2019;s stockholders
on December 30, 2025. On September 23, 2026, the Company effected a &lt;span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20260923__20260923_zYgJJ5FbKAQg" title="Reverse stock split"&gt;1-for-12.62&lt;/span&gt; reverse stock split (the &#x201c;Reverse Stock Split&#x201d;)
of its issued and outstanding common stock, par value $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260923_zeuspfWBDHpd" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share, pursuant to an amendment to its Certificate of Incorporation filed
with the Secretary of State of Nevada. The Reverse Stock Split reduced the number of issued and outstanding shares of common stock from
approximately &lt;span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pn5n6_c20260923__srt--RangeAxis__srt--MaximumMember_z3DYaITw9e0h" title="Common stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pn5n6_c20260923__srt--RangeAxis__srt--MaximumMember_zzgie9R2z5I8" title="Common stock, shares outstanding"&gt;107.8&lt;/span&gt;&lt;/span&gt; million to approximately &lt;span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pn5n6_c20260923__srt--RangeAxis__srt--MinimumMember_ztkMzlgKJiCl" title="Common stock, shares issued"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pn5n6_c20260923__srt--RangeAxis__srt--MinimumMember_z1v6SO5VV992" title="Common stock, shares outstanding"&gt;8.6&lt;/span&gt;&lt;/span&gt; million. The Reverse Stock Split did not affect the number of authorized shares, par
value per share, or voting rights of the Company&#x2019;s common stock. No fractional shares were issued, and any fractional shares resulting
from the Reverse Stock Split were rounded up to the nearest whole share. In accordance with ASC 260-10-55-12, all historical share and
per-share amounts presented in the accompanying condensed consolidated financial statements, including weighted-average shares outstanding
and basic and diluted earnings (loss) per share, have been retrospectively adjusted to reflect the Reverse Stock Split for all periods
presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-Based Compensation
&#x2013; &lt;/i&gt;&lt;/b&gt;Impact records stock-based payment expense related to options and warrants based on the grant date fair value in accordance
with FASB ASC 718. Stock-based compensation includes expense charges for all stock-based awards to employees, directors and consultants.
Such awards include option grants, warrant grants, and restricted stock awards. On October 1, 2024, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20241001__20241001_zq6jtC621p6h" title="Stock based compensation, option grants"&gt;69,731&lt;/span&gt; option grants with a purchase
price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241001_zNOPpmTWYkQi" title="Purchase price per share"&gt;37.86&lt;/span&gt; per share were awarded to certain officers, directors and consultants of Impact BioMedical. These options have various
vesting periods, and all expire on October 31, 2031. Potential proceeds of these grants is $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20241001__20241001_zpu5XDGJGBd3" title="Proceeds from grants"&gt;2,640,000&lt;/span&gt; and are fair valued using a Black-Scholes
model at approximately $&lt;span id="xdx_906_ecustom--FairValueGrants_c20241001__20241001_zHhFDGtSc16d" title="Fair value grants"&gt;50,000&lt;/span&gt;. Impact recorded stock-based compensation expense of approximately $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20250701__20250930__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--SellingGeneralAndAdministrativeExpense_zXWz0R9VNehj" title="Stock based compensation expense"&gt;2,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250930__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--SellingGeneralAndAdministrativeExpense_zL8cRPR43CHl" title="Stock based compensation expense"&gt;4,000&lt;/span&gt; for the three and
nine month and year ended September 30, 2025, respectively, and is included in Sales, general and administrative compensation (inclusive
of stock-based compensation) on the accompanying Statement of Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In January 2026, the Impact BioMedical
granted and issued &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260131_zxZpjHPZwkJ7" title="Number of grants shares issued"&gt;253,577&lt;/span&gt; shares of common stock to various individuals including executives, board members, audit committee members,
etc. Agreement included the individuals rescinding and cancelling any and all unexercised stock options previously granted. Impact Biomedical
recorded stock-based compensation expense of approximately $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260930_zSR5S34p1Yxk" title="Stock based compensation expense"&gt;&lt;span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20260701__20260930_zoCUUo7oogU5" title="Stock based compensation expense"&gt;1,440,000&lt;/span&gt;&lt;/span&gt;, of which $&lt;span id="xdx_908_eus-gaap--NoncontrollingInterestInVariableInterestEntity_iI_c20260930_zSCfppW0zimg" title="Non controlling interest"&gt;158,000&lt;/span&gt; has been classified as non-controlling interest
in subsidiary, for the nine months ended September 30, 2026, and is included in Sales, general and administrative compensation (inclusive
of stock-based compensation) on the accompanying Condensed Consolidated Statement of Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-02-062025-02-06_custom_EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001531"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-02-062025-02-06_custom_EquityIncentivePlanMember"
      decimals="0"
      id="Fact001533"
      unitRef="USD">870000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-03-212025-03-21_custom_ImpactBioMedicalIncMember"
      decimals="INF"
      id="Fact001535"
      unitRef="Shares">499800</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-03-212025-03-21_custom_ImpactBioMedicalIncMember"
      decimals="0"
      id="Fact001537"
      unitRef="USD">1500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:MinorityInterest
      contextRef="AsOf2026-06-30_custom_ImpactBioMedicalIncMember"
      decimals="0"
      id="Fact001539"
      unitRef="USD">205000</us-gaap:MinorityInterest>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-02-042026-02-04_custom_AegisCapitalCorpMember"
      decimals="INF"
      id="Fact001541"
      unitRef="Shares">900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-02-04_custom_AegisCapitalCorpMember"
      decimals="INF"
      id="Fact001543"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2026-02-042026-02-04_custom_AegisCapitalCorpMember"
      decimals="0"
      id="Fact001545"
      unitRef="USD">657000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-03-192026-03-19_custom_AegisCapitalCorpMember"
      decimals="INF"
      id="Fact001547"
      unitRef="Shares">50000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2026-03-192026-03-19_custom_AegisCapitalCorpMember"
      decimals="0"
      id="Fact001549"
      unitRef="USD">46000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-02-062025-02-06_custom_EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001551"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-02-062025-02-06_custom_EquityIncentivePlanMember"
      decimals="0"
      id="Fact001553"
      unitRef="USD">870000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2025-02-252025-02-25_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001554"
      unitRef="USD">1150000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2025-02-252025-02-25_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001555"
      unitRef="Shares">43189</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-02-26"
      decimals="INF"
      id="Fact001557"
      unitRef="Shares">2887</us-gaap:SharesIssued>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="AsOf2025-02-26"
      decimals="0"
      id="Fact001559"
      unitRef="USD">29000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-06-23"
      decimals="INF"
      id="Fact001561"
      unitRef="Shares">7924</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-10-162025-10-16_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001563"
      unitRef="Shares">2531000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2025-11-242025-11-24_srt_MinimumMember"
      id="Fact001565">1-for-12.48</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2025-11-242025-11-24_srt_MaximumMember"
      id="Fact001567">1-for-50</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2026-09-232026-09-23" id="Fact001569">1-for-12.62</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-09-23"
      decimals="INF"
      id="Fact001571"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-23_srt_MaximumMember"
      decimals="-5"
      id="Fact001573"
      unitRef="Shares">107800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-09-23_srt_MaximumMember"
      decimals="-5"
      id="Fact001575"
      unitRef="Shares">107800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-09-23_srt_MinimumMember"
      decimals="-5"
      id="Fact001577"
      unitRef="Shares">8600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-09-23_srt_MinimumMember"
      decimals="-5"
      id="Fact001579"
      unitRef="Shares">8600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-10-012024-10-01"
      decimals="INF"
      id="Fact001581"
      unitRef="Shares">69731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharePrice
      contextRef="AsOf2024-10-01"
      decimals="INF"
      id="Fact001583"
      unitRef="USDPShares">37.86</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-10-012024-10-01"
      decimals="0"
      id="Fact001585"
      unitRef="USD">2640000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <DSS:FairValueGrants
      contextRef="From2024-10-012024-10-01"
      decimals="0"
      id="Fact001587"
      unitRef="USD">50000</DSS:FairValueGrants>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpense"
      decimals="0"
      id="Fact001589"
      unitRef="USD">2000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpense"
      decimals="0"
      id="Fact001591"
      unitRef="USD">4000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2026-01-012026-01-31"
      decimals="INF"
      id="Fact001593"
      unitRef="Shares">253577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001595"
      unitRef="USD">1440000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2026-07-012026-09-30"
      decimals="0"
      id="Fact001597"
      unitRef="USD">1440000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="AsOf2026-09-30"
      decimals="0"
      id="Fact001599"
      unitRef="USD">158000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001601">&lt;p id="xdx_80D_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_z6joNOyeZG04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15. &lt;span id="xdx_824_zrz0Z3GN47zl"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zD9pmPIhSXjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;The following table summarizes
supplemental cash flows for the nine months ended September 30, 2026 and 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zLN6EXjTy2C3"&gt;Schedule
of Supplemental Cash Flow Information&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260101__20260930_zcTaNRs3AqWc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250930_zQcGSQYBPqrj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestPaidNet_z4DXBxfC6tAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash paid for interest&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;176,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,963,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zW1JUPJwWjh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-cash investing and financing activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FairValueAdjustmentRelatedToConvertibleBondReceivedFromRelatedParty_i01_zJYVJTfiDtK5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Fair value adjustment related to convertible bond received from related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,198,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1612"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ConversionOfConvertibleBondInvestmentRelatedPartyIntoEquityMethodInvestment_i01_z9peCG1968Q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Conversion of convertible bond investment &#x2013; related party into equity method investment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,647,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1615"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--TransferOfInvestments_i01_z4iNOsQNNuDj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Transfer of investment in equity securities to equity method investment upon obtaining significant influence&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,600,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IssuanceOfWarrantsInConnectionWithConvertiblePromissoryNoteFromRelatedParty_i01_zNY6lOrKqSZc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Issuance of warrants in connection with convertible promissory note from related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,571,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zWQFnGA8U8R4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001603">&lt;p id="xdx_89A_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zD9pmPIhSXjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;The following table summarizes
supplemental cash flows for the nine months ended September 30, 2026 and 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zLN6EXjTy2C3"&gt;Schedule
of Supplemental Cash Flow Information&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260101__20260930_zcTaNRs3AqWc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20250930_zQcGSQYBPqrj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestPaidNet_z4DXBxfC6tAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash paid for interest&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;176,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,963,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zW1JUPJwWjh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-cash investing and financing activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FairValueAdjustmentRelatedToConvertibleBondReceivedFromRelatedParty_i01_zJYVJTfiDtK5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Fair value adjustment related to convertible bond received from related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,198,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1612"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ConversionOfConvertibleBondInvestmentRelatedPartyIntoEquityMethodInvestment_i01_z9peCG1968Q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Conversion of convertible bond investment &#x2013; related party into equity method investment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,647,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1615"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--TransferOfInvestments_i01_z4iNOsQNNuDj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Transfer of investment in equity securities to equity method investment upon obtaining significant influence&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,600,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IssuanceOfWarrantsInConnectionWithConvertiblePromissoryNoteFromRelatedParty_i01_zNY6lOrKqSZc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Issuance of warrants in connection with convertible promissory note from related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,571,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001605"
      unitRef="USD">176000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-012025-09-30"
      decimals="0"
      id="Fact001606"
      unitRef="USD">1963000</us-gaap:InterestPaidNet>
    <DSS:FairValueAdjustmentRelatedToConvertibleBondReceivedFromRelatedParty
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001611"
      unitRef="USD">6198000</DSS:FairValueAdjustmentRelatedToConvertibleBondReceivedFromRelatedParty>
    <DSS:ConversionOfConvertibleBondInvestmentRelatedPartyIntoEquityMethodInvestment
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001614"
      unitRef="USD">8647000</DSS:ConversionOfConvertibleBondInvestmentRelatedPartyIntoEquityMethodInvestment>
    <us-gaap:TransferOfInvestments
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001617"
      unitRef="USD">3600000</us-gaap:TransferOfInvestments>
    <DSS:IssuanceOfWarrantsInConnectionWithConvertiblePromissoryNoteFromRelatedParty
      contextRef="From2026-01-01to2026-09-30"
      decimals="0"
      id="Fact001620"
      unitRef="USD">3571000</DSS:IssuanceOfWarrantsInConnectionWithConvertiblePromissoryNoteFromRelatedParty>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001623">&lt;p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zuuzeLRtlBvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16. &lt;span id="xdx_820_z9XZPFqeOxui"&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company reports its
segment information to reflect the manner in which the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) reviews
and assesses performance. The Company&#x2019;s Interim Chief Executive Officer has responsibilities as the CODM and reviews and
assess the performance of each reporting segment individually and the Company as a whole. The primary financial measures used by the
CODM to evaluate performance and allocate resources are net income (loss) and operating income (loss). The CODM uses net income
(loss) and operating income (loss) to evaluate the performance of the Company&#x2019;s ongoing operations and as part of the
Company&#x2019;s internal planning and forecasting processes. Information on Net income (loss) and Operating income (loss) is
disclosed in the Consolidated Statements of Operations. Segment expenses and other segment items are provided to the CODM on the
same basis as disclosed in the Consolidated Statements of Operations. The CODM does not evaluate performance or allocate resources
based on segment assets, and therefore such information is not presented in the notes to the financial statements. During the fourth
quarter of 2025, we realigned our internal reporting to better reflect how management reviews operating results and allocates
resources. As a result of this CODM realignment, Direct Marketing is no longer a reportable segment and is now reported within
Corporate and Other or the year ended December 31, 2025 and the three and nine months ended September 30, 2026. This change did not
impact consolidated revenue, consolidated net income (loss), total assets, or cash flows for any period presented; it only impacted
the presentation of segment information. Segment information for prior periods presented has been recast to conform to the
current-period segment presentation. Our &lt;span id="xdx_902_eus-gaap--NumberOfReportableSegments_dc_uSegments_c20260101__20260930_zndS6VlPE2Yg" title="Number of reportable segments"&gt;four&lt;/span&gt;
reporting segments are:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Product
Packaging:&lt;/i&gt;&lt;/b&gt; (&#x201c;Packaging&#x201d; or &#x201c;Premier&#x201d;) The Company&#x2019;s consumer packaging and security printing
business is led by its wholly owned subsidiary, Premier Packaging Corporation, which provides custom packaging services and serves
clients in the pharmaceutical, nutraceutical, consumer goods, beverage, specialty foods, confections, photo packaging and direct
marketing industries, among others. The group also provides active and intelligent packaging and document security printing services
for end-user customers. In addition, the division produces a wide array of printed materials, such as folding cartons and paperboard
packaging, security paper, vital records, prescription paper, birth certificates, receipts, identification materials, entertainment
tickets, secure coupons and parts tracking forms. The division also provides resources and production equipment for our ongoing
research and development of security printing, brand protection, consumer engagement and related technologies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commercial Lending:&lt;/i&gt;&lt;/b&gt;
(&#x201c;Commercial Lending&#x201d;) through its operating company, American Pacific Financial, Inc. (&#x201c;APF&#x201d;) represents our
financing business line. is organized for the purposes of being a financial network holding company, focused providing commercial loans
and on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies
operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in&#x2014;nonbanking activities
closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan
servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting, and advisory capital raising
services. From this financial platform, the Company shall provide an integrated suite of financial services for businesses that shall
include commercial business lines of credit, land development financing, inventory financing, third party loan servicing, and services
that address the financial needs of the world Gig Economy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Biotechnology: &lt;/i&gt;&lt;/b&gt;(&#x201c;Biotech&#x201d;)
targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Biotech drives mission-oriented research,
development, and commercialization of solutions for medical advances in human wellness and healthcare. By leveraging technology and new
science with strategic partnerships, Biotech provides advances in drug discovery for the prevention, inhibition, and treatment of neurological,
oncology and immuno-related diseases. Other exciting technologies include a breakthrough alternative sugar aimed to combat diabetes and
functional fragrance formulations aimed at the industrial and medical industry.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Securities
and Investment Management:&lt;/i&gt; &lt;/b&gt;(&#x201c;Securities&#x201d;) &lt;b&gt;&lt;/b&gt;&lt;/span&gt;Securities was established to develop and/or acquire assets
in the securities trading or management arena, and to pursue, among other product and service lines, real estate investment funds, broker
dealers, and mutual funds management.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Approximate information concerning
the Company&#x2019;s operations by reportable segment for the nine months ended September 30, 2026 and 2025 is as follows. The Company
relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the
results contained herein:&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zBUEEvlkrwzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zgwYfADjCKlc" style="display: none"&gt;Schedule of Operations by Reportable Segment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three Months Ended September 30, 2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ProductPackagingMember_zfipvlvzD3mk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Product Packaging&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialBankingMember_zuCB5L7zBK3d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Commercial Lending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zcgYnzzC9Rid" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Biotechnology&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementMember_zruveoEZo9xe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Securities
    and&lt;br/&gt;
 Investment&lt;br/&gt;
 Management&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zJGjzRcKVOG6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate/&lt;br/&gt; Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zvDl4pMXa5Vc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zhPzPf9optvf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; padding-bottom: 1pt"&gt;Revenue&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;3,371,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;21,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;207,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1633"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;3,604,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_z7b9M78XfBD7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of Revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,741,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,131,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,850,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GrossProfit_zhszUZXb8SHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(370,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;33,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(924,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,246,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingExpenses_z7SdChWObWv9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;778,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;71,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;682,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;625,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;770,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,926,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingIncomeLoss_zXTLuOak6af2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating  loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,148,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(38,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(667,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,549,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(770,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,172,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_zfJLQDoCnjce" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(61,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(900,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;604,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(513,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(866,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zOs28ObJek55" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net loss from operations before taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,209,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(938,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(663,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(945,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,283,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,038,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three Months Ended September 30,2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ProductPackagingMember_ze8HnpYMT9N2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Product Packaging&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialBankingMember_z29NciiSZdU" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Commercial Lending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zOAu931zy0qh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Biotechnology&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementMember_zxssZlBSsAy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Securities&lt;br/&gt;
 and&lt;br/&gt;
 Investment&lt;br/&gt;
 Management&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zUfHvCgbWesi" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate/&lt;br/&gt; Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zREPYaAllNR5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zuiUYADcixpc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; padding-bottom: 1pt"&gt;Revenue&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;4,935,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;11,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;1,439,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1682"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;6,392,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_zz0X8Fg5bh26" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,380,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(192,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,868,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1689"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,058,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GrossProfit_zBH3fknFIeJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;199,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(429,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1696"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;324,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingExpenses_z2QbeaN4xUEb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;894,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;57,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;883,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,754,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,478,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,558,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingIncomeLoss_z4XMN5HyMaE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating income (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(339,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;142,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(884,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,325,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,478,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,234,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_zR1FkWOfBIh2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(35,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;370,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;609,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;58,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,005,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zdF8R6GNVin3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net income (loss) from operations before taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(374,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;512,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(881,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,934,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,420,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,229,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine Months Ended September 30, 2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ProductPackagingMember_zEKzesECv4k4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Product Packaging&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialBankingMember_zTgoSfuaTD9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Commercial Lending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zAKJhKps260k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Biotechnology&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementMember_z9J1mFrTRJ18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Securities&lt;br/&gt;
 and&lt;br/&gt;
 Investment&lt;br/&gt;
 Management&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zkijaVv0ZDr3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate/&lt;br/&gt; Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJoiq9gbg5s2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zbUjV2OxGz5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; padding-bottom: 1pt"&gt;Revenue&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;10,808,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;31,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;682,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1731"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;11,538,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_z1teSWoCN78g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of Revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,536,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,386,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,902,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GrossProfit_zdtm1GnxRSVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(728,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;45,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,704,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1745"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,364,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingExpenses_zZHQrGcBzLx1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,550,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;242,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,686,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,274,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,330,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,082,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iN_di_zYvWQ880WaS" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,278,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(197,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,663,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,978,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,330,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(13,446,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_zRmYXvtWFgh3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(120,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(855,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;765,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,665,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,865,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zsNoSANP6yCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net loss from operations before taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,398,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,052,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,653,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,213,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,995,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,311,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine Months Ended September 30,2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ProductPackagingMember_zR5rpbwBtVrl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Product Packaging&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialBankingMember_z80K38NX1rEf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Commercial Lending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zGyjp9XWlP2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Biotechnology&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementMember_z5RdyBb4fnTa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Securities&lt;br/&gt;
 and&lt;br/&gt;
 Investment&lt;br/&gt;
 Management&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zyOfdSilbnH7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate/&lt;br/&gt; Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zmKlii1XXzbc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zkr6kwWqVNM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; padding-bottom: 1pt"&gt;Revenue&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;13,221,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;37,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;32,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;3,340,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;16,630,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_zPrBR26hVH3i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,274,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;36,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,430,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,753,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GrossProfit_zsnF0bcBb5sb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;947,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,090,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(123,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingExpenses_zmPKICoBtoBg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,357,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;197,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,124,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(855,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,438,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,261,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iN_di_z5sj7vWCl3Pb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,410,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(180,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,128,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(235,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,431,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,384,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_zAy6PV69MHT3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(110,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(46,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;49,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(318,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;655,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;230,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zmuCuWUygjE6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net loss from operations before taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,520,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(220,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,079,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(553,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,776,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,154,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zhJvQVnxjZ06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_znGgYyDwhWHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The following tables disaggregate our business segment
revenues by major source:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z7wcKCMDOWv3" style="display: none"&gt;Schedule of Disaggregation of Revenue&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Printed Products Revenue Information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Packaging Printing and Fabrication&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--PackagingPrintingandFabricationMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zxTL09r7O7Zg" style="width: 16%; text-align: right" title="Revenue"&gt;3,336,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Commercial and Security Printing&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialandSecurityPrintingMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zwvKcjnF1BS4" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;35,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Printed Products Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260701__20260930__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zapTlm3iwYch" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;3,371,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Packaging Printing and Fabrication&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--PackagingPrintingandFabricationMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zWyjDv0YTFv9" style="width: 16%; text-align: right" title="Revenue"&gt;4,841,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Commercial and Security Printing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialandSecurityPrintingMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zeDCevPGTO2d" style="text-align: right" title="Revenue"&gt;78,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Real Property Rental&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RealPropertyRentalIncomeMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zBbXf8XhnDEb" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;16,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Printed Products Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250701__20250930__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_z4mpfYjIvZy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;4,935,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Packaging Printing and Fabrication&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--PackagingPrintingandFabricationMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zHwgLsx8QIvl" style="width: 16%; text-align: right" title="Revenue"&gt;10,402,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Commercial and Security Printing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialandSecurityPrintingMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_z1ocFroW2ipb" style="text-align: right" title="Revenue"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Real Property Rental&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--RealPropertyRentalIncomeMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zNGDDIuYNBAh" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;31,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Printed Products Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_ziQTKFn9ZH28" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;10,808,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Packaging Printing and Fabrication&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--PackagingPrintingandFabricationMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zGnt2QOYTDgi" style="width: 16%; text-align: right" title="Revenue"&gt;12,839,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Commercial and Security Printing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialandSecurityPrintingMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zS27SFBQoylj" style="text-align: right" title="Revenue"&gt;334,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Real Property Rental&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RealPropertyRentalIncomeMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zr2VLg5XpCLi" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;48,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Printed Products Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20250930__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zk1Yr19wuQa7" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;13,221,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commercial Lending Revenue Information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Net investment&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember__srt--ProductOrServiceAxis__custom--NetInvestmentIncomeMember_zxonW75wPM2e" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Commercial Lending Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember_zYIGSpcgICMk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Net Investment&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember__srt--ProductOrServiceAxis__custom--NetInvestmentIncomeMember_zEnbzroyMdOi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;7,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Commercial Lending Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember_zGt86KllXac8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Net investment&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember__srt--ProductOrServiceAxis__custom--NetInvestmentIncomeMember_zGEiDRgOaZ8f" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;17,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Commercial Lending Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember_z0jUsy1e9eye" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;17,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Net Investment&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember__srt--ProductOrServiceAxis__custom--NetInvestmentIncomeMember_zrssLAXu58G2" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;37,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Commercial Lending Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember_znK0oV3L1Ud4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;37,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Biotechnology Revenue Information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Retail internet sales&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__srt--ProductOrServiceAxis__custom--RetailInternetSalesMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_zobGQx9qD6Rf" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;21,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Biotechnology Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_zvrzQVFm0ngd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;21,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Retail internet sales&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__srt--ProductOrServiceAxis__custom--RetailInternetSalesMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_z3ZYMGnoFtvj" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;11,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Biotechnology Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_zavpSKCK6kih" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;11,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Retail internet sales&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__srt--ProductOrServiceAxis__custom--RetailInternetSalesMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_ziP6MnjWN1Oj" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;31,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Biotechnology Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_znrpDuknuBDc" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;31,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Retail internet sales&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__srt--ProductOrServiceAxis__custom--RetailInternetSalesMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_znJHuHTMyZAl" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;32,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Biotechnology Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_zsTxHIBWryXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;32,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-decoration: underline; margin-top: 0pt; margin-bottom: 0pt"&gt;Securities and Investment Management &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Revenue
Information:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Rental &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__srt--ProductOrServiceAxis__custom--RentalIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zqXWrdBNIie4" style="width: 16%; text-align: right" title="Revenue"&gt;162,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Commission&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__srt--ProductOrServiceAxis__custom--CommissionIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zsgvubbQ1gZd" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;45,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Securities Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zKLnEAmf3Z8k" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;207,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Rental&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__srt--ProductOrServiceAxis__custom--RentalIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_z9BMk38QcEa9" style="width: 16%; text-align: right" title="Revenue"&gt;702,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Commission&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__srt--ProductOrServiceAxis__custom--CommissionIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zvhONZYF1vGi" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;737,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Securities Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zd2kV2IuMZZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;1,439,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Rental&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__srt--ProductOrServiceAxis__custom--RentalIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zanR6iKKYQz9" style="width: 16%; text-align: right" title="Revenue"&gt;522,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Commission&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__srt--ProductOrServiceAxis__custom--CommissionIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zBa8HSaElnl4" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Securities Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zXyoWWEXXxF3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;682,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Rental&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__srt--ProductOrServiceAxis__custom--RentalIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zIY0sBCtnjS5" style="width: 16%; text-align: right" title="Revenue"&gt;2,099,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Commission&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__srt--ProductOrServiceAxis__custom--CommissionIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zg0ueyHztz71" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;1,241,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Securities Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zV0ui46lvst3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;3,340,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z3KH8Cm1VwKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2026-01-01to2026-09-30"
      decimals="INF"
      id="Fact001625"
      unitRef="Segments">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001627">&lt;p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zBUEEvlkrwzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zgwYfADjCKlc" style="display: none"&gt;Schedule of Operations by Reportable Segment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three Months Ended September 30, 2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ProductPackagingMember_zfipvlvzD3mk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Product Packaging&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialBankingMember_zuCB5L7zBK3d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Commercial Lending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zcgYnzzC9Rid" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Biotechnology&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementMember_zruveoEZo9xe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Securities
    and&lt;br/&gt;
 Investment&lt;br/&gt;
 Management&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zJGjzRcKVOG6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate/&lt;br/&gt; Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20260701__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zvDl4pMXa5Vc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zhPzPf9optvf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; padding-bottom: 1pt"&gt;Revenue&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;3,371,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;21,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;207,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1633"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;3,604,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_z7b9M78XfBD7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of Revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,741,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,131,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,850,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GrossProfit_zhszUZXb8SHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(370,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;33,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(924,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,246,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingExpenses_z7SdChWObWv9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;778,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;71,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;682,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;625,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;770,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,926,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingIncomeLoss_zXTLuOak6af2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating  loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,148,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(38,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(667,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,549,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(770,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,172,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_zfJLQDoCnjce" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(61,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(900,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;604,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(513,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(866,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zOs28ObJek55" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net loss from operations before taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,209,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(938,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(663,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(945,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,283,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,038,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three Months Ended September 30,2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ProductPackagingMember_ze8HnpYMT9N2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Product Packaging&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialBankingMember_z29NciiSZdU" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Commercial Lending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zOAu931zy0qh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Biotechnology&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementMember_zxssZlBSsAy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Securities&lt;br/&gt;
 and&lt;br/&gt;
 Investment&lt;br/&gt;
 Management&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zUfHvCgbWesi" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate/&lt;br/&gt; Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250701__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zREPYaAllNR5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zuiUYADcixpc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; padding-bottom: 1pt"&gt;Revenue&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;4,935,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;11,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;1,439,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1682"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;6,392,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_zz0X8Fg5bh26" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,380,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(192,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,868,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1689"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,058,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GrossProfit_zBH3fknFIeJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;199,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(429,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1696"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;324,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingExpenses_z2QbeaN4xUEb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;894,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;57,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;883,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,754,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,478,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,558,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingIncomeLoss_z4XMN5HyMaE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating income (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(339,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;142,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(884,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,325,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,478,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,234,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_zR1FkWOfBIh2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(35,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;370,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;609,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;58,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,005,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zdF8R6GNVin3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net income (loss) from operations before taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(374,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;512,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(881,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,934,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,420,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,229,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine Months Ended September 30, 2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ProductPackagingMember_zEKzesECv4k4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Product Packaging&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialBankingMember_zTgoSfuaTD9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Commercial Lending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zAKJhKps260k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Biotechnology&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementMember_z9J1mFrTRJ18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Securities&lt;br/&gt;
 and&lt;br/&gt;
 Investment&lt;br/&gt;
 Management&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zkijaVv0ZDr3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate/&lt;br/&gt; Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260101__20260930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJoiq9gbg5s2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zbUjV2OxGz5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; padding-bottom: 1pt"&gt;Revenue&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;10,808,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;31,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;682,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1731"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;11,538,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_z1teSWoCN78g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of Revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,536,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,386,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,902,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GrossProfit_zdtm1GnxRSVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(728,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;45,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,704,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1745"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,364,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingExpenses_zZHQrGcBzLx1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,550,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;242,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,686,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,274,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,330,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,082,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iN_di_zYvWQ880WaS" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,278,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(197,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,663,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,978,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,330,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(13,446,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_zRmYXvtWFgh3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(120,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(855,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;765,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,665,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,865,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zsNoSANP6yCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net loss from operations before taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,398,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,052,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,653,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,213,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,995,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,311,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine Months Ended September 30,2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ProductPackagingMember_zR5rpbwBtVrl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Product Packaging&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialBankingMember_z80K38NX1rEf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Commercial Lending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyMember_zGyjp9XWlP2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Biotechnology&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementMember_z5RdyBb4fnTa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Securities&lt;br/&gt;
 and&lt;br/&gt;
 Investment&lt;br/&gt;
 Management&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zyOfdSilbnH7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate/&lt;br/&gt; Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zmKlii1XXzbc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zkr6kwWqVNM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; padding-bottom: 1pt"&gt;Revenue&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;13,221,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;37,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;32,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;3,340,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"&gt;16,630,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_zPrBR26hVH3i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cost of revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,274,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;36,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,430,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,753,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GrossProfit_zsnF0bcBb5sb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;947,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,090,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(123,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingExpenses_zmPKICoBtoBg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,357,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;197,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,124,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(855,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,438,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,261,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iN_di_z5sj7vWCl3Pb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,410,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(180,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,128,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(235,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,431,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,384,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_zAy6PV69MHT3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(110,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(46,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;49,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(318,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;655,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;230,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zmuCuWUygjE6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net loss from operations before taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,520,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(220,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,079,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(553,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,776,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,154,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001629"
      unitRef="USD">3371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001630"
      unitRef="USD">5000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001631"
      unitRef="USD">21000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001632"
      unitRef="USD">207000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001634"
      unitRef="USD">3604000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001636"
      unitRef="USD">3741000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001637"
      unitRef="USD">-28000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001638"
      unitRef="USD">6000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001639"
      unitRef="USD">1131000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001641"
      unitRef="USD">4850000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001643"
      unitRef="USD">-370000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001644"
      unitRef="USD">33000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001645"
      unitRef="USD">15000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001646"
      unitRef="USD">-924000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001648"
      unitRef="USD">-1246000</us-gaap:GrossProfit>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001650"
      unitRef="USD">778000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001651"
      unitRef="USD">71000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001652"
      unitRef="USD">682000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001653"
      unitRef="USD">625000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001654"
      unitRef="USD">770000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001655"
      unitRef="USD">2926000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001657"
      unitRef="USD">-1148000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001658"
      unitRef="USD">-38000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001659"
      unitRef="USD">-667000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001660"
      unitRef="USD">-1549000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001661"
      unitRef="USD">-770000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001662"
      unitRef="USD">-4172000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001664"
      unitRef="USD">-61000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001665"
      unitRef="USD">-900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001666"
      unitRef="USD">4000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001667"
      unitRef="USD">604000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001668"
      unitRef="USD">-513000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001669"
      unitRef="USD">-866000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001671"
      unitRef="USD">-1209000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001672"
      unitRef="USD">-938000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001673"
      unitRef="USD">-663000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001674"
      unitRef="USD">-945000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001675"
      unitRef="USD">-1283000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-07-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001676"
      unitRef="USD">-5038000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001678"
      unitRef="USD">4935000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001679"
      unitRef="USD">7000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001680"
      unitRef="USD">11000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001681"
      unitRef="USD">1439000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001683"
      unitRef="USD">6392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001685"
      unitRef="USD">4380000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001686"
      unitRef="USD">-192000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001687"
      unitRef="USD">2000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001688"
      unitRef="USD">1868000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001690"
      unitRef="USD">6058000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001692"
      unitRef="USD">555000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001693"
      unitRef="USD">199000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001694"
      unitRef="USD">-1000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001695"
      unitRef="USD">-429000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001697"
      unitRef="USD">324000</us-gaap:GrossProfit>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001699"
      unitRef="USD">894000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001700"
      unitRef="USD">57000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001701"
      unitRef="USD">883000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001702"
      unitRef="USD">-1754000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001703"
      unitRef="USD">3478000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001704"
      unitRef="USD">3558000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001706"
      unitRef="USD">-339000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001707"
      unitRef="USD">142000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001708"
      unitRef="USD">-884000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001709"
      unitRef="USD">1325000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001710"
      unitRef="USD">-3478000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001711"
      unitRef="USD">-3234000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001713"
      unitRef="USD">-35000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001714"
      unitRef="USD">370000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001715"
      unitRef="USD">3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001716"
      unitRef="USD">609000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001717"
      unitRef="USD">58000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001718"
      unitRef="USD">1005000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001720"
      unitRef="USD">-374000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001721"
      unitRef="USD">512000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001722"
      unitRef="USD">-881000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001723"
      unitRef="USD">1934000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001724"
      unitRef="USD">-3420000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001725"
      unitRef="USD">-2229000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001727"
      unitRef="USD">10808000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001728"
      unitRef="USD">17000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001729"
      unitRef="USD">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001730"
      unitRef="USD">682000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001732"
      unitRef="USD">11538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001734"
      unitRef="USD">11536000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001735"
      unitRef="USD">-28000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001736"
      unitRef="USD">8000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001737"
      unitRef="USD">3386000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001739"
      unitRef="USD">14902000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001741"
      unitRef="USD">-728000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001742"
      unitRef="USD">45000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001743"
      unitRef="USD">23000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001744"
      unitRef="USD">-2704000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001746"
      unitRef="USD">-3364000</us-gaap:GrossProfit>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001748"
      unitRef="USD">2550000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001749"
      unitRef="USD">242000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001750"
      unitRef="USD">3686000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001751"
      unitRef="USD">1274000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001752"
      unitRef="USD">2330000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001753"
      unitRef="USD">10082000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001755"
      unitRef="USD">3278000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001756"
      unitRef="USD">197000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001757"
      unitRef="USD">3663000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001758"
      unitRef="USD">3978000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001759"
      unitRef="USD">2330000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001760"
      unitRef="USD">13446000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001762"
      unitRef="USD">-120000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001763"
      unitRef="USD">-855000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001764"
      unitRef="USD">10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001765"
      unitRef="USD">765000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001766"
      unitRef="USD">-2665000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001767"
      unitRef="USD">-2865000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001769"
      unitRef="USD">-3398000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001770"
      unitRef="USD">-1052000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001771"
      unitRef="USD">-3653000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001772"
      unitRef="USD">-3213000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001773"
      unitRef="USD">-4995000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001774"
      unitRef="USD">-16311000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001776"
      unitRef="USD">13221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001777"
      unitRef="USD">37000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001778"
      unitRef="USD">32000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001779"
      unitRef="USD">3340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001781"
      unitRef="USD">16630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001783"
      unitRef="USD">12274000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001784"
      unitRef="USD">20000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001785"
      unitRef="USD">36000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001786"
      unitRef="USD">4430000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001787"
      unitRef="USD">-7000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001788"
      unitRef="USD">16753000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001790"
      unitRef="USD">947000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001791"
      unitRef="USD">17000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001792"
      unitRef="USD">-4000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001793"
      unitRef="USD">-1090000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001794"
      unitRef="USD">7000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001795"
      unitRef="USD">-123000</us-gaap:GrossProfit>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001797"
      unitRef="USD">2357000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001798"
      unitRef="USD">197000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001799"
      unitRef="USD">3124000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001800"
      unitRef="USD">-855000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001801"
      unitRef="USD">5438000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001802"
      unitRef="USD">10261000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001804"
      unitRef="USD">1410000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001805"
      unitRef="USD">180000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001806"
      unitRef="USD">3128000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001807"
      unitRef="USD">235000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001808"
      unitRef="USD">5431000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001809"
      unitRef="USD">10384000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001811"
      unitRef="USD">-110000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">-46000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001813"
      unitRef="USD">49000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">-318000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001815"
      unitRef="USD">655000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001816"
      unitRef="USD">230000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_ProductPackagingMember"
      decimals="0"
      id="Fact001818"
      unitRef="USD">-1520000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_CommercialBankingMember"
      decimals="0"
      id="Fact001819"
      unitRef="USD">-220000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_BiotechnologyMember"
      decimals="0"
      id="Fact001820"
      unitRef="USD">-3079000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_custom_SecuritiesAndInvestmentManagementMember"
      decimals="0"
      id="Fact001821"
      unitRef="USD">-553000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember_us-gaap_CorporateMember"
      decimals="0"
      id="Fact001822"
      unitRef="USD">-4776000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-09-30_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001823"
      unitRef="USD">-10154000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001825">&lt;p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_znGgYyDwhWHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The following tables disaggregate our business segment
revenues by major source:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z7wcKCMDOWv3" style="display: none"&gt;Schedule of Disaggregation of Revenue&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Printed Products Revenue Information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Packaging Printing and Fabrication&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--PackagingPrintingandFabricationMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zxTL09r7O7Zg" style="width: 16%; text-align: right" title="Revenue"&gt;3,336,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Commercial and Security Printing&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialandSecurityPrintingMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zwvKcjnF1BS4" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;35,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Printed Products Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260701__20260930__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zapTlm3iwYch" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;3,371,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Packaging Printing and Fabrication&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--PackagingPrintingandFabricationMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zWyjDv0YTFv9" style="width: 16%; text-align: right" title="Revenue"&gt;4,841,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Commercial and Security Printing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialandSecurityPrintingMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zeDCevPGTO2d" style="text-align: right" title="Revenue"&gt;78,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Real Property Rental&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RealPropertyRentalIncomeMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zBbXf8XhnDEb" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;16,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Printed Products Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250701__20250930__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_z4mpfYjIvZy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;4,935,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Packaging Printing and Fabrication&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--PackagingPrintingandFabricationMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zHwgLsx8QIvl" style="width: 16%; text-align: right" title="Revenue"&gt;10,402,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Commercial and Security Printing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialandSecurityPrintingMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_z1ocFroW2ipb" style="text-align: right" title="Revenue"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Real Property Rental&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--RealPropertyRentalIncomeMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zNGDDIuYNBAh" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;31,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Printed Products Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260101__20260930__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_ziQTKFn9ZH28" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;10,808,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Packaging Printing and Fabrication&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--PackagingPrintingandFabricationMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zGnt2QOYTDgi" style="width: 16%; text-align: right" title="Revenue"&gt;12,839,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Commercial and Security Printing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialandSecurityPrintingMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zS27SFBQoylj" style="text-align: right" title="Revenue"&gt;334,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Real Property Rental&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--RealPropertyRentalIncomeMember__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zr2VLg5XpCLi" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;48,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Printed Products Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250101__20250930__srt--ProductOrServiceAxis__custom--PrintedProductsRevenueInformationMember_zk1Yr19wuQa7" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;13,221,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commercial Lending Revenue Information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Net investment&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember__srt--ProductOrServiceAxis__custom--NetInvestmentIncomeMember_zxonW75wPM2e" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Commercial Lending Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember_zYIGSpcgICMk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Net Investment&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember__srt--ProductOrServiceAxis__custom--NetInvestmentIncomeMember_zEnbzroyMdOi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;7,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Commercial Lending Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember_zGt86KllXac8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Net investment&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember__srt--ProductOrServiceAxis__custom--NetInvestmentIncomeMember_zGEiDRgOaZ8f" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;17,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Commercial Lending Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember_z0jUsy1e9eye" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;17,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Net Investment&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember__srt--ProductOrServiceAxis__custom--NetInvestmentIncomeMember_zrssLAXu58G2" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;37,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Commercial Lending Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--CommercialLendingRevenueInformationMember_znK0oV3L1Ud4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;37,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Biotechnology Revenue Information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Retail internet sales&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__srt--ProductOrServiceAxis__custom--RetailInternetSalesMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_zobGQx9qD6Rf" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;21,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Biotechnology Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_zvrzQVFm0ngd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;21,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Retail internet sales&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__srt--ProductOrServiceAxis__custom--RetailInternetSalesMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_z3ZYMGnoFtvj" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;11,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Biotechnology Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_zavpSKCK6kih" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;11,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Retail internet sales&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__srt--ProductOrServiceAxis__custom--RetailInternetSalesMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_ziP6MnjWN1Oj" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;31,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Biotechnology Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_znrpDuknuBDc" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;31,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Retail internet sales&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__srt--ProductOrServiceAxis__custom--RetailInternetSalesMember__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_znJHuHTMyZAl" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Revenue"&gt;32,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Biotechnology Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--BiotechnologyRevenueInformationMember_zsTxHIBWryXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;32,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-decoration: underline; margin-top: 0pt; margin-bottom: 0pt"&gt;Securities and Investment Management &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Revenue
Information:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Rental &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__srt--ProductOrServiceAxis__custom--RentalIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zqXWrdBNIie4" style="width: 16%; text-align: right" title="Revenue"&gt;162,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Commission&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__srt--ProductOrServiceAxis__custom--CommissionIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zsgvubbQ1gZd" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;45,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Securities Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260701__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zKLnEAmf3Z8k" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;207,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Three months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Rental&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__srt--ProductOrServiceAxis__custom--RentalIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_z9BMk38QcEa9" style="width: 16%; text-align: right" title="Revenue"&gt;702,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Commission&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__srt--ProductOrServiceAxis__custom--CommissionIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zvhONZYF1vGi" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;737,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Securities Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zd2kV2IuMZZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;1,439,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Rental&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__srt--ProductOrServiceAxis__custom--RentalIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zanR6iKKYQz9" style="width: 16%; text-align: right" title="Revenue"&gt;522,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Commission&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__srt--ProductOrServiceAxis__custom--CommissionIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zBa8HSaElnl4" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Securities Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20260101__20260930__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zXyoWWEXXxF3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;682,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Nine months ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Rental&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__srt--ProductOrServiceAxis__custom--RentalIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zIY0sBCtnjS5" style="width: 16%; text-align: right" title="Revenue"&gt;2,099,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Commission&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__srt--ProductOrServiceAxis__custom--CommissionIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zg0ueyHztz71" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;1,241,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total Securities Revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SecuritiesAndInvestmentManagementRevenueInformationMember_zV0ui46lvst3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;3,340,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_PackagingPrintingandFabricationMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001827"
      unitRef="USD">3336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_CommercialandSecurityPrintingMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001829"
      unitRef="USD">35000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001831"
      unitRef="USD">3371000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_PackagingPrintingandFabricationMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001833"
      unitRef="USD">4841000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_CommercialandSecurityPrintingMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001835"
      unitRef="USD">78000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_RealPropertyRentalIncomeMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001837"
      unitRef="USD">16000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001839"
      unitRef="USD">4935000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_PackagingPrintingandFabricationMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001841"
      unitRef="USD">10402000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_CommercialandSecurityPrintingMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001843"
      unitRef="USD">375000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_RealPropertyRentalIncomeMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001845"
      unitRef="USD">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001847"
      unitRef="USD">10808000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_PackagingPrintingandFabricationMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001849"
      unitRef="USD">12839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_CommercialandSecurityPrintingMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001851"
      unitRef="USD">334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_RealPropertyRentalIncomeMember_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001853"
      unitRef="USD">48000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_PrintedProductsRevenueInformationMember"
      decimals="0"
      id="Fact001855"
      unitRef="USD">13221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_CommercialLendingRevenueInformationMember_custom_NetInvestmentIncomeMember"
      decimals="0"
      id="Fact001857"
      unitRef="USD">5000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_CommercialLendingRevenueInformationMember"
      decimals="0"
      id="Fact001859"
      unitRef="USD">5000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_CommercialLendingRevenueInformationMember_custom_NetInvestmentIncomeMember"
      decimals="0"
      id="Fact001861"
      unitRef="USD">7000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_CommercialLendingRevenueInformationMember"
      decimals="0"
      id="Fact001863"
      unitRef="USD">7000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_CommercialLendingRevenueInformationMember_custom_NetInvestmentIncomeMember"
      decimals="0"
      id="Fact001865"
      unitRef="USD">17000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_CommercialLendingRevenueInformationMember"
      decimals="0"
      id="Fact001867"
      unitRef="USD">17000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_CommercialLendingRevenueInformationMember_custom_NetInvestmentIncomeMember"
      decimals="0"
      id="Fact001869"
      unitRef="USD">37000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_CommercialLendingRevenueInformationMember"
      decimals="0"
      id="Fact001871"
      unitRef="USD">37000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_RetailInternetSalesMember_custom_BiotechnologyRevenueInformationMember"
      decimals="0"
      id="Fact001873"
      unitRef="USD">21000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_BiotechnologyRevenueInformationMember"
      decimals="0"
      id="Fact001875"
      unitRef="USD">21000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_RetailInternetSalesMember_custom_BiotechnologyRevenueInformationMember"
      decimals="0"
      id="Fact001877"
      unitRef="USD">11000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_BiotechnologyRevenueInformationMember"
      decimals="0"
      id="Fact001879"
      unitRef="USD">11000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_RetailInternetSalesMember_custom_BiotechnologyRevenueInformationMember"
      decimals="0"
      id="Fact001881"
      unitRef="USD">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_BiotechnologyRevenueInformationMember"
      decimals="0"
      id="Fact001883"
      unitRef="USD">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_RetailInternetSalesMember_custom_BiotechnologyRevenueInformationMember"
      decimals="0"
      id="Fact001885"
      unitRef="USD">32000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_BiotechnologyRevenueInformationMember"
      decimals="0"
      id="Fact001887"
      unitRef="USD">32000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_RentalIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001889"
      unitRef="USD">162000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_CommissionIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001891"
      unitRef="USD">45000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-07-012026-09-30_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001893"
      unitRef="USD">207000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_RentalIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001895"
      unitRef="USD">702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_CommissionIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001897"
      unitRef="USD">737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001899"
      unitRef="USD">1439000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_RentalIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001901"
      unitRef="USD">522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_CommissionIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001903"
      unitRef="USD">160000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2026-01-012026-09-30_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001905"
      unitRef="USD">682000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_RentalIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001907"
      unitRef="USD">2099000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_CommissionIncomeMember_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001909"
      unitRef="USD">1241000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_SecuritiesAndInvestmentManagementRevenueInformationMember"
      decimals="0"
      id="Fact001911"
      unitRef="USD">3340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact001913">&lt;p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zlEkGfigeabf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17. &lt;span id="xdx_82A_zocHilIYQbla"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company owns &lt;span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20260930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zUOdtWtdirZ4" title="Investment owned"&gt;127,179,291&lt;/span&gt; shares
or approximately &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20260101__20260930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zSDLjxEDAK76" title="Percentage of outstanding shares"&gt;4&lt;/span&gt;% of the outstanding shares of Alset International Limited (&#x201c;Alset Intl&#x201d;), a company incorporated in Singapore
and publicly listed on the Singapore Exchange Limited. This investment is classified as a marketable security and is classified as long-term
assets on the consolidated balance sheets as the Company has the intent and ability to hold the investments for a period of at least one
year. The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of Alset Intl. Mr.
Chan is also the majority shareholder of Alset Intl as well as the largest shareholder of the Company. The fair value of the marketable
security as of September 30, 2026 and December 31, 2025, was approximately $&lt;span id="xdx_902_eus-gaap--MarketableSecuritiesCurrent_iI_c20260930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zLLEcQw8yNgg" title="Fair value of marketable securities"&gt;1,399,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--MarketableSecuritiesCurrent_iI_c20251231__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zUuW8BuVuR03" title="Fair value of marketable securities"&gt;2,277,000&lt;/span&gt;, respectively. During the nine months
ended September 30, 2026 and 2025, the Company recorded unrealized loss of approximately $&lt;span id="xdx_906_eus-gaap--UnrealizedGainLossOnInvestments_c20260101__20260930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zi0GQarKTC4k" title="Unrealized gain loss on investments"&gt;877,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_c20250101__20250930__dei--LegalEntityAxis__custom--AlsetInternationalLimitedMember_zPSwt3UT9hA3" title="Unrealized gain loss on investments"&gt;51,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On September 10, 2020, the Company&#x2019;s
wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware
corporation (&#x201c;BMIF&#x201d;) and BMI Capital International LLC, a Texas limited liability company (&#x201c;BMIC&#x201d;) whereas DSS
Securities, Inc. purchased &lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200910__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DSSSecuritiesIncMember_z5mMq5bHKGxc"&gt;14.9&lt;/span&gt;% membership interests in BMIC for $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200909__20200910__dei--LegalEntityAxis__custom--DSSSecuritiesIncMember_zlwnK3vYwu41"&gt;100,000&lt;/span&gt;. DSS Securities also had the option to purchase an additional
&lt;span id="xdx_90A_ecustom--OutstandingMembershipInterest_pid_dp_uPure_c20210101__20210131__dei--LegalEntityAxis__custom--DSSSecuritiesIncMember_zK1gYphAU6j"&gt;10&lt;/span&gt;% of the outstanding membership interest which it exercised for $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210131__us-gaap--BusinessAcquisitionAxis__custom--BMICapitalInternationalLLCMember_z4y2dqoAi90d" title="Number of shares issued"&gt;100,000&lt;/span&gt; in January of 2021 and increased its ownership to &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BMICapitalInternationalLLCMember_zRrIMT7cpGv9"&gt;24.9&lt;/span&gt;%. The
Company is currently accounting for this investment under the equity method of accounting per ASC 323. The Company&#x2019;s portion of
net loss in BMIC during the nine months ended September 30, 2026 and 2025, approximated $&lt;span id="xdx_90C_ecustom--EquityMethodInvestment_c20260101__20260930__us-gaap--BusinessAcquisitionAxis__custom--BMICapitalInternationalLLCMember_zXhskh8Ig4Gb"&gt;13,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--EquityMethodInvestment_c20250101__20250930__us-gaap--BusinessAcquisitionAxis__custom--BMICapitalInternationalLLCMember_zDKuz2a7ofa"&gt;4,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;BMI Capital International LLC.
(&#x201c;BMIC LLC&#x201d;), a related party, entered into a promissory note (&#x201c;BMIC Note 1&#x201d;) in the principal sum of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20220829__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_zQvIYDlR4bUd" title="Debt instrument, face amount"&gt;100,000&lt;/span&gt;
with interest of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220829__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_zSJnBn6VAEhh" title="Debt instrument, interest rate"&gt;8&lt;/span&gt;%, is due in three quarterly installments beginning on September 14, 2022. All unpaid principal and interest was due
on &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20220828__20220829__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_zcNJJfskMCde" title="Maturity date"&gt;August 29, 2025&lt;/span&gt;. The outstanding principal and interest at September 30, 2026 and December 31, 2025 approximated $ &lt;span id="xdx_901_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_z6WAwm7jYk2a" title="Notes and loans receivable gross current"&gt;83,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember_zEGoK4KRfX4b" title="Notes and loans receivable gross current"&gt;86,000&lt;/span&gt;
respectively, and was fully reserved for as of September 30, 2026 and December 31, 2025. DSS owns &lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220829__us-gaap--ShortTermDebtTypeAxis__custom--NoteFourMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BMICapitalIncMember_zVaoSPhuHYQl" title="Ownership percentage"&gt;24.9&lt;/span&gt;% of the outstanding common shares
of BMIC LLC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On May 8, 2023, DSS Financial
Management Inc and BMIC LLC entered into a promissory note (&#x201c;BMIC Note 2&#x201d;) in the principal sum of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230508__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_zcmG9hh3y5Di" title="Debt instrument face amount"&gt;102,000&lt;/span&gt; with interest
at the prime rate plus &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230508__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_zxVPtgM8YFZ" title="Interest rate"&gt;2&lt;/span&gt;% with a maturity date of &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20230508__20260508__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_zJXI5lkgjPni" title="Maturity date"&gt;May 7, 2026&lt;/span&gt;. The outstanding principal and interest at September 30, 2026, and December
31, 2025 approximated $&lt;span id="xdx_908_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_zYNxTl8zoYQc" title="Notes and loans receivable gross current"&gt;&lt;span id="xdx_908_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember_zP5PnJq2W4K8" title="Notes and loans receivable gross current"&gt;110,000&lt;/span&gt;&lt;/span&gt;, and was fully reserved for as of September 30, 2026 and December 31, 2025. DSS owns &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230508__us-gaap--ShortTermDebtTypeAxis__custom--NoteFiveMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BMICapitalIncMember_zkyGJW9ivxBe" title="Equity method investment ownership percentage"&gt;24.9&lt;/span&gt;% of the outstanding
common shares of BMIC LLC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On July 26, 2022, APF and VEII,
Inc. (&#x201c;VEII&#x201d;) entered into a promissory note (&#x201c;Note 6&#x201d;) in the principal sum of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20220726__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_zhkeMdsCiuQ5" title="Principal amount"&gt;1,000,000&lt;/span&gt; with interest of &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220726__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_zWTmdXPjoa83" title="Interest rate"&gt;8&lt;/span&gt;%
with all unpaid principal and interest due on &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220725__20220726__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_zCyomEExHeWa" title="Debt instrument maturity date"&gt;July 26, 2024&lt;/span&gt;. This note was amended so that all unpaid principal and interest is due July
26, 2025. The outstanding principal and interest as of September 30, 2026 and December 31, 2025 approximates $&lt;span id="xdx_90E_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20260930__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_zdACDACNSzK8" title="Notes and loans receivable gross current"&gt;890,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20251231__us-gaap--ShortTermDebtTypeAxis__custom--NoteSixMember_zn1ovtcGIPB5" title="Notes and loans receivable gross current"&gt;917,000&lt;/span&gt;, respectively.
This note was fully reserved for as of September 30, 2026 and December 31, 2025. Heng Fai Ambrose Chan, the Chairman of DSS, Inc is also
the on the board of directors of VEII.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On October 13, 2021,
Liquid Value Asset Management Limited (&#x201c;LVAM&#x201d;), a subsidiary of the Company,  entered into loan agreement with BMIC
(&#x201c;BMIC Loan&#x201d;), a related party, whereas LVAM borrowed the principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20211013__us-gaap--DebtInstrumentAxis__custom--BMICLoanMember_zLRsMvSseaS9" title="Debt instrument, face amount"&gt;3,000,000&lt;/span&gt;,
with interest to be charged at a variable rate to be adjusted at the maturity date. The BMIC loan contains an auto renewal period of
three months, with a current maturity date of &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_c20211013__20211013__us-gaap--DebtInstrumentAxis__custom--BMICLoanMember_ze3MJ3oQFfBg" title="Maturity date"&gt;October 2026&lt;/span&gt;. As of September 30, 2026, and December 31, 2025, the outstanding principal and interest of approximately $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--BMICLoanMember_zg0eMjhU1gJ7" title="Debt instrument, face amount"&gt;33,000&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--BMICLoanMember_zUonjkG9z507" title="Debt instrument, face amount"&gt;33,000&lt;/span&gt;,
respectively, are included in Current portion of long-term debt &#x2013; related party, net on the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On October 13, 2021, LVAM entered
into a loan agreement with Lee Wilson Tsz Kin (&#x201c;Wilson Loan&#x201d;), a related party, whereas LVAM borrowed the principal amount
of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20211013__us-gaap--DebtInstrumentAxis__custom--WilsonLoanMember_z3gxdNPPaxs5" title="Debt instrument face amount"&gt;3,000,000&lt;/span&gt;, with interest to be charged at a variable rate to be calculated at the maturity date. The Wilson Loan matures on October
12, 2022, and contains an auto renewal period of three months with a current maturity date of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDateDescription_c20211013__20211013__us-gaap--DebtInstrumentAxis__custom--WilsonLoanMember_zGYi0SarZ0P9" title="Maturity date"&gt;October 2026&lt;/span&gt;. As of September 30, 2026, and
December 31, 2025, the outstanding principal and interest of approximately $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--WilsonLoanMember_z1OJWEiILbTb" title="Debt instrument face amount"&gt;145,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--WilsonLoanMember_zMPvDXcxO31d" title="Debt instrument face amount"&gt;145,000&lt;/span&gt;, respectively, are included in Current
portion of long-term debt &#x2013; related party, net on the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In August of 2025, DSS
issued a $&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_c20250831__dei--LegalEntityAxis__custom--AlsetIncMember_zKQz2B3mxuK1"&gt;500,000&lt;/span&gt;
convertible promissory note to Alset, Inc. (&#x201c;holder&#x201d;), the Company&#x2019;s largest shareholder and a related party,
bearing interest at Prime (&lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260930__dei--LegalEntityAxis__custom--AlsetIncMember_zK4JTew45RRh"&gt;6.75&lt;/span&gt;%
at September 30, 2026). The first 12 months&#x2019; interest is to be paid in shares of the Company; thereafter, interest is prepaid
annually in cash or shares at the holder&#x2019;s election. The note is convertible at the holder&#x2019;s option at a fixed $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250831__dei--LegalEntityAxis__custom--AlsetIncMember_zDDbTWjQRYEb"&gt;0.86&lt;/span&gt;
per share, is payable on demand (or July 31, 2028 if not demanded), and may be redeemed by the Company on or after the first
anniversary. The Company is required to reserve sufficient authorized shares and maintain the listing/quotation of its common stock.
Under ASU 2020-06 and ASC 815-40, the debt host&#x2019;s embedded conversion feature is indexed to the Company&#x2019;s own stock and
is equity-classified; accordingly, no embedded derivative is bifurcated and the instrument is accounted for as single-unit debt
using the effective interest method. Interest is recognized in interest expense; when settled in shares, a credit to APIC is
recorded at the fair value of shares on settlement, and any prepaid interest is recorded as a discount/prepaid and amortized to
expense over the related period. The outstanding principal and interest, approximates $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20260930__us-gaap--DebtInstrumentAxis__custom--AlsetNoteMember_zB0H5V9LbWG3"&gt;538,000&lt;/span&gt;
and is included in Convertible note payable, related party on the accompanying consolidated balance sheet at September 30, 2026. The
outstanding principal and interest, approximates $512,000 and is included in Convertible note payable, related party on the
accompanying consolidated balance sheet at December 31, 2025. Interest expense for the nine months ended September 30, 2026 and 2025
approximated $&lt;span id="xdx_904_eus-gaap--InterestExpense_c20260101__20260930__us-gaap--DebtInstrumentAxis__custom--AlsetNoteMember_z65ynVDdu8Q"&gt;36,000&lt;/span&gt;
and $&lt;span id="xdx_90A_eus-gaap--InterestExpense_c20250101__20250930__us-gaap--DebtInstrumentAxis__custom--AlsetNoteMember_ztrTZmq3coWk"&gt;3&lt;/span&gt;,000,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 26, 2026, the Company
issued a $&lt;span id="xdx_900_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20260326__us-gaap--DebtInstrumentAxis__custom--ConvertibleBondInvestmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetInternationalLimitedMember_zsK4Cjf0l2N8" title="Convertible bond investment fair value"&gt;2,450,000&lt;/span&gt;
convertible promissory note to Alset International Limited (&#x201c;AIL&#x201d;), a related party. The note bears interest at &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260326__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetInternationalLimitedMember_zKLcs7ZSqhO4" title="Interest rate"&gt;3.0&lt;/span&gt;%
per annum, is payable on demand by Alset International Limited, or if the demand is not sooner made, is payable on the earliest to occur
of (i) five years from issuance; (ii) the acceleration of the note upon occurrence of an event of default; (iii) upon full conversion
of the note; or (iv) upon repurchase of the note by the Company. This note is convertible at any time into shares of the Company&#x2019;s
common stock at a conversion price of $&lt;span id="xdx_90A_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260326__20260326__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetInternationalLimitedMember_zQm4zdYDCgL3" title="Converted outstanding price"&gt;0.74&lt;/span&gt;
per share. Interest is payable at maturity either in cash or shares of common stock, at the holder&#x2019;s election. The note also contains
a most favored nation provision allowing AIL to exchange the note for a subsequent convertible instrument issued by the Company if AIL
determines that such instrument contains more favorable terms. AIL is a related party because the Company owns approximately 4% of AIL&#x2019;s
outstanding shares, and the Company&#x2019;s Chairman is the Executive Director, Chief Executive Officer, majority shareholder of AIL,
and the largest shareholder of the Company. In connection with the note, the Company issued AIL a warrant to purchase up to &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20260326__20260326__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetInternationalLimitedMember_ziIKKwWDfmai" title="Purchase of warrant"&gt;16,554,055&lt;/span&gt;
shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260326__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetInternationalLimitedMember_zrjzEn8ksoj" title="Exercise price"&gt;0.93&lt;/span&gt;
per share. The warrant expires five years from the issuance date. The Company evaluated the conversion feature, most favored nation provision,
and warrant under ASC 815, ASC 815-40, and ASC 480 and concluded that no derivative liability was required. The conversion feature qualified
for the scope exception for instruments indexed to and classified in the Company&#x2019;s own equity, and the warrant was classified as
equity because it is share-settled, contains a fixed share limit, does not require net cash settlement, and the Company has sufficient
authorized and unissued shares to settle the warrant. &lt;span id="xdx_904_ecustom--BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetInternationalLimitedMember_zFOyxvYrqlrd" title="Allocated description"&gt;The
Company allocated the $2,450,000 proceeds between the convertible note and warrant based on their relative fair values. The warrant valuation
was determined using a Black-Scholes option-pricing model. Significant valuation inputs included the Company&#x2019;s common stock price
of $0.91 per share, exercise price of $0.93 per share, expected term of 5.0 years, risk-free rate of 4.0%, selected volatility of 85.0%,
expected dividend rate of 0.0%, and 16,554,055 warrants outstanding. Based on these inputs, the calculated warrant value was $0.63 per
warrant, resulting in an indicated fair value of $10,368,000. The fair value of the convertible note was determined using valuation techniques
that considered the contractual note terms, conversion feature, most favored nation provision, Company-specific credit risk, market interest
rates, expected volatility, and probability-weighted conversion scenarios. The valuation considered two scenarios: a no subsequent convertible
instrument issuance before expiration scenario, with an indicated value of $3,418,000. For purposes of allocating the $2,450,000 proceeds
at issuance, the Company used the relative fair values of the warrant and convertible note. Accordingly, $1,843,000 was allocated to
the warrant and recorded in additional paid-in capital, and $607,000 was allocated to the note. The allocation resulted in a debt discount
of $1,843,000, which will be amortized to interest expense over the five-year term of the note using the effective interest method. As
of September 30, 2026, the note had a principal amount of $2,450,000, unamortized debt discount of approximately $1,776,000 and a net
carrying amount of approximately $674,000.&lt;/span&gt; The debt discount is being amortized to interest expense over the five-year contractual term
of the note using the effective interest method. Interest expense for the nine months ended September 30, 2026 and 2025 approximated
$&lt;span id="xdx_906_eus-gaap--InterestExpense_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetInternationalLimitedMember_zzuOfHHQtITe" title="Interest expense"&gt;38,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--InterestExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetInternationalLimitedMember_z7c8MXeSROW6" title="Interest expense"&gt;0&lt;/span&gt;, respectively.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On June 23, 2026, the Company
issued a $&lt;span id="xdx_90E_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_z60j3Qy8mo4k" title="Convertible bond investment fair value"&gt;1,000,000&lt;/span&gt;
convertible promissory note to Alset, Inc. (&#x201c;Alset&#x201d;), a related party, and received aggregate proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromConvertibleDebt_c20260623__20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zZLYgsDhBZJc" title="Proceeds from issuance of convertible promissory note"&gt;1,000,000&lt;/span&gt;.
The note bears interest at &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260623__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zR2z3bNNuyti" title="Interest rate"&gt;3.0&lt;/span&gt;%
per annum, calculated based on the actual number of days elapsed over a 360-day year, is payable on demand by Alset, and otherwise matures
on &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20260623__20260623__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zk7vYlDuX1wc" title="Maturity date"&gt;June
23, 2031&lt;/span&gt;. The outstanding principal and accrued interest are convertible into shares of the Company&#x2019;s common stock at a
conversion price of $&lt;span id="xdx_90D_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260623__20260623__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zwEjdkWnVJrl" title="Converted outstanding price"&gt;0.45&lt;/span&gt;
per share, subject to required stockholder approval and customary anti-dilution adjustments. Interest is payable at maturity either in
cash or shares of common stock, at the holder&#x2019;s election. Beginning June 23, 2027, the Company may redeem all or a portion of the
outstanding principal without penalty. Alset is a related party due to common control and overlapping directors and officers, and the
transaction is disclosed in accordance with ASC 850-10-50. In connection with the note, the Company issued Alset warrants to purchase
up to &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20260623__20260623__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zcImlmNt1P21" title="Purchase of warrant"&gt;17,777,776&lt;/span&gt;
shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260623__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zuQoFuhZpxe8" title="Exercise price"&gt;0.50&lt;/span&gt;
per share. The warrants are immediately exercisable and expire on June 23, 2029. The Company evaluated the conversion feature, holder
demand provision, issuer redemption provision, and warrants under ASC 470-20, ASC 815-15, ASC 815-40, and ASC 480 and concluded that
no derivative liability was required. The conversion feature qualified for the scope exception for instruments indexed to and classified
in the Company&#x2019;s own equity. The holder demand and issuer redemption provisions were determined to be clearly and closely related
to the debt host. The warrants were classified as equity because they are share-settled, have a fixed exercise price and fixed share
limit, do not require net cash settlement, and the Company has sufficient authorized and unissued shares to settle the warrants. Accordingly,
the warrants were recorded in additional paid-in capital and are not subsequently remeasured while they continue to qualify for equity
classification. &lt;span id="xdx_903_ecustom--BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zJYz1u3YfYe3" title="Allocated description"&gt;The
Company allocated the $1,000,000 of proceeds between the convertible note and warrants based on their relative fair values in accordance
with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined using a Black-Scholes option-pricing model. Significant
valuation inputs included the Company&#x2019;s common stock price of $0.61 per share, exercise price of $0.50 per share, expected term
of 3.0 years, risk-free interest rate of 4.2%, selected volatility of 85.0%, expected dividend rate of 0.0%, and 17,777,776 warrants
outstanding. Based on these inputs, the calculated warrant value was $0.37 per warrant, resulting in an indicated fair value of $6,651,000.
The fair value of the convertible note at issuance was determined using a binomial lattice model that considered the contractual note
terms, conversion feature, Company-specific credit risk, market interest rates, expected volatility, and the Company&#x2019;s redemption
right. Significant valuation inputs included the Company&#x2019;s common stock price of $0.61 per share, conversion price of $0.45 per
share, contractual term of 5.0 years, risk-free interest rate of 4.2%, selected volatility of 85.0%, and discount rate of 13.25%. Based
on these inputs, the indicated fair value of the convertible note at issuance was $1,531,000. For purposes of allocating the $1,000,000
of proceeds at issuance, the Company used the relative fair values of the warrants and convertible note. Accordingly, $813,000 was allocated
to the warrants and recorded in additional paid-in capital, and $187,000 was allocated to the note. The allocation resulted in an initial
debt discount of $813,000, which is being amortized to interest expense over the five-year contractual term of the note using the effective
interest method. As of September 30, 2026, the note had a principal amount of $1,000,000, an unamortized debt discount of approximately
$802,000, and a net carrying amount of approximately $198,000.&lt;/span&gt; Interest expense for the nine months ended September 30, 2026 and 2025
approximated $&lt;span id="xdx_90C_eus-gaap--InterestExpense_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zMEmTavOBCDl" title="Interest expense"&gt;8,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--InterestExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_z8wRst7zPQab" title="Interest expense"&gt;0&lt;/span&gt;, respectively.&#160;The note is classified as a current liability under ASC 470-10-45 because it is payable
on demand.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 17, 2026, the Company
issued a $&lt;span id="xdx_905_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20260817__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zTwfPIRQEyxe" title="Convertible bond investment fair value"&gt;600,000&lt;/span&gt; convertible promissory note to Alset, Inc. (&#x201c;Alset&#x201d;), a related party, and received aggregate proceeds of
$&lt;span id="xdx_908_eus-gaap--ProceedsFromConvertibleDebt_c20260817__20260817__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zaYpkplXd4U" title="Proceeds from issuance of convertible promissory note"&gt;600,000&lt;/span&gt;. The note bears interest at &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260817__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zn1N101LpQb4" title="Interest rate"&gt;3.0&lt;/span&gt;% per annum, calculated based on the actual number of days elapsed over a 360-day year, is payable
on demand by Alset, and otherwise matures on &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20260817__20260817__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zsXdVghZ9aU4" title="Maturity date"&gt;August 17, 2031&lt;/span&gt;. The outstanding principal and accrued interest are convertible into shares
of the Company&#x2019;s common stock at a conversion price of $&lt;span id="xdx_90A_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260817__20260817__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zJzP9BhJY9p" title="Converted outstanding price"&gt;0.45&lt;/span&gt; per share, subject to required stockholder approval and customary anti-dilution
adjustments. Interest is payable at maturity either in cash or shares of common stock, at the holder&#x2019;s election. Beginning August
17, 2027, the Company may redeem all or a portion of the outstanding principal without penalty. Alset is a related party due to common
control and overlapping directors and officers, and the transaction is disclosed in accordance with ASC 850-10-50. In connection with
the note, the Company issued Alset warrants to purchase up to &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20260817__20260817__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zOz16IfLJpQ9" title="Purchase of warrant"&gt;10,666,667&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise price
of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260817__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_z6UETfJI4hN" title="Exercise price"&gt;0.50&lt;/span&gt; per share. The warrants are immediately exercisable and expire on August 17, 2031. The Company evaluated the conversion feature,
holder demand provision, issuer redemption provision and warrants under ASC 470-20, ASC 815-15, ASC 815-40 and ASC 480 and concluded that
no derivative liability was required. The conversion feature qualified for the scope exception for instruments indexed to and classified
in the Company&#x2019;s own equity. The holder demand and issuer redemption provisions were determined to be clearly and closely related
to the debt host. The warrants were classified as equity because they are share-settled, have a fixed exercise price and fixed share limit,
do not require net cash settlement, and the Company has sufficient authorized and unissued shares to settle the warrants. Accordingly,
the warrants were recorded in additional paid-in capital and are not subsequently remeasured while they continue to qualify for equity
classification. &lt;span id="xdx_906_ecustom--BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zd5943Eq4OD1" title="Allocated description"&gt;The Company allocated the $600,000 of proceeds between the convertible note and warrants based on their relative fair
values in accordance with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined using a Black-Scholes option-pricing
model. Significant valuation inputs included the Company&#x2019;s common stock price of $0.5615 per share, exercise price of $0.50 per
share, expected term of 5.0 years, risk-free interest rate of 4.38%, selected volatility of 85.0%, expected dividend rate of 0.0%, and
10,666,667 warrants outstanding. Based on these inputs, the calculated warrant value was approximately $0.40 per warrant, resulting in
an indicated fair value of approximately $4,271,000. The fair value of the convertible note at issuance was determined using a valuation
approach that combined a discounted cash-flow analysis of the straight-debt component with an option-pricing analysis of the embedded
conversion feature. The valuation considered the contractual note terms, conversion feature, Company-specific credit risk, market interest
rates, expected volatility and the Company&#x2019;s redemption right. Significant valuation inputs included the Company&#x2019;s common
stock price of $0.56per share, conversion price of $0.45 per share, contractual term of 5.0 years, risk-free interest rate of 4.38%, selected
volatility of 85.0%, and a credit-adjusted discount rate of 14.43%. Based on these inputs, the indicated fair value of the convertible
note at issuance was approximately $898,000. For purposes of allocating the $600,000 of proceeds at issuance, the Company used the relative
fair values of the warrants and convertible note. Accordingly, approximately $496,000 was allocated to the warrants and recorded in additional
paid-in capital, and approximately $104,000 was allocated to the note. The allocation resulted in an initial debt discount of approximately
$496,000, which is being amortized to interest expense over the five-year contractual term of the note using the effective interest method
pursuant to ASC 835-30-35. As of September 30, 2026, the note had a principal amount of $600,000, an unamortized debt discount of approximately
$493,000, a net carrying amount of approximately $107,000 and accrued interest of approximately $2,000. Interest expense associated with
the note for the three and nine months ended September 30, 2026 was approximately $5,000, including approximately $3,000 of debt-discount
amortization.&lt;/span&gt; No corresponding interest expense was recognized during the comparable 2025 periods. The note is classified as a current
liability under ASC 470-10-45 because it is payable on demand.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On September 15, 2026, the
Company issued a $&lt;span id="xdx_903_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20260915__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zH8NeVI0Xxaj" title="Convertible bond investment fair value"&gt;500,000&lt;/span&gt; convertible promissory note to Alset, Inc. (&#x201c;Alset&#x201d;), a related party, and received aggregate proceeds
of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_c20260915__20260915__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_ze3SAAaGwStf" title="Proceeds from issuance of convertible promissory note"&gt;500,000&lt;/span&gt;. The note bears interest at &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260915__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zFnYbsmtwrb6" title="Interest rate"&gt;3.0&lt;/span&gt;% per annum, calculated based on the actual number of days elapsed over a 360-day year, is
payable on demand by Alset, and otherwise matures on &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDateDescription_c20260915__20260915__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zmJtIks0sDd7" title="Maturity date"&gt;September 15, 2031&lt;/span&gt;. Following receipt of required stockholder approval, the outstanding
principal and accrued interest are convertible into shares of the Company&#x2019;s common stock at a conversion price of $&lt;span id="xdx_905_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260915__20260915__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zVTCbCMw8QZ1" title="Converted outstanding price"&gt;0.50&lt;/span&gt; per share,
subject to customary anti-dilution adjustments. Interest is payable at maturity either in cash or shares of common stock, at the holder&#x2019;s
election. Beginning September 15, 2027, the Company may redeem all or a portion of the outstanding principal without penalty. Alset is
a related party due to common control and overlapping directors and officers, and the transaction is disclosed in accordance with ASC
850-10-50. In connection with the note, the Company issued Alset warrants to purchase up to &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20260915__20260915__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_z4ZZ7HEWHkej" title="Purchase of warrant"&gt;8,000,000&lt;/span&gt; shares of the Company&#x2019;s common
stock at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260915__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_ze2hMeqStum6" title="Exercise price"&gt;0.55&lt;/span&gt; per share. The warrants are immediately exercisable and expire on September 15, 2031. The Company
evaluated the conversion feature, holder demand provision, issuer redemption provision, and warrants under ASC 470-20, ASC 815-15, ASC
815-40, and ASC 480 and concluded that no separate derivative liability was required. The conversion feature was determined to qualify
for the scope exception applicable to instruments indexed to and classified in the Company&#x2019;s own equity. The holder demand and
issuer redemption provisions remain embedded in the debt host. The warrants were classified as equity because they are share-settled,
have a fixed exercise price and fixed maximum share amount, do not require net cash settlement, and otherwise meet the applicable equity-classification
requirements of ASC 815-40. Accordingly, the warrants were recorded in additional paid-in capital and are not subsequently remeasured
while they continue to qualify for equity classification. &lt;span id="xdx_90B_ecustom--BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription_c20260101__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zorRwJLxRf5c" title="Allocated description"&gt;The Company allocated the $500,000 of proceeds between the convertible note
and warrants based on their relative fair values in accordance with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined
using a Black-Scholes-Merton option-pricing model. Significant valuation inputs included the Company&#x2019;s common stock price of $0.7411
per share, exercise price of $0.55 per share, expected term of 5.0 years, risk-free interest rate of 4.83%, selected volatility of 85.0%,
expected dividend rate of 0.0%, and 8,000,000 warrants outstanding. Based on these inputs, the calculated warrant value was approximately
$0.55154 per warrant, resulting in an indicated fair value of approximately $4,412,000. The fair value of the convertible note at issuance
was determined using a component valuation approach consisting of a discounted cash flow analysis of the straight-debt component and
a Black-Scholes approximation of the embedded conversion feature. The straight-debt analysis considered the contractual cash flows, five-year
expected term, Company-specific credit risk and market interest rates. Significant valuation inputs included a principal amount of $500,000,
contractual interest rate of 3.0%, five-year term, and a credit-adjusted market yield of 15.55%. The indicated fair value of the straight-debt
component was approximately $280,000. The embedded conversion feature was valued using the Company&#x2019;s common stock price of $0.7411
per share, conversion price of $0.50 per share, expected term of 5.0 years, risk-free interest rate of 4.83%, selected volatility of
85.0%, and expected dividend rate of 0.0%. The indicated value of the conversion feature was approximately $562,000, resulting in an
indicated stand-alone fair value of the convertible note of approximately $841,000. For purposes of allocating the $500,000 of proceeds
at issuance, the Company used the relative fair values of the warrants and convertible note. Accordingly, approximately $420,000 was
allocated to the warrants and recorded in additional paid-in capital, and approximately $80,000 was allocated to the note. The allocation
resulted in an initial debt discount of approximately $420,000, which is being amortized to interest expense over the five-year contractual
term of the note using the effective interest method in accordance with ASC 835-30. The resulting effective interest rate is approximately
47.55%. As of September 30, 2026, the note had a principal amount of $500,000, an unamortized debt discount of approximately $419,000,
and a net carrying amount of approximately $81,000, exclusive of accrued contractual interest.&lt;/span&gt; For the period from September 15, 2026
through September 30, 2026, the Company recognized approximately $&lt;span id="xdx_900_eus-gaap--InterestExpense_c20260915__20260930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlsetIncMember_zJueMHy81lQf" title="Interest expense"&gt;1,000&lt;/span&gt; of interest expense. Because the note is payable on demand, it
is classified as a current related-party liability under ASC 470-10-45.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2026-09-30_custom_AlsetInternationalLimitedMember"
      decimals="INF"
      id="Fact001915"
      unitRef="Shares">127179291</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2026-01-012026-09-30_custom_AlsetInternationalLimitedMember"
      decimals="INF"
      id="Fact001917"
      unitRef="Pure">0.04</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2026-09-30_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact001919"
      unitRef="USD">1399000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-12-31_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact001921"
      unitRef="USD">2277000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2026-01-012026-09-30_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact001923"
      unitRef="USD">877000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2025-01-012025-09-30_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact001925"
      unitRef="USD">51000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-09-10_custom_DSSSecuritiesIncMember"
      decimals="INF"
      id="Fact001926"
      unitRef="Pure">0.149</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-09-092020-09-10_custom_DSSSecuritiesIncMember"
      decimals="0"
      id="Fact001927"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <DSS:OutstandingMembershipInterest
      contextRef="From2021-01-012021-01-31_custom_DSSSecuritiesIncMember"
      decimals="INF"
      id="Fact001928"
      unitRef="Pure">0.10</DSS:OutstandingMembershipInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-01-31_custom_BMICapitalInternationalLLCMember"
      decimals="0"
      id="Fact001930"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-01-31_custom_BMICapitalInternationalLLCMember"
      decimals="INF"
      id="Fact001931"
      unitRef="Pure">0.249</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <DSS:EquityMethodInvestment
      contextRef="From2026-01-012026-09-30_custom_BMICapitalInternationalLLCMember"
      decimals="0"
      id="Fact001932"
      unitRef="USD">13000</DSS:EquityMethodInvestment>
    <DSS:EquityMethodInvestment
      contextRef="From2025-01-012025-09-30_custom_BMICapitalInternationalLLCMember"
      decimals="0"
      id="Fact001933"
      unitRef="USD">4000</DSS:EquityMethodInvestment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-08-29_custom_NoteFourMember"
      decimals="0"
      id="Fact001935"
      unitRef="USD">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-08-29_custom_NoteFourMember"
      decimals="INF"
      id="Fact001937"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-08-282022-08-29_custom_NoteFourMember"
      id="Fact001939">2025-08-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2026-09-30_custom_NoteFourMember"
      decimals="0"
      id="Fact001941"
      unitRef="USD">83000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2025-12-31_custom_NoteFourMember"
      decimals="0"
      id="Fact001943"
      unitRef="USD">86000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-08-29_custom_NoteFourMember_custom_BMICapitalIncMember"
      decimals="INF"
      id="Fact001945"
      unitRef="Pure">0.249</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-08_custom_NoteFiveMember"
      decimals="0"
      id="Fact001947"
      unitRef="USD">102000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-05-08_custom_NoteFiveMember"
      decimals="INF"
      id="Fact001949"
      unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-05-082026-05-08_custom_NoteFiveMember"
      id="Fact001951">2026-05-07</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2026-09-30_custom_NoteFiveMember"
      decimals="0"
      id="Fact001953"
      unitRef="USD">110000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2025-12-31_custom_NoteFiveMember"
      decimals="0"
      id="Fact001955"
      unitRef="USD">110000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-05-08_custom_NoteFiveMember_custom_BMICapitalIncMember"
      decimals="INF"
      id="Fact001957"
      unitRef="Pure">0.249</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-07-26_custom_NoteSixMember"
      decimals="0"
      id="Fact001959"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-07-26_custom_NoteSixMember"
      decimals="INF"
      id="Fact001961"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-07-252022-07-26_custom_NoteSixMember"
      id="Fact001963">2024-07-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2026-09-30_custom_NoteSixMember"
      decimals="0"
      id="Fact001965"
      unitRef="USD">890000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2025-12-31_custom_NoteSixMember"
      decimals="0"
      id="Fact001967"
      unitRef="USD">917000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-10-13_custom_BMICLoanMember"
      decimals="0"
      id="Fact001969"
      unitRef="USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2021-10-132021-10-13_custom_BMICLoanMember"
      id="Fact001971">October 2026</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_custom_BMICLoanMember"
      decimals="0"
      id="Fact001973"
      unitRef="USD">33000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_BMICLoanMember"
      decimals="0"
      id="Fact001975"
      unitRef="USD">33000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-10-13_custom_WilsonLoanMember"
      decimals="0"
      id="Fact001977"
      unitRef="USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2021-10-132021-10-13_custom_WilsonLoanMember"
      id="Fact001979">October 2026</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_custom_WilsonLoanMember"
      decimals="0"
      id="Fact001981"
      unitRef="USD">145000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_WilsonLoanMember"
      decimals="0"
      id="Fact001983"
      unitRef="USD">145000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-08-31_custom_AlsetIncMember"
      decimals="0"
      id="Fact001984"
      unitRef="USD">500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-09-30_custom_AlsetIncMember"
      decimals="INF"
      id="Fact001985"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-08-31_custom_AlsetIncMember"
      decimals="INF"
      id="Fact001986"
      unitRef="USDPShares">0.86</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2026-09-30_custom_AlsetNoteMember"
      decimals="0"
      id="Fact001987"
      unitRef="USD">538000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_custom_AlsetNoteMember"
      decimals="0"
      id="Fact001988"
      unitRef="USD">36000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_custom_AlsetNoteMember"
      decimals="0"
      id="Fact001989"
      unitRef="USD">3</us-gaap:InterestExpense>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2026-03-26_custom_ConvertibleBondInvestmentMember_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact001991"
      unitRef="USD">2450000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-03-26_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember"
      decimals="INF"
      id="Fact001993"
      unitRef="Pure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2026-03-262026-03-26_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember"
      decimals="INF"
      id="Fact001995"
      unitRef="USDPShares">0.74</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2026-03-262026-03-26_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember"
      decimals="INF"
      id="Fact001997"
      unitRef="Shares">16554055</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-26_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember"
      decimals="INF"
      id="Fact001999"
      unitRef="USDPShares">0.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember"
      id="Fact002001">The
Company allocated the $2,450,000 proceeds between the convertible note and warrant based on their relative fair values. The warrant valuation
was determined using a Black-Scholes option-pricing model. Significant valuation inputs included the Company&#x2019;s common stock price
of $0.91 per share, exercise price of $0.93 per share, expected term of 5.0 years, risk-free rate of 4.0%, selected volatility of 85.0%,
expected dividend rate of 0.0%, and 16,554,055 warrants outstanding. Based on these inputs, the calculated warrant value was $0.63 per
warrant, resulting in an indicated fair value of $10,368,000. The fair value of the convertible note was determined using valuation techniques
that considered the contractual note terms, conversion feature, most favored nation provision, Company-specific credit risk, market interest
rates, expected volatility, and probability-weighted conversion scenarios. The valuation considered two scenarios: a no subsequent convertible
instrument issuance before expiration scenario, with an indicated value of $3,418,000. For purposes of allocating the $2,450,000 proceeds
at issuance, the Company used the relative fair values of the warrant and convertible note. Accordingly, $1,843,000 was allocated to
the warrant and recorded in additional paid-in capital, and $607,000 was allocated to the note. The allocation resulted in a debt discount
of $1,843,000, which will be amortized to interest expense over the five-year term of the note using the effective interest method. As
of September 30, 2026, the note had a principal amount of $2,450,000, unamortized debt discount of approximately $1,776,000 and a net
carrying amount of approximately $674,000.</DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact002003"
      unitRef="USD">38000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_AlsetInternationalLimitedMember"
      decimals="0"
      id="Fact002005"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="0"
      id="Fact002007"
      unitRef="USD">1000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="0"
      id="Fact002009"
      unitRef="USD">1000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131734"
      decimals="INF"
      id="Fact002011"
      unitRef="Pure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      id="Fact002013">June
23, 2031</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2026-06-232026-06-23_custom_SecuritiesPurchaseAgreementMember_custom_AlsetIncMember"
      decimals="INF"
      id="Fact002015"
      unitRef="USDPShares">0.45</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2026-06-232026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131734"
      decimals="INF"
      id="Fact002017"
      unitRef="Shares">17777776</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-06-23_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131734"
      decimals="INF"
      id="Fact002019"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      id="Fact002021">The
Company allocated the $1,000,000 of proceeds between the convertible note and warrants based on their relative fair values in accordance
with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined using a Black-Scholes option-pricing model. Significant
valuation inputs included the Company&#x2019;s common stock price of $0.61 per share, exercise price of $0.50 per share, expected term
of 3.0 years, risk-free interest rate of 4.2%, selected volatility of 85.0%, expected dividend rate of 0.0%, and 17,777,776 warrants
outstanding. Based on these inputs, the calculated warrant value was $0.37 per warrant, resulting in an indicated fair value of $6,651,000.
The fair value of the convertible note at issuance was determined using a binomial lattice model that considered the contractual note
terms, conversion feature, Company-specific credit risk, market interest rates, expected volatility, and the Company&#x2019;s redemption
right. Significant valuation inputs included the Company&#x2019;s common stock price of $0.61 per share, conversion price of $0.45 per
share, contractual term of 5.0 years, risk-free interest rate of 4.2%, selected volatility of 85.0%, and discount rate of 13.25%. Based
on these inputs, the indicated fair value of the convertible note at issuance was $1,531,000. For purposes of allocating the $1,000,000
of proceeds at issuance, the Company used the relative fair values of the warrants and convertible note. Accordingly, $813,000 was allocated
to the warrants and recorded in additional paid-in capital, and $187,000 was allocated to the note. The allocation resulted in an initial
debt discount of $813,000, which is being amortized to interest expense over the five-year contractual term of the note using the effective
interest method. As of September 30, 2026, the note had a principal amount of $1,000,000, an unamortized debt discount of approximately
$802,000, and a net carrying amount of approximately $198,000.</DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription>
    <us-gaap:InterestExpense
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="0"
      id="Fact002023"
      unitRef="USD">8000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2025-01-012025-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="0"
      id="Fact002025"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="0"
      id="Fact002027"
      unitRef="USD">600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="0"
      id="Fact002029"
      unitRef="USD">600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="INF"
      id="Fact002031"
      unitRef="Pure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      id="Fact002033">August 17, 2031</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2026-08-172026-08-17_custom_SecuritiesPurchaseAgreementMember_custom_AlsetIncMember"
      decimals="INF"
      id="Fact002035"
      unitRef="USDPShares">0.45</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2026-08-172026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131750"
      decimals="INF"
      id="Fact002037"
      unitRef="Shares">10666667</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-08-17_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131765"
      decimals="INF"
      id="Fact002039"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteOneMember_custom_AlsetIncMember"
      id="Fact002041">The Company allocated the $600,000 of proceeds between the convertible note and warrants based on their relative fair
values in accordance with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined using a Black-Scholes option-pricing
model. Significant valuation inputs included the Company&#x2019;s common stock price of $0.5615 per share, exercise price of $0.50 per
share, expected term of 5.0 years, risk-free interest rate of 4.38%, selected volatility of 85.0%, expected dividend rate of 0.0%, and
10,666,667 warrants outstanding. Based on these inputs, the calculated warrant value was approximately $0.40 per warrant, resulting in
an indicated fair value of approximately $4,271,000. The fair value of the convertible note at issuance was determined using a valuation
approach that combined a discounted cash-flow analysis of the straight-debt component with an option-pricing analysis of the embedded
conversion feature. The valuation considered the contractual note terms, conversion feature, Company-specific credit risk, market interest
rates, expected volatility and the Company&#x2019;s redemption right. Significant valuation inputs included the Company&#x2019;s common
stock price of $0.56per share, conversion price of $0.45 per share, contractual term of 5.0 years, risk-free interest rate of 4.38%, selected
volatility of 85.0%, and a credit-adjusted discount rate of 14.43%. Based on these inputs, the indicated fair value of the convertible
note at issuance was approximately $898,000. For purposes of allocating the $600,000 of proceeds at issuance, the Company used the relative
fair values of the warrants and convertible note. Accordingly, approximately $496,000 was allocated to the warrants and recorded in additional
paid-in capital, and approximately $104,000 was allocated to the note. The allocation resulted in an initial debt discount of approximately
$496,000, which is being amortized to interest expense over the five-year contractual term of the note using the effective interest method
pursuant to ASC 835-30-35. As of September 30, 2026, the note had a principal amount of $600,000, an unamortized debt discount of approximately
$493,000, a net carrying amount of approximately $107,000 and accrued interest of approximately $2,000. Interest expense associated with
the note for the three and nine months ended September 30, 2026 was approximately $5,000, including approximately $3,000 of debt-discount
amortization.</DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="0"
      id="Fact002043"
      unitRef="USD">500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="0"
      id="Fact002045"
      unitRef="USD">500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="INF"
      id="Fact002047"
      unitRef="Pure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      id="Fact002049">September 15, 2031</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="From2026-09-152026-09-15_custom_SecuritiesPurchaseAgreementMember_custom_AlsetIncMember"
      decimals="INF"
      id="Fact002051"
      unitRef="USDPShares">0.50</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2026-09-152026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131781"
      decimals="INF"
      id="Fact002053"
      unitRef="Shares">8000000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-09-15_custom_ConvertiblePromissoryNoteMember_custom_AlsetIncMember108131781"
      decimals="INF"
      id="Fact002055"
      unitRef="USDPShares">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription
      contextRef="From2026-01-012026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteTwoMember_custom_AlsetIncMember"
      id="Fact002057">The Company allocated the $500,000 of proceeds between the convertible note
and warrants based on their relative fair values in accordance with ASC 470-20-30-1 and ASC 470-20-30-2. The warrant valuation was determined
using a Black-Scholes-Merton option-pricing model. Significant valuation inputs included the Company&#x2019;s common stock price of $0.7411
per share, exercise price of $0.55 per share, expected term of 5.0 years, risk-free interest rate of 4.83%, selected volatility of 85.0%,
expected dividend rate of 0.0%, and 8,000,000 warrants outstanding. Based on these inputs, the calculated warrant value was approximately
$0.55154 per warrant, resulting in an indicated fair value of approximately $4,412,000. The fair value of the convertible note at issuance
was determined using a component valuation approach consisting of a discounted cash flow analysis of the straight-debt component and
a Black-Scholes approximation of the embedded conversion feature. The straight-debt analysis considered the contractual cash flows, five-year
expected term, Company-specific credit risk and market interest rates. Significant valuation inputs included a principal amount of $500,000,
contractual interest rate of 3.0%, five-year term, and a credit-adjusted market yield of 15.55%. The indicated fair value of the straight-debt
component was approximately $280,000. The embedded conversion feature was valued using the Company&#x2019;s common stock price of $0.7411
per share, conversion price of $0.50 per share, expected term of 5.0 years, risk-free interest rate of 4.83%, selected volatility of
85.0%, and expected dividend rate of 0.0%. The indicated value of the conversion feature was approximately $562,000, resulting in an
indicated stand-alone fair value of the convertible note of approximately $841,000. For purposes of allocating the $500,000 of proceeds
at issuance, the Company used the relative fair values of the warrants and convertible note. Accordingly, approximately $420,000 was
allocated to the warrants and recorded in additional paid-in capital, and approximately $80,000 was allocated to the note. The allocation
resulted in an initial debt discount of approximately $420,000, which is being amortized to interest expense over the five-year contractual
term of the note using the effective interest method in accordance with ASC 835-30. The resulting effective interest rate is approximately
47.55%. As of September 30, 2026, the note had a principal amount of $500,000, an unamortized debt discount of approximately $419,000,
and a net carrying amount of approximately $81,000, exclusive of accrued contractual interest.</DSS:BusinessCombinationValuationAllowanceAllocatedToReduceCapitalDescription>
    <us-gaap:InterestExpense
      contextRef="From2026-09-152026-09-30_custom_SecuritiesPurchaseAgreementConvertiblePromissoryNoteMember_custom_AlsetIncMember"
      decimals="0"
      id="Fact002059"
      unitRef="USD">1000</us-gaap:InterestExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2026-01-01to2026-09-30" id="Fact002061">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_z2IXriEVGhN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18. &lt;span id="xdx_828_z8bByvj03iPh"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company has evaluated
all subsequent events and transactions through November 13, 2026 the date that the condensed consolidated financial statements were
issued and noted no subsequent events requiring financial statement recognition or disclosure other than the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On October 16, 2026, the Company
entered into a loan agreement with Alset Inc. (&#x201c;Alset&#x201d;), a related party and significant stockholder of the Company, providing
for a $&lt;span id="xdx_904_eus-gaap--UnsecuredDebt_iI_c20261016__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zAIv0HVceTj1" title="Unsecured loan"&gt;250,000&lt;/span&gt; unsecured loan. The loan bears interest at &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20261016__20261016__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zlvFk0wgocF1" title="Interest rate"&gt;1.0&lt;/span&gt;% per annum, calculated on an actual/365-day basis, and matures 90 days after
the funding date. Principal and accrued interest are payable at maturity, and the Company may prepay the loan at any time without penalty.
The interest rate increases to &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20261016__20261016__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zrh37jfic543" title="Interest rate increases"&gt;3.0&lt;/span&gt;% per annum on overdue principal amounts. The loan is non-convertible, does not include warrants or
other equity-linked instruments, and the proceeds are intended for general working capital and corporate purposes. The transaction was
approved by the Company&#x2019;s Audit Committee in accordance with its related party transaction policy.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:UnsecuredDebt
      contextRef="AsOf2026-10-16_us-gaap_SubsequentEventMember_custom_LoanAgreementMember"
      decimals="0"
      id="Fact002063"
      unitRef="USD">250000</us-gaap:UnsecuredDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2026-10-162026-10-16_us-gaap_SubsequentEventMember_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact002065"
      unitRef="Pure">0.010</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2026-10-162026-10-16_us-gaap_SubsequentEventMember_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact002067"
      unitRef="Pure">0.030</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
</xbrl>
